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Abstract
Colorectal cancer is a significant health concern in the province of Newfoundland and
Labrador (NL) which has the highest age-standardized incidence and mortality rates for
colorectal cancer in Canada. Several studies have attempted to identify inherited genetic
variants which can serve as independent prognostic markers in colorectal cancer patients.
We have conducted such a study in two colorectal cancer patient cohorts (discovery and
validation sets) from Newfoundland . We investigated 27 genetic polymorphism s in the
discovery cohort and attempted to replicate the positive correlations in the validation
cohort . Our results showed that the MTHFR _Glu429Ala polymorphism was associated
with worse overall survival in two cohorts albeit with an apparently different pattern of
inheritance. An association of the heterozygote genotype of this polymorphism with
shorter overall survival was also detected in male patients from both cohorts. Another
polymorphism , ERCC5_His46His, was also found to be associated with disease-free
survival in these cohorts. Further studies on these polymorphisms may facilitate
understanding of the mechanisms behind prognostic differences among colorectal cancer
patients and aid in better prediction of clinical outcomes.
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Chapter 1. Colorectal cancer
1.1 Cancer
Cancer is a disease characterized by uncontrollable division of certain abnormal cells
which can develop into a tumor that can invade tissues or spread to distant organs (1).
Over one hundred types of cancers have been identified based on the cell types in which
they develop (1). Instability of the genome making the cell's deoxyribonucleic acid
(DNA) hyper-mutable as well as increased inflammation that can favor carcinogenesis
are recognized as the two primary reasons which can enable normal cells to acquire
cancerous properties (2). Through the course of development of cancer cells, distinct
proliferative abilities are acquired in a successive manner. Hanahan and Weinberg
described these unique attributes of cancer cells as 'hallmarks of cancer' (2). Cancer cells
have prolonged cellular growth signaling for proliferation which can be due to self-
production of growth factors, induction of growth factor production in the surrounding
normal cells, high sensitivity to growth factors due to changes in receptor structure or
continually triggered pathways downstream of receptors (2). Normal cell proliferation is
also controlled by the action of tumor suppressor genes which inhibit proliferation and
growth in unfavorable conditions and can also induce cell senescence and death. Cancer
cells escape the suppressive action of these genes to continue proliferating. A
dysfunctional contact inhibition mechanism, which prevents excessive proliferation of
cells under normal conditions, also contributes to continued proliferation in cancer cells
(2). Normal cells have a way of regulating cell proliferat ion through induction of
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apoptosis which causes death of highly stressed and abnormal cells such as cancer cells.
But cancer cells evade apoptosis via multiple mechanisms like loss of function or reduced
activity of apoptotic factors and up-regulation of counter-apoptotic factors (2). In addition
to such prolific properties , cancer cells have an added ability to be immortal, likely due to
the maintenance of telomere lengths at the end of chromatids after each replication (2).
This ability to replicate endlessly enables formation of a fully grown macroscopic tumor
from microscopic cancerous cells. And like all tissues in the body, the growing tumor
also requires a constant supply of blood and nutrients. This is facilitated by formation of
new tumor vasculature by up-regulating pro-angiogenic factors early in neoplastic
development (2). With advancing growth, the tumor cells begin to penetrate the
surrounding normal tissues and vasculature , then spread to distant organs via blood
and/or lymph vessels and develop into micrometastases and eventually grow into
metastatic tumors. Cancer cells may also have the ability to modify cell metabolic
processes in a way to favor tumorigenesis as well as evade destruction by the immune
system (2). Evidently, cancer is a highly complex disease involving aberrations in
multiple genes operating in multiple pathways, the accumulation of which can lead to
initiation of cancer which can then grow into lethal forms by modifying cellular functions
to suit its survival.
1.2 Structure and function s of the colon and rectum
The colon, also known as the large intestine or large bowel, is approximately 1.5 meters
long (3). The colon begins as the caecum and progresses into the ascending colon,
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transverse colon, descending colon and sigmoid colon. The colon terminates in the
rectum which opens exteriorly into the anal canal (Figure 1). A sharp curve at the level
of the liver is known as the hepatic flexure and one at the level of spleen is known as the
splenic flexure (3). Histologically, the colon and rectum are lined by 4 basic membranes.
Beginning outwards, they are (3):
1) Visceral peritoneum: The outermost serous membrane.
2) Muscle layers: They are arranged as longitudinal and circular fibres.
3) Submucosa: This layer contains networks of nerves, blood vessels, lymph vessels
and lymphoid tissue . For defence against microbial infections, the submucosa in
colon has greater amount of lymphoid tissue compared to other parts of the
alimentary canal.
4) Mucosa: This is composed of three layers of tissue. Starting inwards, they are:
Mucous membrane-innermo st layer of columnar epithelial cells
responsible for absorption, secretion and protection .
ii. Lamina propria-loose connective tissue layer responsible for support and
protection.
iii. Muscularis mucosa-provides involutions to the mucous layer.
The primary function of colon is to absorb water from the matter that arrives from the
small intestines (3). This results in the formation of the fecal matter. The fecal matter
then moves along the colon and to the rectum where it propelled by muscle movements to
the anal canal for expulsion. The colon also expels swallowed air and gases produced by
17
Figure 1. Structure of colon and rectum
S ), )t ll lc OtXl\I 't
AdaptedtTom ' PrinciplesofAnatomyand Physiology'(4)
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bacterial action on unabsorbed food matter. The large amount of lymphoid tissue in the
colonic submucosa protects the colon from microbial infections as the fecal matter is rich
in microbes (3).
1.3 Colorectal cancer: Molecular mechanisms and pathology
Cancer of the colonic tissue is called 'colon cancer ' while that of the rectal tissue is called
'rec tal cancer ' and they are referred together as colorectal cancer (5). Development and
growth of colorectal cancer involve multiple and sequential changes in the genome such
as destabilizing the genome by mutations that inactivate chromosome stabilizing genes,
defects in DNA repair machinery, epigenetic silencing by DNA methylation, deactivation
of tumor suppressor genes and activation of proto-oncogenes to oncogenes (6,7). This
series of changes eventually manifests pathologicall y as colorectal cancer. According to
the inheritance patterns, there are two forms of colorectal cancer:
Familial and inherited forms of colorectal cancers with familial clustering. In the
case of inherited forms, there is a strong hereditary predisposition .
ii. Sporadic forms without a strong hereditary predisposition.
The familial and inherited forms comprise approximately 15-25% of all colorectal cancer
syndromes while the sporadic forms comprise the majority with 70-85% of the cases (8-
12). The inherited and sporadic forms may involve different genetic and molecular
mechanisms. Inherited forms are due to high-penetrant mutations in critical genes (8).
Examples of inherited forms include:
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I) Lynch syndrome (previously known as Hereditary Non-polyposis Colorectal
Cancer (HNPCC)) is characterized by germline mutations in the mismatch repair
genes (MMR) such as MLH1. MSH2. MSH6 and PMS2 (8), leading to the
microsatellite instability (MSI) phenotype in tumors.
2) Familial adenomatous polyposis (FAP) is an autosomal dominant form of
colorectal cancer caused by the germline mutations in the adenomatous polyposis
coli (APe) gene (13).
3) mutY homolog (E. coli) (MUTYH)-associatedpolyposis (MAP) is an autosomal
recessive disease where mutations in MUTYH gene predispose the individual to
colorectal cancer (1 I).
4) Examples of other rare forms of colorectal cancer syndromes are Juvenile
Polyposis, Peutz-Jeghers Syndrome, Cowden disease and Bannayan-Ruvalcaba-
Riley Syndrome (8).
The incompletely understood Familial colorectal cancer type X (FCCTX) is a form with a
strong familial clustering of colorectal cancer but no well-defined hereditary
predisposition or molecular mechanism (11,14,15). This form is distinct from the Lynch
syndrome in terms of age of onset, tumor histology, tumor grade and absence of deficient
MMR (16). Recent developments suggest that molecular mechanisms involved in
chromosomal instability may be involved in development of FCCTX (16).
In sporadic colorectal cancer cases, a strong genetic predisposition may not exist. Rather,
interaction of several low susceptibili ty alleles and environmental factors are proposed to
results in carcinogenesis . Genome-wide association studies (GWAS) have identified at
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least 14 such low-susceptibil ity genetic variants that increase the risk of developing
colorectal cancer ( 17).
Molecular mechani sms involved in sporadic forms of colorectal cancer are:
I) Chromosomal instabili ty (CIN) : Characterized by numerical or structural
abnormalities in the chromosomes causing damage to tumor suppressor genes or
oncogenes (18).
2) Defecti ve MMR system leading to MSI: In sporadic cases, MSI is due to
hypermeth ylation of the promoter of the mismatch repair gene MLH1 leadin g to
its silencing (19).
3) CpO island methylator phenotype (CIMP): In CIMP, the CpO islands are
methylated causing inactivation of certain genes (20).
Histological types of colorectal cancer: Pathologically, at least eight different histological
types of epithelial tumors have been defined by the World Health Organization (WHO)
(21). Adenoma is the early benign tumor. Adenocarcinoma is the malignant type, shows
moderate differentiation and can be either mucinous or non-mucin ous (22). It is the most
commonly observed histological type of coloreetaI cancer (-90-95%) (2 1,23). Mucinous
adenocarcinoma, in which the tumor cells secrete mucin (> 50% of tumor mass is due to
mucin) is found in up to 17% of tumors while the majorit y of adenocarcinom as are non-
mucinous (21-23). Other rarer patho logical forms are signet-cell carcinoma , squamous
cell carcinoma, adenosquam ous carcinoma, small cell carcinoma and medullary
carcinoma (2 1,24).
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1.4 Colorecta l cancer incidenc e and mortali ty statistics
1.4.1 Worldwide incidence and mortality: According to WHO's report "The global
burden of disease. 2004 Update" (25), colorectal cancer was responsible for
approximately 639,000 deaths worldwide with 336,000 male deaths and 303,000 female
deaths. On the list of lethal cancers in terms of number of cancer deaths, colorecta l cancer
was the 4th major global killer in the year 2004 (25). Of all the cancers worldwide ,
colorectal cancer ranks the 4th in men and the 3rd in women in terms of incidence (26).
The general trend observed worldwide is high incidence of this disease predominantly in
the western world such as North America, Australia and European countries and low
incidence in South American, Asian and African populations (26).
1.4.2 Colorectal cancer in Canada: Among all cancers (excluding non-melanoma skin
cancers) , the incidence of colorectal cancer across Canada was expected to be the 4th
highest with 22,200 estimated new cases in 2011 (27). In 2011, the mortality due to
colorectal cancer was expected to be the 2nd highest among all cancers with 8,900
patients estimated to die because of it (27). Relative survival rate of colorectal cancer
patients (survival of colorectal cancer patients compared to that of the general population
from the same region) over a 5-year period is 63-64% (27). It is reported that the Atlantic
Provinces in Canada have higher colorectal cancer incidence and mortality rates when
compared to western provinces like Alberta (AB) and British Columbia (BC) (27).
Multiple factors such as lifestyle factors (exercise, diet), family history, intensity of
screening programs, differential participation as well as quality and availabilit y of
healthcare and diagnostic services may account for this inter-provincial variation in
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colorectal cancer incidence and mortality rates (27).
Figures 2 and 3 show the inter-provincial variation and the east-west gradient in
incidence and mortality rates of colorectal cancer across Canada (27). NL shows the
highest age-standardized incidence and mortality rates for both men and women. Other
Atlantic provinces such as Prince Edward Island (PE), Nova Scotia (NS) and New
Brunswick (NB) as well as Quebec (QC) have higher incidence and mortality rates
compared to the western provinces of AB and BC.
1.4.3 Colorectal cancer in Newfoundland and Labrador (NL): When Canadian
provinces are compared, the age-standard ized incidence rate is the highest for both males
and females from NL (27). Eighty nine cases per 100,000 new male colorectal cancer
patients were expected in NL in 2011 while the national expected rate was 611100,000.
For females, fifty two new cases per 100,000 were expected in NL while the national
average of incidence for females was 40/100,000 (Figure 2). Also, according to the
Canadian Cancer Statistics 20 II , men and women patients from NL have the highest age-
standardized colorectal cancer mortality rates across Canada (27). Forty-five deaths per
100,000 men were expected in NL in 2011 while the national average was 25
deaths/100,000 males. For females, twenty-three deaths per 100,000 are expected in NL
while the national expected number of deaths is 15 deaths/100,000 (Figure 3). These
statistics show the relatively greater burden of colorectal cancer in NL when compared to
other Canadian provinces.
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Figure 2. Estimated age-standardized incidence rat es for colorectal cancer in
Canadian provinces, 2011
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Figure 3. Estimated age-standardized mortali ty rate s for colorectal cancer in
Canadian provinces, 2011
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1.5 Prognosis
Prognosis is the prediction of the course of a disease leading to specific health conditions,
known as clinical outcomes, after diagnosis of the disease (28). The US National Library
of Medicine defines clinical outcome as "a measure ofhow a patient (or study subje ct)
fee ls, f unctions, or survives; or a clinical measurement of the incidence or severity ofa
disease (e.g., diagnosis ofdisease) " (29). Clinical outcomes in cancer include recurrence
of cancer, metastasis or death. Two of the commonly used measures of clinical outcome,
which are also the end-points analyzed in this thesis project are overall survival (OS) and
disease free survival (DFS). While their definitions may change from one study to other,
we refer to OS and DFS in this study as defined below.
os: It is the survival period of the patient from the time of diagnosis until his/her
death from any cause. OS rate, usually expressed as a 5-year survival rate, is the
proportion of patients alive five years after diagnosis of the disease.
ii. DFS: DFS is the survival of patients after diagnosis without relapse (i.e.
recurrence or metastasis) or death from any cause.
1.5.1 Fac tors affecting pr ognosis in colorecta l cancer patien ts: Prognosis and clinical
outcomes in cancer patients are highly variable and dependent on multiple factors.
Currently, the tumor-node-metastasis (TNM) staging is the standard tool for
prognostication in colorectal cancer patients (30). The TNM stage is a measure of the
extent of tissue invasion by the tumor (T) and metastasis to lymph nodes (N) or distant
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organs (M). The TNM staging published by American Joint Committee on Cancer
(AJCC) is the widely accepted standard for staging of colorectal cancer (30). The latest
classification (published 2010) is depicted in Table 1.
In addition , there are a large number of acknowledged prognostic factors but their use in
clinical practice is limited. In 1999, the College of American Pathologists (CAP)
convened a consensus statement (31) categorizing the prognostic factors in colorectal
cancer into five categories:
Category I: It includes factors which are conclusively established to have prognostic
value based on the results of multiple trials considered statistically robust. These factors
are routinely used in the clinic for patient management. This category includes depth of
tumor invasion (T of TNM staging) , metastasis to regional lymph nodes (N of TNM
staging), lymphatic or vascular invasion , presence of residual tumor after surgical
removal and levels of pre-operative carcinoembryonic antigen (CEA) in the serum.
CategorY IIA: This category includes factors which are considered important for
inclusion in pathology reports and have repeatedly shown prognostic relevance.
However, they await validation in large studies . This category includes tumor grade ,
circumferential resection margins (CRM) and tumor staging after neoadjuvant therapy .
Category lIB: This category includes factors which show prognostic relevance in
multiple studies but further studies are needed for inclusion in category I or 1IA. It
includes tumor histology , MSI status in tumor cells , loss of heterozygosity (LOH) at 18q,
allelic loss of Dee gene and the configuration of tumor border .
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Table 1. Stage grouping for colorectal cancer
Stage Designation TNM Characteristics
stage 0 Tis, NO, MO
T1, NO,MO or
stage I
T2, NO, MO
stagelIA T3,NO ,MO
stage lIB T4a, NO,MO
stagelIC T4b, NO, MO
T1-T2, N I/N lc , MOor
stage IlIA
TI ,N2a,MO
T3-T4a, NI/Nlc, MOor
stage IIIB T2-T3, N2a, MOor
T1-T2, N2b, MO
14a, N2a, MOor
stage IIIC T3-T4a, N2b, MOor
14 b, NI-N2, MO
stage IVA any T, any N, M Ia
stage IVB anyT,anyN,M l b
Tis=carcinoma in situ limited to lamina propria or basement membrane, Tl =submucosallayer invaded
by tumor cells, T2=tumor penetrated deeper into muscularis propria, T3=tumor penetrated into sub-
serosa or tissues surrounding colon/rectum, T4a=direct penetration through the peritoneum, T4b=direct
penetration into or attachment to other organs. NO=no metastasis of tumor cells into regional lymph
nodes, NI =I -3 lymph nodes affected, N la= 1 lymph node affected, Nlb=2-3 lymph nodes affected,
Nlc=no metastasis into regional lymph nodes but tumor deposit(s) present, N2a=4-6 lymph nodes
affected, N2b=7 or more lymph nodes affected , MO=distant metastasis not observed. Ml a=distant
metastasis to a single organ/site, Mlb=distant metastasis to multipleorgan slsites.
Adapted from AlCC Cancer Staging Handbook, 7th Edition (20 10) (30)
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Category III: This category includes factors which have not been well-studied for their
prognostic relevance. It includes DNA content , a large set of putative molecular markers
including genes and proteins which may have prognostic roles due to altered function or
abnormal expression (tumor suppressor genes affected due to LOH at I p/pS3, 8p, I p, Sq,
oncogenes (KRAS, MYC), apoptotic and cell suicide-related genes (BCL2, BAX), genes
involved in DNA synthesis, growth factor-related genes (TGF, EGFR), cyclin-dependent
kinase inhibitor genes (CDKls) , genes involved in angiogenesis (VEGF), glycoprotein
genes and adhesion molecules (E-cadherin, sialo-Tn antigen, CD44), matrix
metalloproteases (MMPs) and inhibitors of MMPs, genes that suppress metastasis
(NME1)) and other features such as perineural invasion, microvessel density, cell proteins
and carbohydrates, peritumoral fibrosis, neuroendocrine differentiation foci, nucleolar
organizing regions and proliferation indices.
Category IV: This category includes factors for which absence of prognostic relevance
has been well established. It includes tumor size and gross tumor configuration .
A decade later, the t h edition of AJCC cancer staging manual published in 2010 includes
updates and recommendations for improved prognostication based on scientific evidence
(30). TNM staging system still remains the most powerful prognostic tool. Stage-
independent factors that are used on a general basis include tumor histology, tumor grade,
presence/absence of residual tumor after surgical removal, serum CEA levels, serum
cytokine levels, extramural venous invasion and vascular invasion into submucosa.
However, they are not a part of an objective prognostic tool such as TNM staging. AJCC
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also recommends collection of eight parameters due to their prognostic significance (30).
These are pre-operative serum CEA level, number of tumor depo sits detached from
primary tumor , tumor regression grade following neoadjuvant therapy to assess response
to therap y (grades 0-3, grade 0 indic ates total respon se to therap y and grade 3 indic ates
worst respon se), CRM measured from the tumor bound ary to the closest margin of
surgical removal , MSI status in tumor cells , perineural invasion (i.e invasion around local
nerves by tumor cells) , mutation status in codons 12 or 13 of KRAS gene in tumor cells,
especially in advanced stage patients since mutation s in these codons are strongly
correlated with absence of response to monocl onal antibodie s directed against epidermal
growth factor receptor (EGFR) and 18q LOH status in tumor cells. Although these factor s
are not currently a part of a clinical progno stication system such as the TNM staging
system, further studies may lead to their incorporation in future editions (30). Hence, the
collecti on of data on these factors in patholo gy reports is strongly recommend ed by
AlCC . Apart from these molecul ar and pathological factors, demographic factors such as
gender, age and ethni city may also play a strong role in the variable prognosis in
colorect al cancer patient s (30) . For this thesis project, we used data on ten dem ographi c,
clinico -path ological and molecular variables for analysis.
1.5.2 Clinicopathologica l and molecular variables included in this thesis project
Ten demographic, clinico-pathological and molecu lar variables included for analysis in
this thesis project are briefly described below . The data on these variables were ava ilable
to us and many of them have been acknowledged by Al CC to have possible pro gnostic
role s in colorect al cancer (30). These variables were included in the study to test their
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association with patient survival in our cohorts and for adjustment in the multivariate
analyses to account for their effects in the model.
a) Stage : Stage is the only well-established and routinely used prognostic factor in
colorectal cancer patients. The generally observed trend is that patient prognosis
worsens with increasing disease stage (30).
b) Tumor grade: Based on the apparent differentiation of tumor cells, four tumor
grades have been defined: GI for a well differentiated tumor to G4 for a virtually
undifferentiated tumor (30). The AlCC (30) as well as CAP consensus statement (31)
recommend a two-tiered classification with low grade (GI and G2) and high grade
(G3 and G4) colorectal tumors. In this project, we have classified patients according
to this two-tiered system for analyses. Low grade tumors generally have a low cell
proliferation rate and metastatic potential while high grade tumors have a high cell
proliferation rate and metastatic potential (32) which has been demonstrated to have a
stage-independent adverse prognostic correlation in multiple studies (24). However,
since grading is a subjective criterion, designation of a tumor grade varies from one
observer to another (31). Due to lack of a widely accepted grading protocol, accurate
use of tumor grade in prognostication is difficult and hence limited (24,31).
c) Vascular/lymphatic inva sion : Presence of vascular or lymphatic invasion has been
documented to be associated with unfavorable prognosis (24,30,31) and is routinely
included in pathology reports. AlCC recommends inclusion of this information as a
part of V and L staging classification (30). However, its objective use as a prognostic
marker is limited by several factors. CAP recommends examination in at least 3
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tumor blocks (ideally 5 tumor blocks) to conclusively establish presence or absence
of invasion (31). This makes the process cumbersome , time-consuming and costly.
Moreover, there is no standard protocol for assessing invasion adding undesirable
inter-observer variability to the judgement , especially in cases of small and large
vessel invasions (24). Due to these reasons, vascular/lymphatic invasion data are not
included in an objective prognostication system. In this study, we have included
vascular/lymphatic invasion as an exploratory variable in our analyses.
d) Tumor histology: After non-mucinous adenocarcinoma , mucinous adenocarcinoma
is the next most common histological type of colorectal cancer (21-23). The
prognostic significance of mucinous tumor type is undecided due to several
conflicting reports (24,31).
e) MSI stat us: Mismatch repair proteins are responsible for correcting wrongly inserted
nucleotide bases after DNA replication . Defects in mismatch-repair proteins (MLHI ,
MSH2, MSH6, PMS2) due to germline mutations can lead to increase or decrease in
length of microsatellites which are repeating units of nucleotides , (commonly
dinucleotides of cytosine and adenine (CA)), present in thousands of locations in the
genome (9). This is termed "rnicrosatellite instability" (MSI) (9). In a large meta-
analysis conducted by Popat et al (33) including over 7,500 patients from 32 different
studies, it was shown that patients with MSI-high (MSI-H) status have a significantly
longer survival when compared with patients with microsatellite stable (MSS) or
MSI-Iow (MSI-L). The i h edition of AlCC cancer staging manual published in 2010
recommends the collection of MSI-status of patients for prognostic purposes (30).
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Tumor location: Literature reports have consistently suggested that patients with
rectal cancers have a worse survival compared to patients with colon cancer (34).
However, tumor location is not clinically used as a prognostic factor nor is it
considered in the guidelines and recommendation s by CAP and AlCC.
g) Familial ri sk status: Familial risk status was assigned to the patients in the
Newfoundland Colorectal Cancer Registry (NFCCR) previously as described by
Green et al (35). Literature reports on association of familial risk status with
prognosis are deficient. Therefore its role in prognosis of patients is not known.
h) BRAFl_Val600Glu mutation status: v-rafmurine sarcoma viral oncogene homolog
BI (BRAFl) is a proto-oncogene and is a part of a signal transduction pathway
(Ras/Raf/MEKIMA P pathway) (36). Activation of this pathway leads to cell
proliferation. The somatic Val600Glu mis-sense mutation in BRAFl makes it
oncogenic . As a result, the gene is continuously activated which causes cell
proliferation and inhibited apoptosis (36). The correlation of this mutation with
unfavorable prognosis has also emerged in the literature (37-39). For patients in
NFCCR, the data on this mutation in tumor samples was collected for a previous
study by Wish et al (40).
Age: It is acknowledged by AlC C that age may play a strong role in prognosis in
colorectal cancer patients (30) although it is not a part of a clinical prognostication
system yet. Since OS is our primary end-point for analysis, age may be a significant
factor since the chances of survival are expected to be reduced with increasing age.
j ) Sex: Gender is also acknowledged by AlCC to play an important role in variable
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prognoses in colorectal cancer patients (30) although further studies are required
before it can be objectively used for prognostication .
1.5.3 Surv ival end-points anal yzed in this th esis proj ect
Two end-points were analyzed in this thesis project. The primary end-point was as for
which as status and as time are required for analysis. as was our primary end-point
since the selected 27 genetic polymorphisms for analysis in this study were associated
with as in at least one study in the literature. The secondary end-point was DFS for
which DFS status and DFS time are required for analysis.
a) OS status: It indicates if the patient was alive or dead at the time of last follow up.
The death of the patient could be due to any cause.
b) OS time : It is the time in years from diagnosis of colorecta l cancer until death from
any cause
c) DFS status: It indicates if the patient had recurrence of cancer, metastasis or died
from any cause during the follow-up period. In the discovery cohort, recurrence and
metastasis were identified using the information from the response to follow-up
questionnaires and pathology reports. In the validation cohort, recurrence and
metastasis were identified from surgical reports, pathological reports, imaging data
and cancer clinic charts.
d) DFS time: It is the time in years from diagnosis of colorectal cancer until the first
occurrence of the event (recurrence, metastasis or death).
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1.6 Genetic variations and genetic prognostic research
Genetic variations can range from large scale structural or numerical karyotypic
abnormalities affecting entire chromosomes to changes in single nucleotides (41).
Chromosomal aberrations can be either structural where chromosomes have unrepaired or
mis-repaired breaks; or numerical where there are more or less than the normal number of
chromosomes causing polyploidy or aneuploidy (42). Single Nucleotide Polymorphisms
(SNPs) are alterations in a single base in the DNA sequence and it is estimated that there
are more than 10 million SNPs in the human genome (43). SNPs can occur within a gene
and may alter a coding sequence. A SNP is silent when the substitution in the codon does
not change the encoded amino acid, missense when the substituted codon encodes a
different amino acid, or nonsense when it creates a stop codon producing truncated
protein. SNPs can also occur in the untranslated regions (UTRs), in promoter regions or
in splice sites (42). Copy number variations (CNVs) are variations in number of large
segments of the DNA arising due to deletion or duplication events, and range from I
kilobase to several megabases (42). CNVs may include a gene(s) or its parts. Insertion-
deletion (indel) polymorphisms involve insertion or deletion of one or few nucleotides to
large number of nucleotides in the DNA sequence. Inversion is another type of
polymorphism where a sequence is present in an inverted manner in the DNA (42).
Genetic variations can be either germline or somatic. Somatic variations are tissue
specific and non-inheritable. An example is the Val600Glu missense mutation in the
BRAFl gene in tumor cells, such as in colorectal cancer (see section 1.5.2). Germline
variations are inherited variations and occur in all cell types (44).
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A large number of studies have been conducted in the past decade to find polymorphisms
associated with prognosis in colorectal cancer. Currently , the identified polymorphisms
are not used in the clinical setting as further studies in the field are required (44).
Recently, the commercial Oncotype DX® Colon Cancer Assay was developed by
Webber and colleagues using tumor gene expression data for 12-genes in stage-II patients
to predict risk of recurrence (45). On similar lines, ColoPrint® prognostic index was
developed by Salazar and others and validated using gene expression profiles of 18 genes
in colorectal tumor samples (46). If prognostic relevance of a germline variation is
established, similar prognostic indices using germline variations may be valuable since
germline DNA can easily be obtained from blood.
Of the large number of common germline polymorphisms investigated for their
prognostic relevance, the 27 polymorphisms which are a part of this thesis project are
discussed in the following section (section 1.7). The selection of these polymorphisms is
described in section 3.1 and the literature findings described below are based on the
curations posted in the dbCPCO database as of late 2011 (47). These studies are not
entirely homogenous in terms of study design, cohort characteristics , treatment regimen
and statistical analyses. Hence, it is not surprising to find that several results reported in
different studies are conflicting. In addition, study power issues and potential
confounders not accounted for in different studies can yield different results .
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1.7 Genetic polymorphisms investigat ed in this study and pr evious
literature finding s in colorectal canc er cohorts
I ) rs9344, NG_ 007375. I:g .12038G>A, Pr o241 P ro A1G syno ny mous polym orphism
in cyelin DI (CCNDl) gene. The activity of CCND! protein is required for transition
of the cell cycle from growth I (GI) phase to the synthesis (S) phase (48). The G
allele for this synonymous polymorphism, located in the splice donor site following
exon 4, prod uces an isoform of CCNDI messenger ribon ucleic acid (mRNA) by
facilitating alternative splicing (49). In one study , young male patients from
Singapo re with GG genotype for this polymorphism had shorter cancer -specific
surviva l following surgery in univariate surviva l analysis (50). In another study,
advanced colorectal cancer patients with AA genotype (from a mixed population)
treated with the monoclonal antibody cetuximab had poorer OS in univariate survival
analysis when compared to patients with GA or GG genotypes (51). Thus the two
results were not entire comparable, possibly due to different treatment characteristics
and outcomes analyzed. In four other studies , no correlation was observed between
this polymorphism and OS in colorectal cancer (52-55).
2) rs2229080 , NG_ 013341.1: g.57106IC> G, Arg 20 lG ly C/G mis-sen se
polymorphism in the deleted in colore cta l carcinoma (DCC) gene. DCC is a tumor
suppressor gene (56) . Schmitt et al (57) reported that the G allele (Gly) of this
polymorp hism was associated with lowered expression of the DCC gene. In a
Swedis h cohort , colorectal cancer patients homozygous for the C alle le (Arg/Arg)
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were reported to have better OS when compared to patient s having C/G (Arg/Gly) or
G/G (Gly/Gly) genotypes in univariate analysis (58), but multi variate analysis was
not performed in this stud y. In another study in an Asian cohort , no correlati on was
observed with OS in colore ctal cancer in univariate analysis (55).
3) rs2227983 , NG_ 007726.1:g.147531G>A, Arg 521Lys G/A in th e epide r ma l
growth fact or r ecept or (EGFR) gene. EGFR is a transmembrane protein which
upon binding to the EGF, initiates a signaling cascade which leads to cell
prolifera tion (59). Functional charac terization of EGFR_Arg52ILys polymorphism
performed in Chinese hamster ovary cells is suggestive of impaired ligand bindin g to
extracellular domain of EGFR and the reduced abilit y of EGFR to induce cell growth
(60). Patien ts with metastatic colorectal cancer with an allele encoding lysine amin o
acid (Al A or G/A genot ypes ) were reported to have better progre ssion -free surv ival
(PFS) and OS in a French cohort (univariate analysis) (6 1), favorable OS in cohort of
male patien ts from mixed population (univariate analysis) (62), and better OS in an
Asian cohort (multivariate anal ysis) (63). Thus all these studies reported favorable
survival in the presence of the allele encodin g lysine. In five other studies, no
association was observed between this polymorphi sm and OS in colorectal cancer
(51 ,52,64-66 ).
4) rs11615 , NG_ 015839.1:g.8525T>C, Asn118 Asn CIT synonymous polymorphism
in excision repair cro ss-complementing rodent repair deficien cy,
complement ati on gro up 1 (ERCCl) gene. ERCC I repair s the abnormal lesions in
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the DNA by nucleotide excisio n repair (67). The presence ofT allele in Asn l 18Asn is
associated with reduced gene expression by altering codon usage (68). Previously, T
allele (CT and IT genotypes) was correl ated with worse OS in Asian cohorts in
multivariate (69) and univariate analysis (70,71) and IT genotype was correlated with
worse PFS in an Italian cohort in univariate analysis (72). In mixed population
cohorts, similar correlations were reported; i.e. patients with CC genotypes had better
OS in univariate (73) as well as in multivariate analysis (74). A contradi ctory result
was reported in a Spanish cohort (75) where the C allele (CC and CT genotypes) was
correlated with worse OS in multivariate analysis. In three other similar studies, no
association was observed between rsl1615 and OS in colorectal cancer (76-78).
5) rs13181, NG_007067.2:g.23927A>C, Lys751GIn Gff in ERCC2 gene. ERCC2
protein is involved in DNA repair machinery by nucleotide excis ion repair (79). Cells
expressing Lys variant have inefficient DNA repair and abnormalities in chromatids,
such as breaks in the DNA strand or damaged unrepaired bases (80). Poor OS in
colorectal cancer patient s (mixed population) carrying T allele (GIn/Gin and Lys/Gln)
was previously found using univariate analysis (74,81). The genotypes for Lys/Lys
and Gln/Lys werealso associated with poor PFS compared to patients with genotype
for GIn/GIn in the Italian cohort treated with 5-fluorouracil (5-FU), leucovorin and
oxaliplatin in multivariat e analysis (72). However , in a Chinese patient cohort, also
treated with 5-FU, leucovorin and oxalipl atin, homozygotes for lysine (Lys/Lys) had
better OS and PFS comp ared to heterozygotes in multivariate analysis, presumably
due to enhanced efficacy of oxaliplatin in patients with poor DNA repair function of
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ERCC2 (due to Lys75 lG ln) (82). Also, in a Turkish cohort of metastatic colorectal
cancer patients, GIn/Gin homozygotes had a shorter OS compared to Lys/Lys
homozygotes (83). Six other studies reported no significant correlation between this
polymorphism and OS in colorectal cancer (71,75,76,78,84,85).
6) rsl047768, NG_007146.1:g.11344T>C, His46His CIT in ERCC5 gene. ERCC5 is
also a DNA repair protein functioning in the nucleotide excision repair pathway (86).
The functional impact of this synonymous polymorphism is not clearly established
yet. Earlier, patients with the CC genotype for this synonymous polymorphism were
reported to have a better OS in univariate analysis (84) and PFS in multivariate
analysis (87) while one study reported no statistically significant correlation with OS
in colorectal cancer (75).
7) rs9350, NC_OOOOOl.lO:g.242048674C>T, Pro757Leu CIT in exonuclea se 1
(EXOI) gene. EXO I has a 5' .....3' double stranded DNA exonuclease activity and
functions in the DNA mis-match repair mechanism to remove the mis-matched DNA
bases (88). The functional impact of this polymorphism is yet to be established . In a
Japanese cohort, the patients with the Leu/Leu genotype were found to have worse
OS relative to other genotypes in univariate analysis (55).
8) rs1800682, NG_011541.1:g.6185T>C, c-24+733T>C in Fas (TNF receptor
superfamily, member 6) (FAS) gene. FAS is a cell membrane receptor and has a
fundamental role in inducing cell death (apoptosis) upon binding to its ligand (89).
The functional impact of this polymorphism has not been conclusively established.
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Previously, patients with CC genotype were reported to have significantly worse OS
in univariate analysis when compared to patients with IT or TC genotypes in a study
by Hofmann and others (90).
9) rs3S18SS, NG_012067.1:g.11323G>A, Gly388Arg AlG in fibroblast growth
factor receptor 4 (FGFR4) gene. The receptors belonging to FGFR family activate a
cascade of signals which induce cell division and differentiation but the exact
function of this particular member of the family is currently unknown (91). In a study
using breast cancer cells, the cells having an allele for Arg (GG or AG genotypes)
were reported to have greater motility in vitro and potential for progression (92). The
same study also reported univariate analysis results where colorectal cancer patients
having the FGFR4 with Arg variant had a significantly worse OS compared to
homozygotes for Gly in the early months after diagnosis (92). One study reported no
correlation of this polymorphism with OS in colorectal cancer (93).
10) Glutathione S-t ransferase mu-l (GSTMl) gene deletion . The primary function of
GSTM I enzyme is to detoxify the electrophilic xenobiotics including drugs by
conjugating them with glutathione (94). A homozygous deletion of the gene would
cause a total loss of enzyme. In one study published by Csejtei et al. (95), Hungarian
Dukes' stage B colorectal cancer patients with homozygous deletion of GSTMl gene
had significantly poorer OS in univariate analysis when compared to patients with at
least one copy of the gene. Five other studies reported no significant correlation of
GSTMl gene deletion with OS in colorectal cancer (74,77,78,96,97).
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11) rs169S, NG_01207 S.1:g.6624A>G, I1elOSVal AJG in glutathione S-transferase pi
1 (GSTPl) gene. GSTPI enzyme, like other members of the GST family of enzymes,
is also involved in metaboli sm of xenobiotics (98). The GSTPI enzyme with the
valine residue at amino acid position 105 has been reported to have a reduced activity
(99). In a Dutch cohort of colorectal cancer patient s, patients with the valine variant
(lleNal+VaINal) treated with capecitabine and irinotecan were found to have better
PFS than patients with lle/Ile genotype in multivariate analysis, likely because of
reduced metabolism of irinotecan by GSTPI due to this polymorphi sm, as authors
suggested (100) . A similar result was observed in a mixed population cohort of
metastatic colorectal cancer patients treated with 5-FU and oxaliplatin where carr iers
ofan allele for valine (lieNal and ValNal) had significantly better OS than the lle/Ile
homozygotes in univariate analysis (101). A similar association with favorable OS in
univariate analysis and favorable PFS in multivariate analysis was found in another
study of Caucasian patient s (102) . In addition , in two studies with Chinese subjects,
patients homozygotes for the allele coding for valine were detected to have better OS
(univariate analysis) (103) and the carriers of the same allele were detected to have
favorable PFS (univariate analysis) and OS (multivariate analysis) (104). Contrary to
these reports, the carrier s of the valine variant were reported to have a worse OS in a
Swedish-Cauca sian colorectal cancer patient cohort in multivariat e analysis (105) and
homozygo sity for valine was correlated with poor PFS in univariate analysis in a
Korean colorectal cancer patient cohort (106). Also, six studies reported no
significant correlation of this polymorphism with OS in colorectal
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(71,76,77,96,97,107).
12)Glutathione S-transferase theta-l (GSTTl) gene deletion. GSTT I enzyme
metabolizes the electrophilic and hydrophobic xenobiotics by conjugating them with
glutathione (108). Homozygous deletion of this gene results in loss of enzyme. In an
age-stratified analysis, Rajagopal et al. (109) reported that young colorectal cancer
patients with the homozygous deletion of this gene have a significantly favorable OS
in univariate analyses while older patients with the gene deletion have poorer OS.
Four other studies reported no significant association of GSITI gene deletion with
OS in colorectal cancer (74,78,95,101).
13) rs1800795 , NG_011640.1:g.4880C>G, -174G/C in promoter in interleukin 6
(interferon, beta 2) (IL6) gene. IL6 is a cytokine and is involved in a wide range of
inflammatory responses (110). In vitro analysis of this polymorphism performed
using the HeLa cells has shown that the C allele reduced the gene expression (111). In
one study of a Swedish colorectal cancer patient cohort, patients with the CC
genotype showed better OS compared to heterozygotes after univariate analysis
(112).
14) rs1799977, NG_007109.1:g.23590A>G, I1e291Val AlG in mutL homolog 1, colon
cancer, non polyposis type 2 (E. coli) (MLHl) gene. MLH1 protein plays a role in
the MMR machinery which repairs the mis-matched bases in the DNA (1 13). The
definite functional impact of this polymorphism is not known. The GG and AG
genotypes were reported to be correlated with a favorable OS in multivariate analys is
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in a Spanish cohort of sporadic colorectal cancer patients (114). In another large study
of Caucasian colorectal cancer patients, no association was observed between this
polymorphism and OS in colorectal cancer (115).
IS)rsI7997S0 , NG_01l 740.I :g.3471deIG, -1607 indel G in promoter of matrix
metallopeptidase 1 (inters titial collagen ase) (MMPl) gene. This protein belongs to
the MMP family of enzymes . The primary function of these enzymes is to catalyze
the breakdown of the extracellular matrix during events like embryonic development,
tissue remodeling and reproduction and MMP I particularly breaks down interstitial
collagen types I, II and III (116). They are also found to playa role in diseases such
as arthritis and metastasis of cancer cells (116). Functionally, insertion of G (insG)
has been reported to enhance the transcription of MMP1 gene by facilitating an extra
binding site for the transcription factor v-ets erythroblas tosis virus E26 oncogene
homolog I (avian) (117). In a study conducted in colorectal cancer patients from
Australia, patients homozygous for insG had significantly better OS compared to
other genotypes (insG/insG vs insG/deIG+delG/deIG) in a multivariate analysis
(118). In a contradictory report, patients in a French study homozygous for insG
(insG/insG) had significantly worse cancer-specific survival, OS and DFS in
multivariate analysis when compared to the deletion homozygotes (deIG/deIG) (119).
16) rs24386S, NG_008989.I :g.3726C>T, -1306 crr in promoter region of matrix
metallopeptidase 2 (gelatinase A, 72kDa geiatinase, 72kDa type IV collagena se)
(MMP2) gene. MMP2 is involved in the degradation of type IV collagen found in the
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basement membranes, regulates inflammatory response and vascularization and is
involved in endometrial breakdown (120). For this polymorphism, the presence ofT
allele has been reported to abolish an SPI binding site in the promoter of MMPl
lowering its gene expression (121). A Dutch study of 215 colorectal cancer patients
previously showed that the C allele (CC and CT genotypes) was associated with
favorable OS in multivariate analyses (122). In another study by Hettiaratchi et al
(118), no correlation for this polymorphism was observed with OS in colorecta l
17)rs1801133, NG_013351.1:g .14783C>T , Ala222 Val crr missense polymorphism
in meth ylene tetrahydrofolate reductase (NAD(P)H) (M THFR) gene. The role of
this enzyme is the conversion of 5, IO-methylenetetrahydrofolate (5, IO-MTHF) to 5-
methyltetrahydrofolate (5-MTHF) (123). 5-MTHF acts as a co-substrate in synthesis
of methionine from homocysteine (123). For this polymorphism, studies have
reported that presence of T allele (CT or IT genotypes) is associated with reduced
amount ofMTHFR enzyme (124) and reduced enzymatic activity (125). In one study,
Caucasian colorecta l cancer patients homozygous for C allele had better OS and
cancer specific survival in multivariate analysis (124). A similar association was
observed in stage III patients in a Swedish cohort (multivariate analys is) (126).
However, in a Mexican cohort of colorectal cancer patients, a conflicting result was
obtained where patients homozygous for the C allele had a significantly worse OS in
univariate analysis (127). Nine other studies reported no significant correlation of this
polymorphism with OS in colorectal cancer (55,128-135).
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18)rsI801131 , NG_0133Sl.1 :g.1668SA>C, Glu429Ala AlC missense polymorphism
in MTHFR gene. The C allele for this polymorphism is reported to reduce the
activity of MTHFR enzyme (136). In metastatic colorectal cancer patients from a
mixed population, a sex-specific association was observed where females
homozygous for A allele had a favorable OS relative to other genotypes in univariate
analysis (133). Similar association was also observed in a Spanish colorectal cancer
patient cohort where patients homozygous for A allele showed favorable OS in the
multivariate analysis (137). In six other studies, no correlation was observed between
rs l 801131 and OS in colorectal cancer (76,78,128,130,134,135).
19) rsl0S2133, NG_012106.1:g.121 46C>G, Ser326Cys C/G in 8-oxoguanine DNA
glycosylase (OGGI) gene. OGG I enzyme excises the abnormal 8-oxoguanine base
formed due to exposure of guanine to reactive oxygen (138). OGGI enzyme with
cysteine at amino acid position 326 instead of serine has been reported to have a
reduced DNA-binding ability and reduced ability to repair damaged DNA (139). A
correlation of this polymorphism was observed with both OS and PFS in univariate
analysis in a Dutch cohort treated with capecitabine and oxaliplatin (140). However,
whether the prognosis was favorable or worse was not described by these authors. In
another study, no significant correlation was observed between rs l052 133 and OS
(75).
20) rs4648298, NC_000001.10:g.186641682T>C, c.3618A1G in 3'- UTR of
pro staglandin-endoperoxide synthase 2 (prostaglandin GIH synthase and
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cyclooxygenase) (PTGS2) gene. PTGS2 is an essential enzyme in prostaglandin
synthesis during inflammatory responses (141). The functional consequence of this
polymorphism is currently unknown. Previously, in a Spanish colorectal cancer
patient cohort, the G allele was correlated with a favorable OS in multivariate
analysis (142).
21) rs1799889, NG_013213.I :g.4332_4333in sA, -675 indel 4G/5G in promoter of
ser pin peptidase inhibitor, clade E (nexin, plasminogen acti vator inhibitor type
I), member 1 (SERPINEl) gene. This protein inhibits fibrinolysis by inhibiting
tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) (high
amounts of this protein are associated with formation of blood clots) (143). In a study
which assessed the functional impact of this polymorphism, the insertion allele (insG)
was linked to lower transcriptional activity (144). In a Swedish cohort, in univariate
analysis in Dukes' stage Al B colorectal cancer patients, the patients with insG/insG
genotype were detected to have better OS compared to patients with delG/delG or
delG/insG genotypes (145).
22) rs34743033, NC_000018.9:g.657730(28 base pairs (bp»2/3/4, 2/3 repeats of 28bp
in 5'- UTR in thymid ylate synthetase (TYMS) gene. TYMS enzyme, together with
5, IO-MTHF, converts deoxyuridylate to deoxythymidylate which is used for DNA
replication and repair. The drug 5-FU exerts its anti-neoplastic effect primarily by
inhibiting this enzyme (146). There is a variable number of tandem repeat (VNTR) of
28 bp sequence in 5' -UTR of TYMSgene. Reportedly, the three repeat allele (3R) has
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an enhanced transl ational efficiency (147). In a Hungarian study, color ectal cance r
patient s hom ozygous for the 2-repeats (2R) allele had a worse OS comp ared to
patients with 3R allele in univariate anal ysis (148 ). Similarly, in another mult i-center
study with patient s from acros s Europe and Austra lia, patient s treated with the dru gs
pemetre xedlirinotecan and hom ozygou s for 3R showe d a significantly favorable PFS
in multi variate analysis (149 ). However , in another study with patient s treated with 5-
FU, leucovor in and oxa liplatin, those with 2R homo zygotes and heterozygotes
(2R/3R) had a favorabl e PFS in multivariate anal ysis (78). In a Dutch cohort , it was
reported that patient s younger than 60 year s and homoz ygous for 2R had a favor able
OS in univariate analysi s (150 ). In a Spanish cohort of rectal cancer patien ts, 3R
homoz ygote s showed favorable PFS and OS followin g multi vari ate analysis ( 151).
Contradictorily, stage III colorectal cancer patient s from Asia homozygous for 3R
were found to have worse OS in univari ate analysis (152) . In at least 2 1 other studies ,
no corre lation was observe d for this polymorphism with OS in co lorecta l cancer
(7 1,74,76-78, I04,129,130,135 ,153-164).
23) rs16430, NC_000018.9:g.673 444deITinsTTAAAG, ind el 6 bp in 3 ' -UTR of TYMS
gene. In an in vitro study using the human embryo nic kidne y cell line , the allele with
deletion of the 6 bp sequence was linked to lowered stability of TYMS mRN A (165).
The same study reported reduced gene expre ssion in the presence of 6 bp deletion in
tumor cells obtained from metastatic colorectal cancer patients. In a Spanish
colorectal cancer patient cohort treated with 5-FU based chemotherapy regimen, it
was observed that patient s with homoz ygous deletion of 6 bp had favorable OS in the
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multivariate analysis (155). On the contrary, in a French cohort, patients homozygous
for the 6 bp insertion had favorable as compared to heterozygotes after univariate
analysis (157). At least thirteen other studies did not find an association between
rs l6430 and as in colorectal cancer (74,76,78,130,135,148,151,153,154,162-
164,166).
24) rs2010963, NG_008732.1:g.5398C>G, -634G/C polymorphism in 5'- UTR in
vascular endothelial growth factor A (VEGFA) gene. The VEGFA protein targets
endothelial cells and induces angiogenesis, increased vascular permeability, cell
migration and inhibition of apoptosis (167). In a Greek study to understand the
functional impact of polymorphisms in VEGFA gene, tumors from patients with non-
small cell lung cancer were used. This study reported that tumor cells homozygous
for the G allele had low VEGFA expression level as well as low tumor vascularization
(168). In another Greek cohort of colorecta l cancer patients, those patients with the
genotype CC of this polymorphism had a significantly worse as relative to those
with GG genotype in multivariate analysis (169). No association with as in
colorectal cancer was observed in three other studies (170-172).
25)rs3025039, NG_008732.1:g.19584C>T, +936C IT polymorphism in 3'- UTR in
VEGFA gene. A study conducted in healthy post-menopausal women from Austria
showed that homozygotes for the C allele had higher levels of plasma VEGF protein
levels than those carrying the T allele (CT+TT combined) (173). In a study
investigating Greek colorectal cancer patients, it was reported that patients
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homozygous for the T allele had worse OS compared to homozygotes for C allele
(169). Three other studies did not find a significant correlation between rs3025039
and OS in colorectal cancer (51,171,172).
26) rs25487, NC_000018.9:g.44055726T>C, Arg399Gln G/A in X-ray repair
complementing defecti ve repai r in Chin ese ham ster cells I (XRCC1) gene.
XRCC I protein repairs single strand breaks in the DNA caused by alkylating agents
and ionizing radations via base excision repair mechanism (174). Wang et al (175)
reported that cells homozygous for A allele (Oln/Oln) had a relatively greater number
of breaks in the chromosome per cell than other genotypes, indicative of an impaired
function of XRCCl gene. In a Spanish cohort, patients homozygous for the A allele
(OIn/G1n) had a significantly favorable OS after univariate analysis (75). However,
contradictory associations were observed in Korean, Chinese and Turkish cohorts
after univariate analysis: in their analyses, patients homozygous for the A allele
(OIn/G1n) showed worse OS compared to homozygotes for 0 allele (71,83,131). In
six other reports, this polymorphism was not associated with OS in colorectal cancer
(74,76,77,176-178).
27) rs861539, NG_OII 516.1:g.21071C>T, Thr241 Met CIT in XR CC3 gene. XRCC3 is
involved in the homologous recombination, maintenance of the stability of
chromosome as well as DNA damage repair (179). Cells expressing XRCC3 protein
with the methionine variant have been reported to have a defective DNA repair
mechanism leading to abnormalities in chromosomal structure (180). The allele
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coding for the amino acid methionine was correlated with significantly favorable
prognosis after univariate analysis in a Spanish cohort of colorectal cancer patients
(75). In another study by Grimminger et al (178), a statistically significant correlation
between this polymorphism and OS in colorectal cancer was not observed.
Evident from the literature , for a given polymorphism, conflicting results in relation to
prognosis do exist. This is in fact a common observation. The cohorts described in these
studies may be heterogenous in terms of size, patient characteristics (ethnicity, age,
stage), study design, treatment regimen as well as the definition of endpoints and
statistical approaches, and different results for same polymorphisms may be obtained due
to these differences (181,182). In addition, it is possible that the associations reported
might be false positives or false negatives . Hence before genetic markers can find
application into clinical patient management, large and well designed studies in
homogenous patient cohorts are requ ired to validate the correlations of genetic markers
with outcome (183).
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Chapter 2. Thesis project
2.1 Research Objectives
This thesis project has two main objectives:
I) To test the associations of 27 genetic variations with prognosis using a large
cohort of colorectal cancer patients from Newfoundland (the discovery set). These
polymorphisms were previously reported to be associated with prognosis in
colorectal cancer.
2) To replicate the findings obtained in the discovery cohort in an independent
colorectal cancer cohort from Newfoundland (the validation set).
To achieve these objectives, genotypes for the 27 genetic variations were first obtained in
the discovery set. These data were analyzed together with the clinicopathological,
molecular and prognostic data of the patients using statistical analyses. The variables
which were found to be correlated with survival in the discovery set were then chosen for
replication in the validation set.
2.2 Hypothesis
Many genetic polymorphisms have been reported to be correlated with measures of
prognosis such as OS and DFS in colorectal cancer patient cohorts from around the world
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(see section 1.7). We have selected a total of 27 such polymorphisms and hypothesized
that these polymorphisms are also correlated with prognosis in colorectal cancer patients
from Newfound land. After this first phase of the study, we also hypothesized that the
significant correlations detected can also be replicated in an additional cohort of
colorectal cancer patients from Newfoundland.
2.3 Patient cohorts
We investigated two independent cohorts of colorectal cancer patients from
Newfoundland in our study.
The discovery set includes colorectal cancer patients from the NFCCR who were
diagnosed over a period of 5 years from January I 999-December 2003 (35). Patients age
under 75 years at diagnosis , with colorectal cancer confirmed pathologically, with
available tumor tissue and informed consent obtained from either the patient or the next-
of-kin (proxies) were included in the registry (35). Patients with familial colorectal
cancer syndromes were also included in this registry. Patients having recurrent cancer,
showing presence of carcinoma in situ (stage 0 colorectal cancer) and carcinoid tumor
were excluded from the registry and/or analysis (35). Out of a total of 1983 colorectal
cancer cases diagnosed with colorectal cancer in Newfoundland in the 5-year recruitment
period, over 730 patients meeting these criteria were included in NFCCR (35). Molecular
and genetic characteristics of this cohort have been described in detail by Woods et al
(184). Out of these 730, DNA and prognostic data were available for 537 patients. Four
52
patients having stage 0 colon cancer (carcinoma in-situ) were excluded from analysis .
Two of the patients belonged to the same family and one was excluded randoml y to have
the cohort consisting of unrelated individuals. Thus in the end, 532 patients from NFCC R
were included in the discovery set. Patients' clinical and vital status data was collected
until April 2010 . Their baseline characteristics are shown in Ta ble 2.
In the discover y set, the median age of diagnosis is 61.4 years and the median follow-up
time is 6.4 years. Females, stage IV patients , patients with mucinous tumor histology,
lymphatic and vascular invasion, rectal cancer, and poorly differentiated tumor grade are
each present in a minority of the cohort. The cohort also has a low proportion of patients
with tumors having MSI-H status (10.50%) and BRAFl Val600Glu mutation (9.20%).
One-third of the patient s (33.3%) died durin g the follow up. The age-adju sted surviva l
curve of the discovery cohort is depicted in Fig ure 4. The median survival time of the
patient s in the discovery cohort is - 9.5 years and the 5-year survival rate is - 79%. The
median survival time of the entire NFCC R cohort is - 7 years and the 5-year survival rate
is - 62% (see Fig.AI in appendix). The percentage of stage IV patients in the discovery
cohort is low (9.80%) and this can account for the high survival characteristics of this
cohort. In fact, the entire NFCCR cohort has a higher proportion of stage IV patients
(20.9%) when compared to patients included in this study (9.80%), and this difference is
statisticall y significant (p<O.OOI). This may be because of the fact that the termin ally-ill
stage IV patients are more likely to have died before their blood samples were collected,
indicating a select ion bias in our study. The discovery cohort is thus biased toward early
stage colorecta l cancer patient s and is not representative of the entire NFCCR cohort.
53
Table 2. Baseline characteristics of 532 patients in the discovery set
Variable Number of patients 0/0
Sex
male 327 61.50%
female 205 38.50%
Median age 61.36 years (20.7-75)
Histology
non-mucinous 471 88.50%
mucinous 61 11.50%
Location
colon 353 66.40%
rectum 179 33.60%
Stage
I 99 18.60%
II 206 38.70%
III 175 32.90%
IV 52 9.80%
Grade
well diff/moderately diff 489 91.90%
poorly diff/undiff 39 7.30%
unknown 4 0.80%
Vascular invasion
326 61.30%
+ 166 31.20%
unknown 40 7.50%
Lymphatic invasion
315 59.20%
+ 174 32.70%
unknown 43 8.10%
OS status
dead 177 33.30%
alive 354 66.60%
unknown 1 0.10%
Median OS follow-up time (ra nge) 6.36 vears(0.3 8-1O.88)
DFS statu s
event 208 39.10%
no event 323 60.71%
unknown 1 0.19%
Median DFS follow-up time (r ange) 6 years (0.22-10.88)
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Familial risk
low 256 48.10%
high/intermediate 276 51.90%
MSI Status
MS1-H 56 10.50%
MSI-LlMSS 455 85.50%
unknown 21 4%
BRAFl mutation status
+ 49 9.20%
435 81.80%
unknown 48 9%
Ethnicity
Caucasian 486 91.35%
non-Caucasian 12 2.26%
unknown 34 6.39%
Treatment
5-FU based 330 62.03%
other/no chemotherapy 199 37.41%
unknown 3 0.56%
diff: differentiated,MS I: microsatelliteinstability,5 -FU:5 -fluorouracil,e thnicity is based on the ethnicitie s
of all four grandparents of the patients as reported by the patients.
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Figure 4. Age-adjuste d survival curve of discovery cohort
Median survival time is -9.5 years
5-yearsurviv alra tei s - 79%
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The validation set: The discovery set was used to validate, in the Newfoundl and
population, the genetic polymorphisms correlated with outcome in other populations. To
confirm the validity of the significant correlations detected in the discovery set, we also
studied a second Newfoundland colorectal cancer cohort. All patients in this validation
set were from Avalon Peninsula of Newfoundland and were diagnosed with primary
colorectal cancer between January I, 1997 and December 31, 1998. An eligibility
criterion was presence of carcinoma in the polyp with invasion into the stalk. On the
contrary to NFCCR, the age of diagnosis was not a criterion for inclusion. Exclusion
criteria were recurrence of an earlier colorectal cancer, secondary colorectal cancer which
is due to metastasis from a primary cancer elsewhere in the body, carcinoma in situ,
mucosal carcinoma or carcinoid tumors and patients with FAP. Currently, the data and
the biological specimen of these patients are preserved at the NFCCR. Although consent
was not obtained from the patients or their proxies, collection of patient data, and the use
of these data and biospecimen for research purposes were approved by the Regional
Health Boards and Human Investigation Committee (HIC) (now known as Health
Research Ethics Authority) of Memorial University of Newfoundland as long as the data
were handled and analyzed anonymously. In this study, genotypes were obtained for 252
out of the total 280 patients who were included in our analyses. The baseline
characteristics of this cohort are shown in Table 3. In this cohort , the median age of
diagnosis is 68.7 years. Majority of patients (61.51%) had died till the time of last follow-
up. The age-adjusted survival curve of the validation cohort is depicted in Figure 5. The
median survival time of the patients in the validation set is -6 years and the 5-year
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Table 3. Baseline characteristics of 252 patients in the validation set.
Variable Number of patients (n) 0/0
Sex
male 133 52.78%
female 119 47.22%
Median aae 68.7 years (25.3-91.6)
Histology
non-mucinous 211 83.73%
mucinous 41 16.27%
Location
colon 202 80.16%
rectum 50 19.84%
Stage
I 48 19.05%
II 88 34.92%
III 68 26.98%
IV 41 16.27%
unknown 7 2.78%
Grade
well diff/moderately diff 211 83.73%
poorly difflundiff 37 14.68%
unknown 4 1.59%
Lymphatic invasion
64 25.40%
+ 101 40.08%
unknown 87 34.52%
OS status
dead 155 61.51%
alive 97 38.49%
Median OS follow-up time (ranze) 5.43 years (0-12.48)
Median DFS follow-up time (range) 3.25 years (0-12.48)
DFSstatus
event 167 66.27%
no event 85 33.73%
MSlstatus
MSI-H 24 9.52%
MSI-L/MSS 228 90.48%
Treatment
5-FU based 88 34.92%
other/no chemotherapy 148 58.73%
unknown 16 6.35%
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Figure 5. Age-adjusted survival curve of the validation cohort
Median survival time is -6years
Median 5-yearsurv ival rate is -55 %
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survival rate is - 55%. The validation cohort is not significantly different from the entire
cohort (n=280) in terms of distributi on of clinicop atho logical/mol ecular variable s (see
Fig.A2 in appendix). It is assumed that most of the patients in the validat ion cohort are
Caucasians since there was very low ethnic diversit y in the Avalon Peninsula during the
patient recruitment period (1997-98 ). Simi lar to the discovery set, females, stage IV
patients , patients with mucinous tumor histology, lymphatic invasion, rectal cancer, and
poorly differentiated tumor grade are each present in lower proportion in this cohort .
The Kaplan-Meier plots comparing the survival of the discovery and validation cohort s
without age-adjustment is depicted in Figur e 6. Without age-adjustment , the discovery
cohort patient s had a median survival time of - 9 years in contrast to - 9.5 years after age
adjustment , although the 5-year survival rates are similar (- 80% without age-adju stment
and - 79% with age-adjustment) (Figure 4). For the validation cohort , the median
survival time is - 5.2 years compared to - 6 years after age-adju stment and the 5-year
surviva l rate is - 50% compared to - 55% after age-adjustment (Figure 5). The
differences indicate the affect of age on OS, as generall y, OS is expected to reduce with
increasing age. For further comparis ons between the discovery and validation cohorts,
see section 4.3.3 .
Ten clinicopathological and molecular variable s were used in this study for analyses.
These include stage, tumor grade, vascular or lymphatic invasion, tumor histo logy, MSI
status, tumor location, familial risk status, BRAFl _Val600Glu mutation status, age and
sex (see section 1.5.2). The discovery set was used for analysis of 27 genetic
60
Figure 6. Kaplan-Meier curve comparing the survival of discovery (n=532) and
validation (n=252) sets
~ 0,6
~
E8 0.•
Discoverv set: Median survival time is - 9 years. 5-year survival rate is - 80%
Validation set: Median survival time is - 5.2 years. 5-year survival rate is - 50%
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polymorphisms (see section 3.1). The variables which were correlated with OS in the
discovery set after multivariate analysis, including genotypes of 4 polymorphisms, were
also analyzed in the validation set. Of the variables present in the final multivariate model
for DFS in the discovery set, two polymorphisms for which the genotypes were available
in the validation set were also analyzed for validating the results obtained in the
discovery set.
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Chapter 3. Method s
Ethics approval
This study was approved by HIC of Memorial University of Newfoundland (HIC
Reference # 10.I 17).
Contr ibutions and cr edit s
Amit Negandhi: Performed TaqMan® SNP genotyping assays for rsl799889
(SERPINEI gene) and rs l799 750 (MMPI gene) in the discovery set, rsl80 1131 (MTHFR
gene), rs1047768 (ERCC5 gene) and rsl 799889 (SERPINEI gene) in the validation set.
Performed PCR reaction and gel electrophoresis for GS7Tl and GSTMI gene deletions
and genotyping of the VNTR in TYMS gene in the discovery set and for GSTlvll gene
deletion in the validation set. Performed coding of the genotype data and statistical
analyses described in the thesis document. Performed literature research to interpret and
discuss the results obtained.
Michelle Simms: Prepared stock DNA plates ofNFCCR and validation set samples.
J essica Squires : Performed dilution of stock DNA samples and provided technical
assistance in the lab.
Angela Hyde: Provided clinicopatho logical and prognostic data of the validation set
samples.
Dr. Roger Green: Provided DNA samples from NFCCR and the validation set samples.
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Dr. Sevtap Savas: Processed the raw clinicopathological, ethnicity , prognostic , and other
data for the NFCCR samples and coded them for the statistical analyses , provided the
Kaplan Meier survival curves for the entire NFCCR cohort and entire validation cohort
and provided the baseline characteristics tables for the entire NFCCR samples , entire
validation cohort samples and the validation set samples.
Dr. Patrick Parfrey , Dr. Wei Xu and Dr. Michelle Liu provided assistance with study
design and statistical methods.
Fun ding age ncies
This study was funded by the Memorial University of Newfoundland and The Medical
Research Foundation of Faculty of Medicine-Cox Award (2010) , Memorial University.
3.1 Selection of polymorphisms
For this thesis project, 30 polymorph isms were selected which were previously found to
be correlated with survival in colorectal cancer patients from populations other than
Newfoundland. The polymorphisms were selected based on the information collected and
posted in the dbCPCO database (47) as of September 2010. The selection was based on
the following order of priorities :
I) The polymorphisms which showed statistically significant correlations with
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overall survival and/or disease specific survival in at least one study.
2) The polymorphisms which can be genotyped by methods available to us i.e.
Sequenom MassArray®, TaqMan® SNP Genotyping assays and gel
electrophoresis of polymerase chain reaction (PCR) products.
The polymorphisms selected for inclusion in this study are listed in Table 4. An attempt
was made to genotype twenty-five polymorphisms using the Sequenom MassArray®
technology. Among these, the TP53_rsI042522, PTGS2_rs20417, and EGF_rs4444903
polymorphisms failed to be genotyped by this method. The two gene deletions (GSTMI
and GSTTI gene deletions) and the VNTR in TYMS gene were genotyped by gel
electrophoresis of PCR products. SERPINEl _-675 indelG and MMPl_ -1607 indelG
polymorphisms were genotyped using the TaqMan® SNP genotyping assays. Therefore a
total of 27 polymorphisms were genotyped in the discovery set using the MassArray,
TaqMan®, and PCR and gel electrophoresis methods (Table 4).
3.2 Plates containing DNA samples
Discoverv set: Patients recruited to the NFCCR and with available prognostic data and
genomic DNA were included in this study. DNA samples were provided by Dr. Roger
Green and were previously extracted from the blood samples of colorectal cancer
patients. The stock DNA plates contained 541 DNA samples ( IOng/ul in water)
distributed over seven 96-well plates. For the purpose of genotyping by Sequenom
MassArray system, the same concentration of DNA was used. For performing TaqMan®
assays, the stock solutions were aliquoted to seven other plates and diluted to 4ng/1l1
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Table 4. Genetic polymorphi sms selected for inclusion in this thesis project.
Gene Polymorphi sm rsnumber Type Genotyping methodology
symbol
CCND1 Pro241Pro N G rs9344 SNP Sequenom MassArray®NG 007375.1:g.12038G>A
DCC Arg201G1yC/G rs2229080 SNP Sequenom MassArray®NG 013341.1:g.571061C>G
*EGF A6 1G in 5'-UTR rs4444903 SNP Sequenom MassArray®NG 011441.1:g.5071A>G (failed genotyping)
EGFR Arg521Lys G/A rs2227983** SNP Sequenom MassArray®NG 007726.1:g.147531G>A
ERCC 1 Asn118Asn CIT rs11615 SNP Sequenom MassArray ®NG 015839.1:g.8525T>C
ERCC2 Lys751Gin GIT rs13181 SNP Sequenom MassArray®NG 007067.2:g.23927A>C
Sequenom MassArray® in discovery
ERCC5 His46His CIT rs1047768 SNP setNG_007146.1:g.11344T>C TaqMan® assay in validation set
EX01 Pro757Leu CIT rs9350 SNP Sequenom MassArray®NC 000001.10:g.242048674C>T
FAS c.-24+733T>C rs1800682 SNP Sequenom MassArray®NG 011541.1 :g.6185T>C
FGFR4 Gly388Arg NG rs351855 SNP Sequenom MassArray®NG 012067.1:g.11323G>A
GSTM 1 Gene deletion n/a gene PCR and agarose gel electrophoresisdeletion
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GSTP l Ile105Vai AlG rs1695 SNP Sequenom MassArray ®NG 012075.1:g.6624A>G
GSTT l Gene deletion n/a gene PCR and agarose gel electrophoresisdeletion
lL6 -174 G/C in promoter rs1800795 SNP Sequenom MassArray ®NG 011640.1:g.4880C>G
MLHl Ile219Vai AlG rs1799977 SNP Sequenom MassArray ®NG 007109.1:g.23590A>G
MMPl -1607 indel G in promoter rs1799750 Indel TaqMan® SNP genotyping assayNG 01l 740. 1:g.3471delG
MMP2 -1306CIT in promoter rs243865 SNP Sequenom MassArray ®NG 008989.1 :g.3726C>T
MTHF R A1a222Val CIT rs1801133 SNP Sequenom MassArray ®NG 01335 1.1:g. l4 783C>T
Sequenom MassArray ® in discovery
MTHFR Glu429Ala AlC rs1801131 SNP setNG_0 13351.1:g.16685A>C TaqMan® assay in validation set
OGGl Ser326Cys C/G rs1052133 SNP Sequenom MassArray ®NG 012106.1:g.12146C>G
*PTGS2 -765G/C in promoter rs20417 SNP Sequenom MassArray ®NC 00000 1.l0:g. 186650321C>G (failed genotyping)
PTGS2 c.3618A1Gin 3' -UTR rs4648298 SNP Sequenom MassArray ®NC 00000 1.l0:g. 186641682T>C
SERPINEl -675 indelG in promoter rs1799889 Indel TaqMan® SNP genotyping assayNG 0132 13.1:g.4332 4333insA
*TP53 Arg72Pro C/G rs1042522 SNP Sequenom MassArray ®NG 017013.1:g.16392C>G (failed genotyping)
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TYMS 2/3 repeats of 28bp in 5'-UTR rs34743033 VNTRNC 000018.9:g.657646 (28bp) /2/3/4 PCR and agarose gel electrophoresi s
TYMS indel6 bp in 3' -UTR rs16430 IndelNC 00018.9:g.673444delTins6bp Sequenom MassArray®
VEGF A -634G/C in 5' -UTR rs2010963NG 008732.1 :g.5398C>G SNP Sequenom MassArray®
VEGFA +936C/T in 3' -UTR rs3025039NG 008732.1:g.19584C>T SNP Sequenom MassArray®
XR CCI Arg399Gln G/A rs25487 SNPNC 000019.9:g.44055726T>C Sequenom MassArray®
X RCC 3 Thr24 1Met CIT rs861539NG 011516.1:g.21071C>T SNP Sequenom MassArray®
'Aimed to be designed in Sequenom MassArray® multiplex reactions. *These polymorphi sms failed to be genotyped by Sequenom MassArra y®
method and were excluded from this project. VNTR: variable number of tandem repeats. **SNP is also designated as rs 11543848.
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concentration with water. In these DNA plates, the last column of each plate (column 12)
contained 3 non-templ ate control s (NTCs) and 5 duplicate DNA samples to test for PCR
contamination and concord ance of genotyping reactions, respectively.
Validation set : An additi onal set of 280 colorectal cancer patient s constituted the
validation set. DNAs that were previously extracted from blood (J ng/ul) or formalin-
fixed paraffin -embedded (FFPE) non-tumor tissue (Sng/ ul) were used to genotype the
MTHFR_Glu429Ala, ERCC5_His46His, SERPINEl_-675indeIG polymorphi sms and
GSTMI gene deletio n.
3.3. Solution s
1) 5X Tris-borate -EDTA (TBE) Buffer
Made by mixing 54 grams (gms) OmniPu r® Tris-Hydrochloride (Tris-HCI)
(Product code 9310, EMD Chemicals Inc. NJ, USA), 27.5 gms Boric acid
(Product code BX0865, EMD Chemicals Inc. NJ, USA), 20 milliliters (ml) 0.5
Molar (M) EDTA (pH=8±0. 1) (Catalog number (cat. #) 46-034-CI, Mediatech
Inc, VA, USA) in one liter of deionized (dH20). The buffer solution was
autocla ved, pH was adjusted to 8.3 with sodium hydroxide (Product code
SX0590 , EMD Chemicals Inc. NJ, USA) and solution was stored at room
temperature .
2) 1X TBE buffer
This solution was prepared by diluting 5X TBE solution in dH20.
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3) IX Tris-EDTA (TE) buffer
Made by mixing the following chemicals in sterile dH20 in a total volume of
200ml: 0.3152 gms Tris-HCI (Product code 9310, EMD Chemicals Inc. NJ, USA)
equivalent to 10 millimoles (mM) Tris-HCI and 0.4 ml of 0.5M stock solution of
EDTA (pH: 8±0.1) (cat. # 46-034-Cl, Mediatech Inc, VA, USA) equivalent to I
mM EDTA.
3.4 Obtaining the genotype data
3.4.1 Using Sequenom MassA rrav® technique
The Sequenom MassArray® system was the first choice for genotyping. This multiplex
reaction system facilitates simultaneous genotyping of multiple polymorphisms in a
reasonably short time and is cost-effective. The genotyping reactions were outsourced to
the Analytical Genetics Technology Centre (AGTC) facility at University Health
Network (UHN), Toronto. Seven DNA plates containing 541 DNA samples and duplicate
samples ( l Ong/ul) were sent for genotyping. The DNA sample identifiers (IDs) were re-
coded prior to sending to the facility. Initially we aimed for genotyping of 27
polymorphisms (Table 4). However, assays for only 25 polymorphisms (except
MMPI J sl7 99750 and SERPINEJs I799889) could be designed by the facility. An
additional 3 polymorphisms (TP53_rs I042522, PTGS2J s20417 and EGFJs4444903)
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failed genotyping by these assays after the reactions were run. Thus genotypes for a total
of22 polymorphisms were obtained by Sequenom MassArray® technology.
3.4.2 Design of primers and pr obes for Custom Tag Man ® SNP Genotyping Assays
Polymorphisms in SERPINEl (rs I799889) and in MMPl (rs I799750) could not be
incorporated in the MassArray multiplex reactions. Therefore we used the TaqMan®
SNP genotyping assays to obtain genotypes for these SNPs. The primers and probes for
these polymorphisms were custom designed using the ' Custom TaqMan® Assay Design
Tool' available online (185). The sequences flanking these polymorphisms were obtained
from the dbSNP database (186) (Table 5). These assays were used in genotyping of 541
samples in the discovery set.
3.4.3 Pr e-designed Ta gM an® SNP Genotv ping Assavs
The predesigned TaqMan ® SNP genotyping assays for MTHFR_Glu429Ala (assay ID
C_850486_20) and ERCC5_His46His (assay ID C_l 891769_20) were obtained from the
Applied Biosystems (187) (primer and probe sequence information for these assays are
proprietary of Applied Biosystems and thus were not provided to us). Assays for these
SNPs were performed for samples in the validation cohort.
TagM an® SNP Genotv ping assay procedure: Upon arrival, 40X TaqMan® assay mix
(Applied Biosystems, CA, USA) containing the primers and probes for the TaqMan®
genotyping reactions was diluted to 20X with IX TE buffer, aliquoted and stored at -
20°C. For a 96 well plate, the reaction mix was prepared by adding 525J.ll2X TaqMan®
Universal PCR Master mix (part. # 4304437, Roche, NJ, USA), 26.25J.l120X TaqMan®
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Table 5. Primer and probe inform ation for SNPs in MMPI and SERPINEI genes
SNP MMPI rs1799750 SERPINEI rs1799889
*Assay ID AHVI4S6 AHWR2ZE
Forward primer ACATGTTA TGCCAC AGACAAGGTTGT
Seq. TT AGATGAGGAAA TGACACAAGAGA
Reverse prim er CGTCAAGACTGATA TCTT GGCCGCCTC
Seq. ACTCATAAACAATACTTC CGATGATAC
**Probe 1 Seq. TGAGATAAGTCATA TCCTTTC ACGGCTGACTCCCCCAC
***Probe 2 Seq. TGAGATAAGTCA TA TCTTTC CGGCTGACTCCCCAC
'ID by Applied Biosystems (USA) . "" Reporter 1 dye is VIC, which recognizes the G alle le. """Reporter 2
dye is FAM, which recognizes the deletion of G allele . Underlined are the sequences on probes that are
complementary to the polymorphic sequences. Seq: sequence.
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assay mix (Applied Biosystems, CA, USA) for the particular polymorphism and 393.75111
of sterile water. 114111 of the reaction mix was transferred to each well of an 8-well strip
tube using a single channel pipette. 9111 of the reaction mix from each well of the strip
tube was subsequently transferred to the wells of the MicroAmp® Fast Optical 96-well
reaction plate with barcode (0. 1 ml) (part. # 4346906, Applied Biosystems, CA, USA)
using a multi channel pipette . These plates are custom-made for use in the 7900HT Fast
Real Time PCR System (part. # 4330966 , Applied Biosystems, CA, USA). 1111 of DNA
extracted from blood with a concentration of 4ng/Il1 for SERPINE1_rs1799889 and
MMP1_rs1799750 in the discovery set samples and either 3ng/Il1 (extracted from blood)
or Sng/p! (extracted from FFPE) DNA for MTHFRJs l801131 and ERCC5_rsI047768 in
the validation set samples was added to the plate containing the reaction mix. The final
react ion volume was 10111. A PCR-compatible optica l adhesive cover (part . # 4360954,
Applied Biosystems, CA, USA) was applied over the plate, sealed tightly, and the plate
was centrifuged at 1000 revolutions per minute (rpm) for - 5-10 seconds in a bench top
centrifuge (cat. # 75004367, Sorvall Legend T+ Centrifuge, ThermoFis her Scientific,
MA, USA) prior to the PCR amplification.
The ABI 7900HT Sequence Detection Systems (SDS) software, version 2.4 accompanies
the 7900HT Fast Real Time peR System. For SNP genotyp ing assays , the allelic
discrimination (AD) and absolute quantification (AQ) files were created using the SDS
softwa re following the instructions in 'Applied Biosystems 7900HT Fast Real-ti me PCR
System Allelic Discrimination Getting Started Guide' (part. # 43640 15, Applied
Biosystems, CA, USA). The AD file contains information about the detec tor which is
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composed of a pair of fluorescent probes to detect the particular alleles, sample
information in the plate and enables analysis of the fluorescence data after the PCR run is
completed. The AQ file contains data for the real-time PCR run such as the
thermocycling conditions. These files are essential for performing the PCR run and for
calling the genotypes based on the fluorescence information generated. These files were
initially prepared in a desktop computer , transferred to a USB drive and copied on the
computer adjoining the 7900HT Fast Real Time PCR System. For the PCR amplification ,
the reaction plate was inserted in the machine and a pre-read procedure was performed
using the AD file prepared for the plate. The pre-read is performed to record background
fluorescence which is used as a reference against which the fluorescence recorded after
amplification is compared to give the genotype in each well. After performing the pre-
read, PCR amplification of the DNA samples using the AQ file was performed in the
7900HT Fast Real Time PCR System (part. # 4330966 Applied Biosystems , CA, USA).
The PCR thermocycling condition s are as follows: 50°C for 2 minutes (activation of
AmpErase ® UNG in TaqMan® Universal PCR Master Mix), 95°C for 10 minutes
(activation ofAmpliTaq Gold'E)DNA Polymerase in TaqMan® Universal PCR Master
Mix) and 40 cycles of 95°C for 15 seconds (melting DNA) and 60°C for I minute
(annealing/extension ofprimer) .
After the completion of the PCR run, a post-read was performed using the AD file. Pre-
read and the post-read data in the AD file were automatically analyzed by the software
and genotypes were called (F igure 7). The plots were also manually examined by an
independent researcher (Dr. Savas) to confirm the genotype callings . In case of a
74
Figure 7. AD plot for TaqMan assay for MTHFRJs1801131
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A sample AD plot for TaqMan® SNP genotyping assay
Each dot represents a sample. The black squares at the bottom left show no amplification, which are the
NTCs. The blue dots are homozygotes for the T allele while the red dots are homozygotes for the G allele.
The green dots in the center are heterozygotes.
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discrepancy between the visual inspection of the plots and the automatic genotype
calling, the genotyping reaction was repeated. For failed samples up to three repeat
attempts were made to obtain genotypes , whenever the DNA was available. The finalized
genotyping data was exported into an excel sheet and organized for data analysis.
3.4.4 Genotv ping for GSTTI and GSTMI gene delet ions
To detect GSTTl and GSTMl gene deletions, we performed a multiplex PCR reaction
followed by gel electrophoresis as previously described by Arand et al (188). This PCR
reaction is a triplex reaction including the forward and reverse primers for amplification
of three genes: GSTT1 , GSTMl and albumin gene (ALB). ALB gene serves as a positive
control for successful PCR amplification . ALB gene yields a PCR product which is 350
bp long, GSTTl gene product is 480 bp long and the GSTMI gene product is 215 bp long.
The primer sequences for the three genes are shown in Table 6.
For a 96 well plate, reaction mix was prepared by adding 525JlI 2X Amp1iTaq Gold® 360
Master Mix (product. # 4398790 , kit part. # 4398881 , Applied Biosystems, CA, USA),
26.25JlI GC enhancer (product # 4398799, kit part. # 4398881, Applied Biosystems, CA,
USA), 288.75JlI of sterile water and 105JlIprimers (Integrated DNA Technologies , Iowa,
USA) containing 10JlM of each primer (forward and reverse) for all three genes. The
reaction mix was then equally distributed in wells of a 8-well strip tube using a single
channel pipette. 9JlI of the reaction mix was subsequently transferred to each well of the
MicroAmp® Fast Optical 96-well reaction plate with barcode (0.1 ml) (part. # 4346906,
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Table 6. Primer sequenc es for peR amplific ation of GSTTl, GSTMl , ALB gene
fragments and VNTR in TYMS gene
Primer Sequence Reference5' to 3'
GSTTI F: TTCCTT ACTGGTCCTCACATCTC (188)R: TCACCGGATCA TGGCCAGCA
GSTMI F: GAACTCCCTGAAAAGCTAAAGC (188)R: GTTGGGC TCAAATATACGGTGG
ALB F: GCCCTCTGCT AACAAGTCCTAC (188)R: GCCCTAAAAA GAAAATCGCCAATC
TYMS F: GTGGCTCCTGCGTTTCCCCC (189)R: TCCGAGCCGGCCACAGGCAT
F=forward, R=reverse
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Applied Biosystems, CA, USA) from the strip tube using a multichannel pipette . I JlI of
DNA solution (4ng/ JlI) was added to the reaction mix in the reaction plate . Optical
adhesive cover (part . # 4360954, Applied Biosystems, CA, USA ) was applied , sealed
tightl y, and the reaction plate was spun at 1000 rpm for - 5-10 seconds in a bench-top
centrifuge (cat. # 75004367, Sorva ll Legend T+ Centrifuge, ThermoFisher Scientific,
MA , USA) . An AQ file was set up for each plate and the PCR runs were perform ed on
the 7900HT Fast Real Time PCR System (part. # 4330966 , Applied Biosystems, CA,
USA) with the following thermocycling conditions: 95°C for 10 minut es (primary
denaturation and activation of Ampli Taq Gold 360 DNA po lym erase in AmpliTaq Gold®
360 Master Mix) , 34 cycles of 95°C for 30 seconds (denaturation), 64°C for 30 seconds
(primer annealing) and ire for I minute (primer extension) and a final cycl e of rr c
for 7 minute s (final elongation) follo wed by a hold at 4 "C until plate remo ved from the
thermo cycler. The plate was spun again at 1000 rpm for - 5 second s after the completion
of the PCR run and PCR produ cts were then ana lyzed using the agaro se gel
electrophoresis .
Agarose gel electrophoresis to genotype GSTT 1 and GSTM 1 gene deletion s:
A 1.5% maxi gel was prepared by dissolving and meltin g 3.75 grams OmniPur® Aga rose
PCR Plus (Product code 2010 , EMD Chemica ls Inc. NJ , USA) in 250 ml IX TBE buffer
in a microwave. Eighteen JlI of 10,000X SYBR ® Safe DNA gel stain (cat. # S33 102,
Invitrogen , Oregon, USA) was added to the molten agar solution and mixed by gentle
swirling. The mixtur e was then pour ed into the ge l apparatus and allowed to solidify . The
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gel cast had two combs of 20 wells each and one comb of 17 wells . After solidification,
the combs and rubber edges were removed and the gel was placed in the electrophoresis
tank filled with IX TBE buffer. 151-11 of 6X DNA Gel loading buffer (cat. # ACI0097,
Omega Bio-tek, GA, USA) was added to each well of an 8-well strip tube .
Approximately - 11-11 of loading buffer was mixed with 10 1-11 of PCR products by
pipetting up and down 2-3 times. The mixture was then loaded into the wells of the gel
using a multichannel pipettor. The first well of each row in the agarose gel was loaded
with - 3-41-11 of 135ng/I-II100 bp DNA ladder (cat. # 0 -1030 , Bioneer, Korea) . The gel
was then run at 70 volts (V) and images were taken at 45 and 65 minutes under
ultraviolet (UV) transillumination in an AlphaImager ® EP (Alpha Innotech , CA, USA).
A filter transmitting UV light of wavelength 302 nanometer (nm) was used for
visualizing SYBR® Safe DNA stained gels on the Alphalmage r® EP. An example of the
image is shown in Figure 8. Individuals with the absence of the topmost band have
GSTTI gene deletion while those with the absence of the bottommost band have GSTMI
gene deletion. One agarose gel can accommodate a total of 48 samples. Hence, two gels
were used to analyze samples from one 96-well PCR plate. For the first gel, samples from
columns 7-12 were loaded since column 12 contains the NTCs in plate wells F12, GI2
and H12. If DNA contamination is observed in any of these wells, the PCR products were
discarded and PCR reactions were repeated . If contamination was not observed , then the
electrophoresis of PCR products from columns 1-6 was also performed.
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Figure 8. Gel image for detection of GSTTI and GSTMI gene deletions
500bp GSTTI
1I I I f =GALBGSTMI
The first sample is a 100 bp DNA ladder. Individuals with absence of topmost band have deletion of
GS1Tl gene. Individuals with the absence of bottommo st band have deletion of GSTMI gene.
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3.4.5 Genotv ping for 2/3 rep eat s of28 bp in 5' -untranslated region (5'- UTR) of
TYMS gene (rs34743033)
Primer sequences for region flanking rs3474303 3 in 5'- UTR in TYMS gene were obtained
from the literature (189) and are shown in Table 6.
For a 96 well plate, reaction mix was prepared by adding 525,.11 2X AmpliTaq Gold® 360
Master Mix (product. # 4398790, kit part. # 439888 I, Applied Biosystems , CA, USA),
52.5JlI GC enhancer (product. # 4398 799, kit part. # 439888 1 Applied Biosystem s, CA,
USA), 157.5JlI of steri le water and 210JlI primer solutions (Integra ted DNA
Technologies , Iowa, USA) containing 10JlM forward and reverse primers. The reaction
mix was equa lly distributed across an 8-well strip tube using a single channe l pipette. 9JlI
of reaction mix was then transferred to each well of a MicroAmp ® Fast Optical 96-well
reaction plate with barcode (0. I ml) (part. # 4346906 , Applied Biosystems , CA, USA)
using a multichan nel pipette. IJlI DNA solution (4nglJlI) was then added into the reaction
mix and the plate was sealed with VWRTM adhes ive foil for microp lates (cat. # 60941-
on, VWR, PA, USA). The reaction was run in a Veriti 96-well fast thermal cycler (part.
# 4375305, Applied Biosystems, CA, USA) with the following thermocycli ng conditions:
95°C for 10 minutes (primary denaturation and activation ofAmpliTaq Gold 360 DNA
polymerase in AmpliTaq Gold® 360 Master Mix), 35 cycles of 95°C for 30 seconds
(denaturation) , 70°C for 30 seconds (annealing) and ire for I minute (extension) and a
final cycle of i re: for 7 minutes (final elongation) followed by a hold at 4 "C until
81
removal of the plate from the thermocycler .
Agarose gel electrophoresis for 2/3 repeats of28 bp in 5'-UTR of TYMS gene
The method for electrophoresis is similar to that of gene deletions for GSIT 1 and GSTM1
genes with the following changes:
a) A 4% maxi gel was prepared by dissolving and melting 10 grams OmniPu r®
Agarose PCR Plus (Product code 2010, EMD Chemicals Inc. NJ, USA) in 250 ml
1X TBE buffer in a microwave .
b) The gel images were taken under UV transillumination in Alphalmager ® EP
(Alpha Innotech, CA, USA) at 45, 75 and 95 minutes.
PCR products with 2 repeats of 28bp VNTR (2R) of TYMS gene migrate faster and form
the bottommost band while those with 3 repeats (3R) migrate slower and form the
topmost band (Figure 9). We very rarely also observed a 4-repeat allele in our samples .
These samples were confirmed by re-amplifications run on 4.5% agarose gels .
3.5 Data analysis
The genotype data was organized in an Excel sheet and combined with the
clinicopathological, demog raphic, molecular, and prognostic data of the patients obtained
from NFCC R and processed by Dr. Sevtap Savas. The prognostic data contained the
clinicopat hologica l and molecular variables described in detail in section 1.5.2.
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Figure 9. Gel image for detection of 2/3 repeats of 28bp in TYMS gene
~OObp
The first well is a 100 bp DNA ladder. Individuals with two bands are heterozygotes for 2 and 3 repeats
(2R/3 R). Individ uals with only the topmost band have 3R. Individuals with only the bottommo st band have
2R.
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The minor allele frequencies (mAFs) of the polymorphisms in colorectal cancer patients
in both the discovery and validation sets were separately calculated in an Excel
document. The mAFs in other Caucasian populations were obtained from the dbSNP
(186) database or published reports and compared to the mAFs in our cohorts. Duplicate
genotypes were checked for concordance. In the case of MassArray®, if a discordant
genotype was obtained in duplicate samples, these genotypes were excluded from the
analysis. For the TaqMan® SNP genotyping and the PCR-gel electrophoresis techniques,
the discordant samples were repeated to obtain the final genotype data. For VNTR in
TYMSgene, the 2R allele has been shown to have lower transcription activity than the 3R
allele (190). Therefore, we combined the rarely observed 4R alleles with the 3R alleles
for data analysis since it is likely that both 3R and 4R alleles have activities greater than
2Rallele.
Hardy-Weinberg equilibrium (HWE) calculations were performed in both the patient
cohorts separately to observe deviations of genotype frequencies in the cohort using an
online tool (191) and were confirmed by manual calculations. In case of any discrepanc y,
the manual calculations were repeated and noted.
Statistical tests were performed using the PASW Statistics 18 software Release 18.0.2
(April 2010) assuming three models of inheritance: co-dominant , dominant and recessive.
In the co-dominant model, the survival times of patients with minor allele homozygotes
and heterozygotes were separately compared with the survival times of patients with
major allele homozygotes. In the dominant model, the survival times of patients with
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minor allele homozygotes+heterozygotes were compared with the survival times of
patients with major allele homozygotes. In the recessive model , the survival times of
patients with minor allele homozygotes were compared with the survival times of patients
with major allele homozygotes+heterozygotes.
To illustrate the three models , let us consider a polymorphism with the major allele A and
the minor allele G. In the co-dominant model , AA is the reference category and patients
with genotypes AG and GG are separately compared to patients with AA genotypes . In
the dominant model, AA genotypes are compared to AG+GG genotypes . In the recessive
model, AA+AG genotypes are compared to GG genotypes (192) .
For clinicopathological and molecula r variables, the categorical variables included were
sex (males vs females) , tumor histology (mucinous vs non-mucinous), tumor location
(rectum vs colon) , stage (stages II, III and IV individually vs stage I), tumor grade
(poorly differentiated/undifferentiated vs well differentiated/moderately differentiated),
vascular invasion (presence vs absence) , familial risk status (high/intermediate vs low),
MSI status (MSI-H vs MSI-L/MSS) and BRAFI _Val600Glu mutation status (presence vs
absence). Age was analyzed as a continuous variable . The vascular invasion data for the
validation set were not available , but the lymphatic invasion data were. In the discovery
set, it was observed that vascular invasion and lymphatic invasion were highly correlated
with each other (see section 4.2.5) i.e. almost all tumors having vascular invasion had
lymphatic invasion too. Thus we compared the vascular invasion data in the discovery set
with the lymphatic invasion data in the validation set to test for significant differences
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between the two cohorts in terms of invasion.
Genotype data was available for 532 patients in the discovery set and 252 patients in the
validation set. Following coding the data, univariate , multivariate, Chi-square and other
analyses were performed as explained in the next sections .
3.5.1 Univariate survival analy sis
Univariate analysis tests for one-to-one correlatio n of a particular variable with a time-
dependent outcome . In univariate surviva l analysis, as (the primary end-point) was
analyzed using as status and as time (the time from diagnosis of colorectal cancer until
death from any cause) . DFS (the secondary end-point) was analyzed using DFS status
and DFS time (the time from diagnosis of colorectal cancer until the first occurrence of
recurre nce, metastasis or death from any cause) . The genotype , demograp hic, molecular
and clinicopa thological data and prognostic data collected in an Excel document were fed
to PASW software . Analyses were performed to explore correlations between genotypes
and other variab les and as and DFS.
Cox-regression and Kaplan-Meier surviva l analyses were performed for each variable
separate ly. These analyses were also repeated separate ly for as and DFS. Cox-regression
analysis gave the p-value and the hazard-ratio with 95% confidence interva ls whi le
Kaplan-Meier analysis was used to construct survival curves. We have used Cox-
regress ion analysis for construction of mult ivariate models as well as for univariate
analyses . Cox-regression analysis is a proportional hazard regressio n method for analysis
of time to event outcomes . This method has two main assumptio ns (193). Firstly, the
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patients who do not experience outcome at the time of last follow-up are censored. This
allows the patients who did not experience the event to be included in the analysis.
Secondly, the proportionality assumpt ion states that the relative hazard of an event for
persons in one group is constant over time and does not change over the course of the
follow-up period. One way to check the proportionality assumption is to check the
Kaplan-Meier curves for intersection. Two-sided p-values less than 0.05 were considered
statistically significant. In these analyses, the patients who were alive at the time of last
follow-up were censored . The statistical results obtained were exported from PASW and
organized in an Excel document.
3.5.2 Chi-square test and Mann-Whitnev V-test
Chi-square test was performed to check for multicollinearity between the variables
included in this study (genotypes, clinicopathological , and molecular variables). If two
variables were highly correlated, only one would be included in the multivariate model to
reduce redundancy (e.g. vascular and lymphatic invasion, section 4.2.5). The Chi-square
test was performed using the PASW statistical package using crosstabs analysis under
descriptive statistics . The results obtained were exported from the PASW and organized
in an Excel document. Chi-square test was also performed to test for significant
differences between the discovery set (n=532) and entire NFCCR cohort (n=735);
validation set (n=252) and entire validation cohort (n=280); and between the discovery
set (n=532) and validation set (n=252) to check the comparability of the cohorts. Age,
which is a continuous variable, were not normally distributed in either cohorts . Hence we
used the non-parametric Mann-Whitney U-rest to compare median age between the
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cohorts.
3.5.3 Multivariate survival ana lvsis
Multi variate Cox-regr ession analysis result s show the independent predicti ve potential of
each variable in the final model. To obtain reliable result s in multi variate analyses, it is
desirable to have at least 10 outcome s for each variable (193 ). In the discovery set, for
selection of variables to be enter ed in the final multi variate model, all the variables
(genotypes, demographic , clinicop athological and prognostic data) were entered together
in Cox-regression analysis and backward selection method (likeliho od ratio (LR» was
performed. Backward selection method sequentially eliminates the statist ically
insignificant variables and provides the list of selected variables with highest statistica l
significance (194 ). This method selectivel y reduce s the large number of variables to a
small group of the most relevant variables . It is worth noting that in our analy sis, using
this selection method , variables with well-known prognostic significance (such as sex ,
age, stage, MSI-status) remained in the final model. These selected variables were then
entered into the multi variate Cox-regression analysis to obtain the final mult ivariate
analysis result .
In the validation set, our aim was to test the validity of the variables that were found to be
independently correlat ed with OS in the discovery set. Therefore, these variables were
entered together in multivariate Cox-r egression analysis for OS. For DFS ana lysis in the
validation set, only the variables with available data were entered in the multi variate
analysis. The discovery and the validation sets were also pooled together and Cox -
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regression analysis was repeated for both OS and DFS. Although the two cohorts were
found to be dissimilar in many aspects (see section 4.3.3), for exploratory purposes we
combined the cohorts (i.e. the pooled cohort) and repeated the analysis to observe the
associations of polymorphism s in a larger sample set. We also analyzed the multivariate
model for OS in the discovery , validation and pooled sets in the male and female patients
separately. In this study, we did not perform correction for multiple testing .
3.6 Construction of linkage disequilibrium (LD) maps
For MTHFR_Glu429Ala and ERCC5_His46His polymorphism s, the LD maps were
created using the Haploview 4.2 software (195). For this purpose , the SNP genotype data
for a IOOkb region containing the gene of interest for Caucasian population was
downloaded from the International HapMap Project website using the data in HapMap
Genome Browser release #28 (Phases 1, 2 & 3-merged genotypes and frequencies) (196).
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Chapter 4. Results
4.1 Genotype data
The quality control measures in terms of successful duplication rate and successful
genotyping and the missing genotype data for 27 polymorphisms in the discovery set and
4 polymorphisms in the validation set are enlisted in Table 7.
To verify the genotypes obtained , at least 5.9% of the genotypes were successfull y
duplicated for each polymorphism with at least 99.7% concordance rate. The minimum
successful genotyping rate was 97.4% in the discovery cohort and 94.4% in the validation
cohort . The mAF of polymorphisms in the discover y and validation cohorts were also
similar to those described in dbSNP (186) or to literature reports for Caucasian
populations and are shown in Tabl e 8.
Hardy-Weinberg Equilibrium fHWE) Calculations
In the discovery cohort, four poIymorphism s deviated from HWE : ERCC2_Lys75IOln,
OGG1_Ser326Cys, VEGFA_-634 O/C and XRCC3 _Th r24IMet. The remaining
polymorphisms in the discovery set and the four polymorph isms analyzed in the
validation set were in HWE. Reasons for deviation of genotype frequencies from HWE
can be many such as errors in genotyp ing, founder effect , genet ic drift , assorted mating or
reproductive benefit for heterozygotes over wild-type homozygotes (197). However , it is
suggested in the literature that deviation of genotype frequencies from HWE should not
be a critical parameter for inclusion or exclusion ofa polymorphism in the analysis (197).
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Table 7. Genotype data quality measure s
Successful Missin g 0/0Gene Polymorphism SNP ID genotype successful
duplication rate geno type s (n) genotyping
Discovery set
ERCC2 Lys75 IGin o/r rsl3 181 6.43% 8 98.5
GSTPl Ile l OSVal N G rsl695 6.23% 7 98.7
MTHF R Glu429Ala NC rs l80 1131 6.40% 6 98.9
MTHFR Ala222Va i crr rs1801133 6.24% 8 (I discordant) 98.5
VEGFA -634G/C in 5' -UTR rs2010963 6.43% 8 98.5
XRCCl Arg399Gln G/A rs25487 6.12% 14 (I discordant) 97.4
ERCC5 His46His CIT rs1047768 6.36% 2 99.6
OGG l Ser326Cys C/G rs l052 133 6.34% 1 99.8
ERCCl Asn 118Asn crr rs l1615 6.34% 1 99.8
TYMS indel 6 bp in 3' -UTR rsl6430 6.16% 6 98.9
MLHl Ile219VaiNG rs1799977 6.34% 1 99.8
FAS c.24+733T>C rsl800682 6.36% 2 99.6
lL6 - I74G/C in promoter rsl800795 6.17% 2 99.6
EGFR Arg521Lys G/A rs2227983 6.36% 2 99.6
DCC Arg20 lGly C/G rs2229080 6.36% 2 99.6
MMP2 -1306Crr in promoter rs243865 6.36% 2 99.6
VEGFA +936Crr in 3' -UTR rs3025039 6.34% 1 99.8
FGFR4 Gly388Arg NG rs351855 6.34% 1 99.8
PTGS2 c.3618NG in 3'UTR rs4648298 6.26% 10 98.1
XRCC3 Thr24 1Met crr rs861539 6.34% 1 99.8
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CCNDI Pro241Pro AlG rs9344 6.17% 2 99.6
EXO I Pro757Leu crr rs9350 6.34% I 99.8
MMP I -1607inde1G in promoter rs l799 750 7.08% 0 100
SERPINE I -675 indelG in promoter rs l 799889 7.45% 0 100
GSITI gene deletion 6.90% 0 100
GSTMI gene deletion 6.30% 0 100
TYMS 2/3 repeats of 28 bp rs34743033 7.09% I 98.7
Validation set
MTHFR Glu429Ala AlC rs l80 1131 8.80% 2 99.2
ERCC5 His46His rs1047768 13.22% 10 96.0
SERPINEI -675indeiG in promoter rsl799889 8.98% 7 97.2
GSTM I Gene deletion 5.90% 14 94.4
Successful genotype duplication rate is the ratio of the number of samples successfully genotyped more than once to the total number of samples
successfully genotyped. % successful genotyping is the percentage of samples successfully genotyped. Concordance for the duplicate genotypes
obtained from UHN is 99.73% whereas in TaqMan® assays it was 100%. Concordance is the percentage of duplicated genotypes yielding concordant
results. The discordant genotypes obtained in the duplicated samples using Sequenom MassArray® were not included in the analyses.
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Table 8. Minor allele frequencies (mAF) of the polymorphisms stud ied
Gene Symbol Polymorphism mAF mAF in discoveryCa ucas ian (va lidation) set
CCNDI Pro241Pro AlG 48-63% 45.28%
DCC Arg201Gly C/G 33-42% 36.98%
EGFR Arg521Lys G/A 22-30% 26.89%
ERCCI Asn118Asn CIT 33-45% 37.57%
ERCC2 Lys751GIn GIT 27-42% 35.69%
ERCC5 His46His CIT 32-51% 41.13% (42.15%)
EXOI Pro757Leu CIT 15-27% 14.60%
FAS -670AlG in promoter 39-50% 44.91%
FGFR4 Gly388Arg AlG 26-31% 31.26%
GSTM I gene deletion *38-62% 45. 10% (44.54%)
GSTP I lie I05Val AlG 29-42% 36.67%
GSTTI gene deletion *15-20% 17%
IL6 -174G/C in promoter 50-57% 44.25%
MLHl lIe219Vai AlG 0-35% 28.63%
MMPI -1607 indelG in promoter 43.30% 46.90%
MMP2 -1306CIT in promoter 18-25% 22.92%
MTHF R Glu429Ala A/C 33-38% 30.6 1% (30.00%)
MTHFR Ala222Val CIT 21-37% 31.77%
OGGI Ser326Cys C/G 15-22% 23.54%
PTGS2 c.3618A1Gin 3'-UTR 1.7-1.8% 1.63%
SERPlNEl -675 indeiG in promoter 54.30% 46.71% (46.5 3%)
TYMS indel6 bp in 3'-UTR 37.00% 34.13%
TYMS 2/3 repeats of 28-bp 44.60% 46.60%
VEGFA -634G/C in 5'-UTR 20-43% 29.10%
VEGFA +936CIT in 3'-UTR 10-22% 10.73%
XRC CI Arg399Gln G/A 37-58% 34.36%
XRC C3 Thr241 Met CIT 37-65% 39.74%
*mAFs obtained from a published report (198) . mAF information for other variations were retrieved from
the dbSNP database (186) .
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In addition, founder effect is promi nent in the Newfoundland popu lation ( 199) and
therefo re HWE assu mptions may not be fulfi lled. Hence , we included the four
polymorphi sms which deviated from HWE in our ana lyses . For HWE calculations for the
polymorp hisms included in this study , see Table Al in appendix. The polymorph isms
with i value greater than 3.84 were considered to be deviating from HW E (191 ). Of
special note , none of the polymorphisms that deviated from HWE were in the
multivariate ana lysis models described in this thesis . Therefore, their inclusion into our
ana lysis did not alter our main results.
4.2 Univa riate anal ysis
4.2.1 Polymorphisms correlated with OS
For explo ratory purposes, univariate Cox-regres sion analysis was performed and Kaplan-
Meier surviva l plots were obtained for each polymorp hism . Since we observe d that the
co-dom inant model gives a more robust resu lt compared to the recessive and domi nant
models , statistically significant correl ations (p<O.05) in only the co-dominant inheritance
model are discussed here . For comple te tabulated results of the analyses for co-dominant,
recessive and dominant mode ls, refer to Tables A2, A3 and A4 in the appendix.
Six polymorp hisms showed statist ically significan t corre lations with OS in univariate
ana lysis , assuming a co-domi nant inheritance mode l (F igur e 10).
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Figure Hla-Hlf, Kaplan-Meier survival plots Corpolymorphi sms and OS in the discovery set (co-dominant model)
"i~l.~ \:
lOa. MTHFR_Glu429Ala and OS, HR: 1.73 [1.07-2.81], p=0.025
l:j~
10e. PTGS2_c.3618 AlG and OS, HR: 2.02 [1.03-3 .95], p=0.041
l';~
lOb. ERCC5_His46 His and OS, HR: 1.87 [1.24-2.82], p=0.003
,,.,lJ~
10d. SERPl NE1_-675 indelG and OS, HR: 0.56 [0.35-0 .89], p=O.013
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I) MTHFR_Glu429Ala (NG_013351.1:g.16685A>C) (r sI801131 ). Patients
homozygo us for alanine (CC) have a worse OS compared to patients homozygous for
glutamate (AA) (p=0.025, HR=1.733, 95% CI: [1.070 -2.807]) (Figure lOa).
2) ERCC5_His46His (NG_007146.I :g.11344T>C) (rsI047768). Patients homozygous
for T allele have a worse OS compared to patients homozygous for C allele (p=O.003,
HR= 1.87, 95% CI: [1.238-2.824]) (Figure lOb).
3) PTGS2_c.3618 A/G in 3'-UTR (NC_OOOOOl.lO:g.186641682T>C) (rs4648298).
Heterozygotes (GA) have a worse OS compared to patients homozygous for A allele
(p=0.041, HR=2.016, 95% CI: [1.030-3.946]). The mAF for this polymorphism is
very low (1.63%). Hence we excluded this polymorphi sm from mulitivariate analysis
to prevent obtaining unreliable statistical results (193) (Figure 10c).
4) SERPINEl_-675 indelG (NG_013213.1:g.4332_4333in sA) (rsI799889). Patients
homozygous for insG allele had a favorable OS compared to patients homozygous for
delG (p=0.013, HR=0.557, 95% CI: [0.351-0.885]) (Figure lOd).
5) MMPl_-1607 indelG (NG_011740.I :g.3471deIG) (rs1799750). Patients
homozygous for insG allele had a worse OS compa red to patients homozygous for
delG (p=0 .044, HR= 1.539, 95% CI: [1.012-2.339]) (Figure IOe).
6) GSTMI gene deletion. Patients having at least one copy of the gene had a worse OS
when compared to patients homozygous for deletion of the gene (p=0.009,
HR=1.484, 95% CI: [1.104-1.994]) (Figure 10f).
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The results on polymorph isms without statistically significant associatio ns with OS are
shown in Table A2 in appendix.
4.2.2 Clinicopathological features correlated with OS
We also performed univariate Cox-regression analysis and constructed Kaplan-Meier
surviva l plots to test correlation of clinicopatho logica l variables with OS. The results are
depicted in Table 9.
Sex, higher stages, vascular invasion, lymphatic invasion and MSI status were correlated
with OS (Figure 11).
I ) Sex: Males had approximately 50% greater hazard of death when compared to
females (p=0.012, HR= 1.501, 95% CI: [1.09-2.06]) (Figure lIa).
2) Stage: Stage III (p=0.005 , HR=2.151, 95% CI= 1.26-3.68) and stage IV (p<O.OOI,
HR=10.211, 95% CI: [5.80-17.98]) patients had a greater hazard of death when
compared to stage I patients (Figure l lb ).
3) Vascular inva sion: Patients with tumor vascular invasion had - 67% greater hazard
of death when compared to patients without tumor vascular invasion (p=0.001,
HR= I.674, 95% CI: [1.23-2.28]) (Figure llc).
4) Lymphatic invasion: Patients with lymphatic invasion had an approximately 54%
greater hazard of death when compared to patients without lymphatic invasion
(p=0.006, HR=1.535, 95% CI: [1.13-2.08]) (Figure lId)
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Tabl e 9. Clinicopathological featu res correlated with OS in univariate anal ysis
(discovery set)
Variable p-value HR 95%CI n
Sex (males vs females) .012 1.501 1.09-2.06 531
Age at diagnosis .230 1.010 0.99-1.03 531
Histology (mucinous vs non-mucinous) .990 0.997 0.63-1.59 531
Location (rectum vs colon) .129 1.264 0.93-1.71 531
Stage <.001
II vs I .182 1.449 0.84-2.50
III vs I .005 2.151 1.26-3.68
IVvsI <.001 10.211 5.80-17.98 531
Grade (poorly/undifferentiated vs
.735 0.900 0.49-1.66 527
well/moderately differentiated)
Vascular invasion (+ vs-) .001 1.674 1.23-2.28 49 1
Lymphatic invasion (+ vs -) .006 1.535 1.13-2.08 488
Familial risk (high/intermediate vs low) .751 1.049 0.78-1.41 531
MSI status (MSI-H vs MSI-L /S) <.001 0.156 0.06-0.42 510
BRAFJ -VaI600Glu mutation status (+ vs-) .447 0.813 0.48-1.39 483
HR: hazard ratio , CI: confidence interval , n: number of patient s, HR> I implies increased hazard of death,
HR<1 implies reduced hazard of deat h.
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5) MSI statu s: Patients with MSI-H tumors had a surviva l advantage compared to
patients with MSI-L/MSS tumors: they had - 85% reduced hazard of death (p<0.001,
HR=0. 156, 95% CI: [0.06-0.42]) (Figure lIe).
4.2.3 Polymorphisms correlated with DFS
In univariate analysis assuming co-dominant inheritance model, two polymorphisms were
significantly correlated with DFS (Figures 12).
I ) ERCC5_Hi s46His (NG_007146.I:g.1I344T>C) (rsI047768). Patients homozygous
for T allele had a worse DFS compared to patients homozygous for C allele (p=O.Ol,
HR=1.647, 95% CI: [1.124-2.414]) (Figure 12a).
2) GSTMl gene deletion. Patients with at least one copy of the gene had a worse DFS
when compared to patients homozygous for gene deletion (p=0.004, HR=1.489, 95%
CI: [1.133-1.957]) (Figure 12b).
Both these polyporphisms were also associated with as in the discovery cohort in
univariate analysis (section 4.2.1). The results on polymorphisms without statistically
significant associations with DFS are shown in Tabl e AS in the appendix. Results for
recessive and dominant models are shown in Tables A6 and A7 in app endi x.
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Figures 12a-12b. Kaplan-Meier survival plots for polymorphisms and DFS in the
discovery set (co-dominant model)
12a. ERCC5_His46His and DFS, HR: 1.65 [1.12-2.41 ], p=O.OI
~ 0 ,6
~a 04
12b. GSTMI gene deletion and DFS, HR: 1.49 [1.13-1.96], p=O.004
A=absenceofgeneand P=presenceofgene
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4.2.4 Clinicopathological features correlated with DFS
The results for univariate Cox-regression analysis for correlation between
clinicopathological features and DFS are shown in Table 10. Six clinicopathological
features were correlated with DFS in univariate Cox-regression analysis (Figure 13).
1) Sex: Males had an approximate 47% greater hazard of event compared to females
(p=O.O I, HR=I.471 , 95% Cl: [1.097-1.973]) (Figure 13a).
2) Location: Patients with rectal cancer had - 40% greater hazard of event when
compared to colon cancer patients (p=0.017, HR=1.403, 95% Cl: [1.062-1.854])
(Figure I3b ).
3) Stage: Stage III patients have - 100% greater hazard of event (p=0.002, HR=2.096,
95% Cl: [1.314-3.345]) while stage IV patients have - 478% greater hazard of event
(p<O.OOI, HR=5.778, 95% Cl: [3.476-9.604]) when compared to stage 1 patients
(Figure I3c ).
4) Vascu lar invasion: Patients with tumor vascular invasion have - 60% greater hazard
of event when compared to patients without tumor vascular invasion (p=O.OO I,
HR=1.604. 95% Cl: [1.206-2.134]) (Figure I3d ).
5) Lymphatic invasion: Patients with lymphatic invasion have - 50% greater hazard of
event when compared to patients without lymphatic invasion (p=0.005, HR=I.4 98,
95% Cl: [1.129-1.988]) (Figure l3e ).
6) MSI status: Patients with MSI-H tumors had favorable survival when compared to
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Tabl e 10. Clinicopathological features corr elated with DFS in univariate an alysis
(d iscovery set)
Variable p-value HR 95% CI n
Sex (male vs female ) 0.01 1.471 1.097 1.973 530
Age at diagnosis 0.62 1.004 0.989 1.019 530
Histology (mucinous vs non-mucinous) 0.861 0.962 0.624 1.484 530
Location (rectum vs colon) 0.017 1.403 1.062 1.854 530
Stage <0.001
11vs I 0.248 1.324 0.823 2.131
IIIvs I 0.002 2.096 1.314 3.345
IVvsI <0.001 5.778 3.476 9.604 530
Grade (poorly diff/undiffvs well 0.534 0.831 0.464 1.489 526diff/modera tely diff)
Vascula r invasion (+ vs -) 0.001 1.604 1.206 2.134 490
Lymphatic invasion (+ vs-) 0.005 1.498 1.129 1.988 487
Familial risk (high/moderate vs low) 0.33 1.146 0.871 1.506 530
MSI status (MSI-H vs MSI-LIMSS) <0.001 0.279 0.137 0.566 509
BRAFl Val600Glu mutation (+ vs-) 0.714 0.915 0.57 1.47 483
HR: hazard rat io, CI: confidence interval, n: number of pat ients , diff : differe ntiated, HR> l implies
increasedhazardofevent,HR<1 implies reduced hazard of event.
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patients with MSI-L/MSS tumors with an approximately 72% reduction of hazard for the
event (p<0.001, HR=0.279, 95% CI: [0.137-0.566]) (Figure 131).
4.2.5 Chi- square test result s for correlation between clinicopathological and
molecular variables
We performed this analysis in the discovery set to test for association amongst
clinicopathological and molecular variables. The statistically significant correlations
(p<0.05) are depicted in (Table 11).
Female sex was correlated with colonic location, MSI-H tumors and presence of
BRAFI _Val600Glu mutation in the tumors . Majority of the mucinous tumors were found
in the colon and were also correlated with MSI-H and BRAFl_Val600Glu mutation in the
tumors. BRAFl _Val600Glu mutation was also correlated with MSI-H tumors and
mucinous histology. MSI-H tumors were mostly found in the colon, had high grade and
were mostly found in early stage (stage I and II) patients. Presence of vascular and
lymphatic invasions was correlated with increasing stage and high grade tumors.
Vascular and lymphatic invasions were highly correlated with one another (p=2.68xlO-
!OO). Hence for multivariate analyses, only the data on vascular invasion status was
included into the survival analysis to reduce redundancy .
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Table 11. Cor relation betwe en clinicopathological and molecular var ia bles
(dis covery set)
Var iables p-value Correlation between n
Location and Sex 0.039 females and colon 532
MSI and Sex 0.01 females and MSI-H 511
BRAFI mutation and Sex <0.001 females and mutation 484
Histolo gy and Location 0.014 mucinous and colon 532
MSI and Location <0.001 MSI-H and colon 511
BRAFI Val600Glu and Location <0.001 mutation and colon 484
Stage and Histology 0.027
stage I and non-muci nous,
532
stage II and mucinous
MSI and Histology 0.G38 MSI-H and mucinous 511
BRAFI mutation and Histology 0.048 mutation and mucinous 484
Vascular inva sion and Stage <0.00 1 invasion and stage 492
Lymphatic inva sion and Stage <0.001 invasion and stage 489
MSI and Stage 0.037 MSI-H and stages I & II 511
Vascular inva sion and Grade 0.014 invasion and poorly 488diffe rentiated
Lymphatic invasion and Gra de 0.041 invasion and poorly 485differentiated
MSI and Grade 0.01 MSI-H and poorly diff/undiff 507
Lymphatic and Vascular invasions <0.001 presence of invasion 486
BRAFl Val600Glu and MSI <0.001 mutation and MSI-H 477
Only statistically significant associations are shown in the table, n: numbero f patients.
4.3 Multivariate anal ysis for OS
4.3.1 Multi vari ate analy sis for OS in the discovery set (co-domin ant model)
Multivariate analysis is performed to test for independent predictive value of a variable
when adjusted for other variables in the model. The variables were selected for entry into
multivariate analysis as explained in section 3.5.3. Table 12 shows the multivariate
analysis result for OS assuming co-dominant inheritance in the discovery set. For all the
polymorphisms associated in the multivariate analysis in discovery cohort , the
proportionality assumption was met in the univariate analysis (Figure 10).
In multivariate analysis, four polymorphisms showed an independent prognostic potential
when adjusted for sex, age, stage and MSI status. For MTHFR _Glu429Ala
(NG_0 l3351.1 :g.16685A>C), patients homozygous for the alanine variant had - 72%
greater hazard of death when compared to patients homozygous for glutamate (p=0.036,
HR=1.715, 95% CI: [1.036-2.839]) . For ERCC5_His46His (NG_007146.1:g .11344T>C),
patients homozygous for T had significantly worse OS with - 78% greater hazard of death
when compared to patients homozygous for C (p=O.OI, HR=1.782, 95% CI: [1.l50-
2.763]). For SERPINEl_-675 indeiG (NG_013213 .1:g.4332_4333insA), patients
homozygous for insG had favorable OS with -48 % reduced hazard of death when
compared to patients homozygous for deiG allele (p=0.008, HR=0.5 17, 95% C1: [0.319-
0.840]). In case of GSTMI gene deletion, patients with at least one copy of the gene had
worse OS (-40% increased hazard) compared to patients homozygous for deletion of the
gene (p=0.033, HR=1.404, 95% C1: [1.027-1.919]). Male sex, increasing age and stages
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Table 12. Multivariate analysis result for OS in th e discov ery se t (n= 504)
(co-dominant model)
Var iable p-value HR (95% CI) n
MTHFRJsI 801131 0.105
CAvsAA 0.342 1.175(0 .842-1.639) 230 vs 232
CCvsAA 0.036 1.715 (1.036-2.839) 42v s232
ER CCS_ rsl 047768 0.034
TCvsCC 0.098 1.365 (0.944-1.973) 240vs l73
TTvsCC 0.01 1.782(1.15-2.763 ) 91 vs 173
SERPINEl_r s1799889 0.029
G/- vs -/- 0.238 0.809 (0.569-1.15) 258vs l4 1
GG vs -/- 0.008 0.517(0.319-0.84) 105v s 141
GSTMI gene deletion (+ vs-) 0.033 1.404(1.027-1.919) 228 vs 276
Sex (malevs female) 0.031 1.456 (1.036-2.047) 313vs191
Age at diagnosi s 0.046 1.018(1 -1.036)
Stage <0.001
ll vs l 0.18 1.473 (0.836-2.594) 194 vs 95
III vs I 0.01 2.084 (1.194-3.637) 165 vs95
IV vsl <0.001 11.685 (6.454-21.158) 50 vs 95
MSI status (MSI-HI MSI-L-MSS) 0.004 0.233 (0.086-0.635) 56 vs448
MTHF R rs1801131 is MTHFR G1u429Ala, ERCC5 rs1047768 is ERCC5 His46His ,
SE RPINEI rsl 799889 is SERPINEI -675 indelG, G allele for SERPINEI -675 inde lG is referred to as
insG allele -;;nd - alle le is referred to ~ delG alle le in the text, HR: hazard r<uio,CI: confidence interva l, n:
number of patients, HR> I implies increase d hazard of death, HR< I implies reduced hazard of death.
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III and IV had an increased hazard of death while patients having tumors with MSI-H
status had a significantly favorable OS.
After obtaining these results, we aimed to replicate them in another independent
colorectal cancer patient cohort also from Newfoundland (the validation set). For this
purpose, we obtained their genotypes for four polymorphisms (MTHFR _Glu429Ala,
ERCC5_His46His, SERPlNEI_-675 indelG and GSTMI gene deletion) correlated with
OS in the multivariate analysis in the discovery set, and the multivariate analysis was
repeated.
4.3.2 Multivariate analvsi s for OS in the validation set (co-dominant model)
In the validation set, only the MTHFR _G lu429Ala polymorphism showed independent
prognostic value when adjusted for age, stage and MSI status (Table 13). Interestingly,
while we had found the association of Ala/Ala homozygotes with worse OS in the
discovery set, in the validation set, heterozygotes (Glu/Ala) had - 71% increased hazard
of death when compared with Glu/Glu homozygotes (p=O.005, HR=1.713, 95% CI:
[1.181-2.487]). Thus the same polymorphism (MTHFR _Gl u429Ala) was correlated with
worse OS in the discovery and validation sets, although with different patterns
(homozygosity for alanine in the discovery set and heterozygosity in the validation set).
In order to explore more, we also performed separate multivariate analysis with
MTHF R_G lu429Ala genotypes assuming recessive and dominant models, together with
the other clinicoptahological variables in the model (sex, age, stage and MSI status).
Again we have found that the CC (Ala/Ala) genotype was associated with worse OS in
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Table 13. M u lt iva r ia te analysi s r es u lt for O S in th e va lid a t ion set (n= 224)
(co-do m ina nt model)
Va riable p-value HR (95% CI ) n
MTHFRJs1801131 .010
ACvsAA .005 1.713 (1.181-2.48 7) 92 vs l1 2
CCvsAA .730 0.889(0.454- 1.738) 20vs l 12
ERCC5Js I04776 8 .609
TCvsCC .387 1.197(0.796-1.8) 112vs76
TTvsCC .398 1.261(0. 737-2.159) 36vs76
SERPINEIJs l799 889 .716
G/-vs-/- .420 1.187(0.782-1.802) 103 vs 69
GGvs -/- .766 1.075 (0.669-1.727) 52 vs 69
GSTMI gene deletion (+ vs-) .261 1.234 (0.855-1.780) 99 vs l25
Sex (males vs females) .175 1.282 (0.895-1.837) 118 vs l 06
Age at diagnosis <.001 1.051 (1.034-1.069)
Stage <.001
II vsl .662 1.144(0.626-2.092) 80vs44
III vsI .001 2.609 (1.446-4 .707) 64 vs 44
IV vsI <.001 11.324 (5.918-21.669 ) 36 vs 44
MSI sta tus (MSI-H vs MSI-LlMSS) .002 0.257(0.108-0.609) 21 vs203
MTHFR rs l801131 is MT HFR Glu429Ala, ERCC5 rs1047768 is ERCC5 His46His,
SE RPINE I rsl799889 is SERPlNE I -675 indelG, G allele for S ERPINEI -675 indelG is referred to as
insG allelea nd - allele is referred to ~ delG allele in the text, HR: hazard ratio, CI: confidence interval, n:
number of patients, HR>1 implies increased hazard of death, HR<I implies reduced hazard of death.
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the discovery set when compared to AA+AC genotypes (i.e. recess ive inheritance
pattern). However, in the validation set, AC+CC (Ala/Glu and Ala/Ala) genotypes were
associated with worse OS when compared to AA (GlufGlu) genotype (data not shown)
(dominant inheritance pattern) .
4.3.3 Differences between discoverY and valida tion sets
Three of the four the polymorphisms correlated with OS in the discovery set were not
correlated in the validation set i.e. ERCC5_His46His, SERPlNEl_-675 indeiG and
GSTMI gene deletion. However, the MTHF R_Glu429A la Ala var iant was associa ted
with shorter OS in both sets (homozygosity for alanine in the discove ry set and
heterozygosity for alanine in the validatio n set corre lated with shorte r OS). We sought to
understand these results by first looking at the differences between the discovery and
valida tion sets in terms of thei r important clinicopathological and prognostic
characteristics. Apart from a large difference in the sample size (discovery set has more
than twice the number of patients in the validation set) , the cohorts also differed in other
features . To test if these differences were significant, we performed chi-square tests and
Mann-Whi tney U tests (Table 14). We observed that the validation set had a significantly
higher median age (68.7 years compared to 61.36 years in the discovery set, p<O.OOI).
This is expected since patients were recruited in the validation set regardless of their age
and in the discovery set below 75 years of age . The validatio n set also had a greater
proportion of deaths (6 1.51% compared to 33.3% in the discove ry set, p<O.OO I) and
greater proportio n of events (recurre nce/metastasis /dea th) (66.27% compared to 39. 1% in
the discovery set, p<O.OO I) which may be due to the longer follow -up times for patients
114
Table 14. Differences between the discovery and validation sets
Discovery Valida tion x/Ma nn- Discovery Va lida tion x2lMa nn-
(n=532) (n=252) Whitn ey U (n=532) (n=252) Whitneytest U test
Sex n( %) n (%) OS sta tus n (% ) n( %)
male 327(61.50%) 133(52 .78%) dead 177 (33.30%) 155(61.51 %)
female 205(38 .50%) 119 (47.22%) p=0.021 alive 354(66.60%) 97(38.49%)
Median age (yrs) 61.36 (20.7-75) 68.7 (25.3-91.6) p<O.OOI unknown 1(0 .10%) p<O.OOI
Histology DFS statu s
non-mucinous 471(88.50%) 211(83 .73%) no event 323(60.71%) 85(33 .73%)
mucinous 61(11.50%) 41(16.27%) p=0.062 event" 208(39.1%) 167 (66.27%)
Locati on unknown 1(0 .19%) p<O.OOI
colon 353(66.40%) 202(80.16%) MSI Statu s
rectum 179(33 .60%) 50(19 .84%) p<O.OOI MSI-H 56(10.50%) 24(9.52%)
Stage MSSIMSI-L 455(85 .50%) 228(90.48%)
I 99(18 .60%) 48(19 .05%) unknown 21(4 %) p=0.543
II 206(38.70%) 88(34 .92%) *Vascular/Lymphaticinvasion
1lI 175(32.90 %) 68(26 .98%) 326(61.30%) 64(25.40%)
IV 52(9 .80%) 41(16.27 %) + 166(31.20 %) 101(40 .08%)
unknown 7(2 .78%) p=0.034 unknown 40(7 .50%) 87(3 4.52%) p<O.OOI
Grade 5-F U based tr eatm ent
welldi fflmoderatelydiff 489(91.90%) 211(83 .73%) 5-FUtreated 330(62.03%) 88(34 .92%)
poorlydifflundiff 39(7 .30%) 37(14.68%) other/nochemotherapy 199(37.41 %) 148(58 .73%)
unknown 4(0 .80%) 4 (1.59%) p=O.OOI unknown 3 (0.56%) 16(6.35 %) p<O.OOI
'Vascular invasion in the discovery set and lymphatic invasion in the validation set were compared. Familial risk status and BRAFl Val600Glu
mutation status data were not available for the validation set samples and hence were not compared."event refers to the first occurrence of recurrence,
metastasis or death.
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in the validation set. Even in the age-adjusted survival curves (section 2.3, Figure 4 and
Figure 5), the difference in survival times of the two cohorts remained significant. In
addition, the proportion of rectal cancer patients was greater in the discovery set (33.6%
compared to 19.84% in the validation set, p<O.OOI). Also, the proportion of patients
without lymphatic/vascu lar invasion in the validation set was low (25.4% compared to
61.3% in the discovery set, p<O.OO I). There were also treatment related differences
between the two cohorts. A large portion of patients in the discovery set received 5-FU
based chemotherapy (-62%) compared to those in the validation set (-35%) and the
difference was statistically significant (p<O.OOI). Additionally, the validation cohort had
significantly greater proportion of female patients (p=O.021), stage IV patients (p=O.034)
and patients with poorly differentiated or undifferentiated tumor grade (p=O.OO I) than the
discovery cohort Thus a large number of differences between the two cohorts might be a
likely reason for inconsistent results. These differences may partly account for the
differences in correlations observed in the discovery and validation sets and are discussed
in section 5.3.
4.3.4 Multivariate analv sis for OS in the pooled set (co-dominant model)
We then combined the discovery and validation sets and performed the analysis again in
this pooled sample set since it has a larger sample size and greater power for detection of
correlations (Table 15). In the pooled set, when adjusted for age, stage and MSI status,
MTHF R_G lu429A la, ERCC5 _His 46His and GSTMI gene deletion show independent
predictive potential for overall survival. For MTHF R_Glu429Ala, similar to the results in
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Table 15. Multi variate anal ysis result s for OS in the pooled sample set (n=728)
(co-dominant model)
Varia ble p-value HR (95% CI)
MTHFRJs l 801 131 .106
ACvsAA .035 1.298 (1.018-1.654) 322 vs344
CCvsAA .660 1.094 (0.732-1.636) 62v s344
ERCC5Js I047768 .007
TCvsCC .016 1.390 (1.064-1.816) 352 vs24 9
TT vs CC .003 1.652 (1.185-2.303) 127 vs249
SERPINE1_rs1799889 .381
G/- vs -/- .500 0.913 (0.700-1.190) 361vs2 10
GG vs -/- .165 0.790 (0.566-1.102) 157 vs 210
GSTMl gene deletion (+ vs -) .040 1.273(1.011-1.604) 327 vs 401
Sex( males vs females) .146 1.197 (0.939-1.526) 431vs297
Age at diagno sis <.001 1.046 (1.034-1.059)
Stag e <.001
II vsl .091 1.419(0 .946-2.127) 274vs139
IIIvsI <.001 2.377 (1.592-3.550) 229v s139
IV vsl <.001 10.735 (6.993-16.481) 86 vs 139
MSI status (MSI-H vs MSI-LlM SS) <.001 0.269 (0.142-0.510) 77vs 651
MTHFR rs l8 0 1131 is MTHFR Glu429Ala , ERCC5 rs1047768 is ERCC5 His46His,
SERPlNEl rsl 799889 is SERPINEI :675 indelG, G allele for SERPlNEl -675 indelG is referred to as
insG allelea nd - allele is referred to as deJG allele in the text, HR: hazard ratio, CI: confidence interva ls, n:
number of patients, HR>l implies increased hazard of death, HR< I implies reduced hazard of death.
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the validation set, the heterozygotes had worse survival when compared to homozygotes
for the allele coding for the amino acid glutamate (Glu/Glu) with - 30% increased hazard
of death (p=0.035, HR=1.30, 95% CI: [1.02-1.65]). For ERCC5_His46His, the
heterozygotes (p=0.016, HR=1.39, 95% CI: [1.06-1.82]) and homozygotes for T allele
(p=0.003, HR=1.65, 95% CI: [1.19-2.30]) had worse survival when compared to
homozygotes for C allele. Patients having at least one copy of GSTMl gene had - 27%
increased hazard of death when compared to patients with null allele (p=0.04, HR=I.27 ,
95% CI: [1.01-1.60]) . Increasing age and stages III and IV were also correlated with poor
OS. MSI-H status of tumor, as expected, was predictive offavorable prognosis.
4.3.5 Summa ry of result s of multi variat e ana lvses for OS
The results of multivariate analysis in the discovery set, validation set and pooled set are
shown together in Tab le 16.
Because of the biological role of the MTHFR enzyme in 5-FU function (the main
chemotherapeutic agent used in treatment of patients in the discovery and validation
cohorts), we also attempted to replicate the multivariate model in those patients treated
with 5-FU. This analysis, however, did not find association of this polymorphism in the
discovery, validation or pooled set (data not shown).
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Table 16. Summary of multivariate anal ysis result s for OS in th e discovery set (n=504), va lidation set (n=224) and
pooled sample set (n=728) (co-dominant mod el)
Discovery set Valida tion set Pooled set
(n=504, dea ths=168) (n=224,death s=134) (n=728, deaths=302)
Variable p-value HR (95% Cl ) p-value HR(95% CI) p-valu e HR(95% CI)
MTHFRJsl801131 0.105 0.01 0.106
CAvsAA 0.342 1.175(0.842 -1.639) 0.005 1.713 (1.181-2.487) 0.035 1.298 (1.018-1.654)
CCvsAA 0.036 1.715 (1.036-2.839) 0.73 0.889(0.454-1.738) 0.66 1.094 (0.732-1.636)
ERCC5Js I047768 0.034 0.609 0.007
TCvsCC 0.098 1.365(0 .944-1.973) 0.387 1.197(0.796 -1.80) 0.016 1.390 (1.064-1.816)
TTvsCC 0.01 1.782 (1.15-2.763) 0.398 1.261(0 .737-2.159) 0.003 1.652 (1.185-2.303)
SE RPlNEIJs 1799889 0.029 0.716 0.381
G/-vs- I- 0.238 0.809(0.569-1 .15) 0.42 1.187(0 .782-1.802) 0.5 0.913(0.700-1.190)
GGvs -l- 0.008 0.517 (0.319-0.84) 0.766 1.075(0 .669-1.727) 0.165 0.790(0.566-1 .102)
GSTMI gene deletion (+ vs -) 0.033 1.404 (1.027-1.919) 0.261 1.234(0.855-1.780) 0.04 1.273(1.011-1.604)
Sex (male vs female) 0.031 1.456( 1.036-2.047) 0.175 1.282(0 .895-1.837) 0.146 1.197(0.939-1.526)
Age at dia gnosis 0.046 1.018(1-1.0 36) <0.001 1.051(1.034-1.069) <0.001 1.046 (1.034-1.059)
Sta ge <0.001 <0.001 <0.001
stage II vs I 0.18 1.473(0 .836-2.594) 0.662 1.144(0.626 -2.092) 0.091 1.419(0.946-2.127)
stage 1II vsI 0.01 2.084 (1.194-3.637) 0.001 2.609 (1.446-4.707) <0.001 2.377(1. 592-3.550)
stage lVvs l <0.001 11.685 <0.001 11.324 <0.001 10.735(6.454-21.158) (5.918-21.669) (6.993-16.481)
MSI sta tus (MSI-HI MSI-L-MSS) 0.004 0.233 (0.086-0.635) 0.002 0.257 (0.108-0.609) <0.001 0.269 (0.142-0.510)
AfTHFR rsl80 1131 is AfTHFR Glu429Ala, ERCC5 rs1047768 is ERCC5 His46His, SERPlN E J rsl799889 is SERPlNEJ -675 indelG, G allele for
SERPI NEJ -675 indelG is referred to as insG allele-and - allele is referred to as deiG allele in the text, HR: hazard ratio, CI: confidence interval,
n=number of patients, HR>I implies increased hazard of death, HR<I implies reduced hazard of death.
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4.3.6 Multiva r iate ana lvsis for OS in sex-stratified patients
To test for sex-spec ific differences in associations , we tested the applicab ility of the
multivariate analysis model in males and females separately in the discovery, validation
and pooled sample sets. The results of analysis in female and male patients are
summarize d in Ta ble 17 and Tab le 18, respecti vely. In the case of female patients, none
of the polymorphisms was associated with OS in the discovery or validation sets.
ERCC5_His46His polymorphism was correlated in the pooled set where the
heterozygotes had - 78% increased hazard of death compared to CC homozygotes.
Interestingly, in male patients, all four polymorphisms were correlated with OS in the
discovery set. For MTHFR_Glu429Ala, both the heterozygotes and Ala/Ala homozygotes
had worse survival when compared to Glu/Glu homoz ygotes . The heterozygotes had
- 52% increased hazard of death when compared to Glu/G lu homozygotes. In the
validation set, the heterozygotes had - 116% increase d hazard of death compared to
Glu/Glu homozygotes. Thus corre lation of heterozygo tes with shorter OS in male patients
was confirmed in the validation set. This suggests a sex-specific corre lation of this
polymorphism with OS. This observation may also be a reflection of the greater study
power in the males than in females since males are present in a larger proportion than
females in both the cohorts. In the pooled set, heterozygo tes were corre lated with worse
OS with - 59% increased hazard of death. The ERCC5_His46His. SERPINEl _-
675indeiG polymorphi sms and GSTMI gene deletion were corre lated with OS in the
discovery set but not in the validation set. Their correlation with OS was also observed in
the pooled set.
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Table 17. Multivariate anal ysis for OS in female patients (co-dominant mod el)
Discovery set Valida t ion set Pooled sa mple set
(n=191,death s=54) (n=106,d eath s=54) (n=297, deaths=108)
Variables n-value HR(95%Cl) n-valu e HR(95% Cl) p-value HR(95%Cl)
MTHFR JsI80 1131 0.586 0.1 0.673
ACvsAA 0.332 0.744(0.409-1.353) 0.163 1.524(0 .843-2.754) 0.643 1.100(0.734-1.651)
CCvsAA 0.92 1.052(0.389-2 .846) 0.223 0.388(0.085-1.779) 0.542 0.774(0.340-1.762)
ERCC5Js 1047768 0.15 0.53 0.057
TCvsCC 0.051 1.968(0 .996-3.89 1) 0.268 1.452(0 .750-2.812) 0.019 1.731 (1.094-2.737)
TTvsCC 0.26 1.686(0.679-4.19) 0.786 1.130(0.468-2.728) 0.105 1.656(0 .900-3.046)
SERPl NEJ_rs1799889 0.91 0.15 0.503
G/-vs-I- 0.934 1.028(0.542-1.94 7) 0.073 1.987(0 .937-4.215) 0.352 1.251(0 .78 1-2.004)
GGvs-l- 0.72 0.806(0.248-2.6 17) 0.088 2.109(0.895-4.965) 0.273 1.418(0 .759-2.648)
GSTMJ ene deletion (+ vs -) 0.455 1.241(0 .705-2 .184) 0.871 0.950(0.51 1-1.765) 0.939 .985 (0.663-1.462)
Aae at dia nosis 0.547 1.01(0 .978-1.043) 0.003 1.040(1.014-1.067) <0.001 1.040(1.021-1.060)
Stage <0.001 <0.001 <0.001
II vsl 0.234 1.957(0 .648-5.911) 0.213 1.963(0 .679-5.675) 0.034 2.254 (1.064-4.773)
IlI vsl 0.074 2.82(0.905-8.794) 0.002 5.264 (1.817-15.250) 0.001 3.846 (1.781-8.305 )
IV vsl <0.001 13.373(4.2-42.584) <0.001 28.262 (9.192-86.895) <0.001 22.33500.257-48.635)
MSI status (MS I-H vs MSSIMSI-L) 0.027 0.193(0.045-0.829) 0.013 0.228(0.071-0.728) 0.001 0.245(0.105-0.568)
MTHFR rs1801131 is MTHFR Glu429Ala , ERCC5 rs1047768 is ERC C5 His46His, SERPJNEJ rsl799889 is SERPJNEJ -675 indelG, G allele for
SERPI NEJ _-675 indelG is referred to as insG allele-and - allele is referred to as delG allele in the text, HR: hazard ratio,-CI : confidence interval,n :
number of patients, HR>I implies increased hazard of death, HR<I implies reduced hazard of death.
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Table 18. Multivariate anal ysis for OS in male patients (co-dominant model )
Discovery Set Valida tion set Pooled set
(n=313, deaths=114) (n=118, dea ths=80) (n=431, dea ths=194)
Variable p-value HR (95% CI) p-value HR (95% CI) p-value HR(95% CI)
MT HF RJs1801131 0.024
.013 .015
ACvsAA 0.048 1.516 (1.004-2.288)
.004 2.168 (1.284-3.660) .004 1.592 (1.161-2.183)
CCvsAA 0.014 2.144(1.168-3.937)
.951 1.025(0.459 -2.293) .267 1.317(0.810-2.142)
ERCC5Js I047768 0.085
.685 .070
TCv s CC 0.661 1.106(0.705-1 .734)
.457 1.236 (0.707-2.162) .171 1.263(0 .904-1.766)
TTvsCC 0.037 1.72 (1.033-2.866)
.439 1.334(0.643-2.769) .022 1.599 (1.071-2.387)
SERPlNEIJs1799889 0.019
.279 .033
G/-v s -/- 0.125 0.71 (0.458-I.I)
.438 .807 (0.470-1.387) .054 0.717(0.511-1.006)
GG vs- /- 0.005 0.458 (0.265-0.789)
.110 .601 (0.322-1.123) .013 0.601( 0.403-0.897)
GSTMI gene deletion (+ vs-) 0.044 1.481 (1.01-2.17)
.222 1.352(0.834-2.192) .018 1.422 (1.061-1.904)
Age at diagnosis 0.129 1.017 (0.995-1.039) <0.001 1.068(1.043-1.095) <0.001 1.055 (1.037-1.072)
Stage <0.001 <0.001 <0.001
llvsl 0.461 1.288(0 .657-2.527)
.885 .947 (0.451-1.988) .474 1.195 (0.734-1.944)
III vsl 0.033 2.024 (1.06-3.867)
.032 2.263 (1.072-4.778) .002 2.122( 1.318-3.416)
IV vsl <0.001 11.808 (5.744-24.276)
. <0.001 6.717 (2.860-15.776) <0.001 7.366(4.333-12.522)
MSI sta tus (MSI-H vs MSSIMSI-L ) 0.062 0.26 (0.063-1.067)
.036 .206(0.047-0.900) .012 0.279 (0.103-0.758)
MTHFR rsl801131 is MTHFR-G1u429Ala, ERCC5 rs l047768 is ERCC5-His46His, SERPlNE I rsl799889 is SERPINE I -675 indelG, G allele for
SERPlNE I -675 indelG is referred to as insG allelea nd - allele is referred to as delG allele in the text, HR=hazard ratio, CI=confidence interval, n:
number of patients, HR> I implies increased hazard of death, HR<I implies reduced hazard of death.
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4.4 Treatment with 5-FU and survival in stage III colon cancer patient s
5-FU alone or in combination with other drugs is the most widely used chemotherapeutic
agent in treatment of stage III colon cancer (200,201). To see the effect of5-FU treatment
on patient survival, we compared survival times of stage III colon cancer patients in the
pooled set treated with 5-FU (n=134) and those who received no chemotherapy or were
treated with other drugs (n=29). Stage III colon cancer patients were chosen since most of
these patients are treated with 5-FU (-82%). In addition, the analysis was performed in
the pooled set to have a large sample size.
In the univariate analysis, as expected (200,201), patients treated with 5-FU had longer
survival times (p<O.OOI) when compared to other patients (Figure 14). A multivariate
analysis including MSI-H status and age also showed that 5-FU treatment is a MSI status
independent prognostic factor and patients who received other chemotherapy or no
chemotherapy had - 235% increased hazard of death (p<O.OOI , HR=3.348, 95% CI:
[2.034-5.511]). These results confirm that 5-FU treatment improves survival in treated
patients .
Since MTHFR enzyme is indirectly involved in the mechanism of action of 5-FU (20 I),
we also analyzed the MTHF R_G lu429A la polymorphism (which reduces MTHFR
activity) with survival in stage III colon cancer patients treated with 5-FU from the
pooled set (n=134). The polymorphism was not correlated with survival in both
univariate and multivariate analyses, suggesting that the MTHFR_G lu429Ala
polymorphism does not affect survival in 5-FU treated stage III colon cancer patients,
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Figure 14. Kaplan -Meier plot for stage III colon cancer patients based on treatment
characteristics (pooled set, OS)
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although these results could have also been obtained due to small sample size. This
analysis was not performed in patients who received other chemotherap y or no
chemotherapy due to small sample size (n=29).
As an exploratory analysis, we also wanted to analyze the combined effect of
polymorphi sms in MTHFR and TYMS genes on survival in 5-FU treated stage III colon
cancer patient s since these proteins are involved in 5-FU pathway. The genotype s for the
four polymorph isms MTHFR (Glu429Ala and Ala222Val) and TYMS (2RJ3R VNTR and
indel6bp) were available only for the samples in the discovery set (n=I06). This small
sample size made it imposib le to perform the statistical analyse s intended above (data not
shown). Thus currentl y it is not known whether these polymorphi sms in MTHFR and
TYMS genes affect survival in our 5-FU treated patients .
4.5 Multivariate analysis for DFS
DFS was our secondary end-point for analysis . In the discovery set, similar to analysis
with as , we selected the variables using the backward elimination LR method and
performed multivariate Cox-regression analysis. The results for analyses in the discovery,
validation and pooled sets are shown in Tabl e 19. In the discovery set, polymorphi sms in
ERCC5 and OGGI genes were correlated with DFS after adjustment for stage and MSI
status. For the ERCC5_His46His polymorphism , patient s homozygous for the T alle le
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Table 19. Multivariate anal ysis for DFS in the discovery set (n=504) , validation set (n=227) and pooled sample set
(n=734) (co-dominant model)
Discovery set Valida tion set Pooled sa mple set
(n=504,ev ents=198) (n=227.events= 148) (n=734. dea t hs=348)
Vari abl e p-value HR (95% CI) p-vaJue HR( 95% CI) p-value HR (95% CI)
ERCC5Js I047768 0.098 0.036 0.007
TC vs CC 0.211 1.235 (0.887-1.72) 0.041 1.483 (1.015-2.167) 0.035 1.304 (1.018-1.670)
TTvsCC 0.032 1.54 (1.039-2.288) O.ot8 1.805 (1.107-2.943) 0.002 1.611 (1.190-2.182)
OGGIJs I052133 0.082
GC vs CC 0.59 1.088 (0.801-1.477)
GGvsCC 0.025 1.81(1.075 -3.038)
ERCCIJs l 16 15 0.152
TC vs TT 0.281 1.193 (0.866-1.643)
CCv sTT 0.054 1.477 (0.993-2.196)
TYMS_rs16430 0.171
6 bp/-vs6 bp/6 bp 0.235 0.831 (0.611-1.128)
-/- vs 6bp /6bp 0.325 1.252 (0.8-1.96)
GSTMIgene deletion( +vs -) 0.09 1.278 (0.962-1.698) 0.366 1.167 (0.835-1.632) 0.125 1.179 (0.955- 1.456)
Location (rectum vs colon) 0.055 1.334( 0.994-1.789) 0.743 1.070(0 .714-1.604) 0.386 1.107 (0.88-1.392)
Stage <0.001 <0.001 <0.001
II vsl 0.099 1.512 (0.925-2.472) 0.036 1.821 (1.041-3.187) 0.0 13 1.588(1.101-2.292)
III vsl 0.003 2.09( 1.281-3.407) <0.001 3.144( 1.793-5.513) <0.001 2.321( 1.614-3.339)
IV vsl <0.001 6.24(3.692-10.533) <0.001 130.162 (52.48-322.83) <0.00 1 7.721(5. 224-11.414)
MSI status (MS I-H vs MSI-U MSS) 0.004 0.35 (0.168-0.71) 0.007 0.366 (0.176-0.758) <0.001 0.373 (0.225-0.621)
ERCC5Js I047768 is ERCC5_His46His, OGGI J s I052133 is OGGI_Ser326Cys , ERCC IJs l 16 15 is ERCCI _A snI18Asn, TYMSJs 16430 is
TYMS_inde16 bp in 3' -UTR, 6 bp in TYMSJs16430 refers to the sequence CTTT AA, HR: hazard ratio, CI: confidence interval , n: number of patients,
HR> I implies increased hazard of event, HR<I implies reduced hazard of event .
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had shorter DFS (-54% increased hazard of event) compared to patients homozygous for
the C allele (p=0.032, HR: 1.542,95% CI: [1.039-2.288]) . For the OGGl _Ser326Cys
polymorphism, patients homozygous for cysteine had significantly reduced DFS (- 81%
increased hazard) compared to patients homozygous for serine (p=0.025, HR:1.808, 95%
CI: [1.075-3.038]). The proportionality assumption was fulfilled for associations of
ERCC5_His46His and OGGl _Ser326Cys polymorphisms with DFS in the univariate
analysis. In addition, tumor stages III and IV were correlated with significantly worse
DFS when compared to stage I, and MSI-H status of tumor was correlated with a
favorable DFS.
For analysis in the validation set, genotypes for OGGl _rsl052133, ERCCIJsl16l5 and
TYMS_rsl6430 polymorphisms were not available . On analyzing the available variables
(ERCC5_His46His, GSTMI gene deletion, location, stage and MSI status) , both the
heterozygotes and minor allele homozygotes for ERCC5_His46His crr were correlated
with worse DFS when adjusted for stage and MSI status. T allele homozygotes had - 81%
increased hazard of event when compared to C allele homozygotes (p=O.O18, HR: 1.805,
95% CI: [1.107-2.943]). Heterozygotes had - 48% increased hazard of the event
(p=0.041, HR: 1.483,95% CI: [1.015-2.167]). Thus the results suggest the association of
ERCC5_His46His with poor DFS in colorectal cancer patients.
In the pooled set, ERCC5_His46His was again correlated with worse DFS when adjusted
for stage and MSI status. Both the heterozygotes (-30% increased hazard) (p=0.035,
HR=1.304, 95% CI: [1.018-1.67]) and homozygotes for T allele (-61 % increased hazard
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of event) (p=0.002, HR=1.611, 95% CI: [1.190-2.182]) had significantly worse DFS
when compared to homozygotes for C allele.
When the multivariate analysis results for DFS and OS were compared,
ERCC5_His46His polymorphism , which was associated with DFS in the discovery ,
validation and pooled sets, was also associated with OS in the discovery and pooled
cohorts (Table 16 and Table 19). MTHFR_Glu429Ala polymorphism was associated
with OS in discovery, validation and pooled cohorts, but did not remain in the
multivariate model of DFS. Two other polymorphisms associated with OS in the
discovery cohort namely SERPINE1_-675indeIG and GSTMl gene deletion, were not
associated with DFS in multivariate analysis. In the case of clinicopathological and
demographic variables, sex, age, stage and MSI status were significantly associated with
OS in the discovery cohort while only stage and MSI status were found to be significantly
associated with DFS in multivariate analysis in all three cohorts .
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Chapter 5. Discussion
Colorectal cancer is a critical health concern in Newfoundland since it has the highest
age-standardized incidence and mortality rates in Canada (27). In recent years, there has
been an upsurge in genetic prognostic studies performed in various colorectal cancer
patient cohorts in an attempt to identify independent genetic prognostic markers.
Identification of genetic prognostic markers may not only help in clinical prognostication
of the patients but will also help us to understand the underlying mechanisms of variable
prognosis in patients . For this thesis project, we have performed genetic prognostic
research in two independent colorectal cancer patient cohorts from Newfoundland. The
survival end-points analyzed were as (primary end-point) and DFS (secondary end-
point).
In the first stage of the project, 27 genetic polymorphisms were analyzed in relation to
as and DFS in a discovery cohort of 532 patients from the NFCCR. The second stage of
the project was for the replication of results obtained in the first stage in a validation set
comprising an additional 252 colorectal cancer patients , also from Newfoundland. For
as, a sex-stratified analysis was also performed in the discovery and validation sets.
Compared to most other genetic prognost ic studies in colorectal cancer, this retrospective
cohort study has certain unique strengths . This is the first such study conducted in the
Newfoundland population and amongst the few in Canada. In addition to external
validation of previously reported correlations, we have performed an internal validation
in which we tried to replicate the initial findings in another cohort from Newfoundland.
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Such internal validation studies are rarely found in the literature . Both cohorts have a
significantly large number of patients followed-up for a significan t duration (up to over
10 years), a resource which only a few research groups have.
5.1 Univariate analysis results for OS in the discovery set
In univaria te analysis, six polymorph isms were correlated with OS in the discovery set in
the co-dominant model: MTHFR_Glu429Ala, ERCC5_His46His, PTGS2_c.3618A/G in
3'-UTR, SERPINEI_-675 indelG, MMPI_-1607 indelG and GSTMI gene deletion .
PTGS2_3618A/G was excluded from multivaria te analysis because of its low minor allele
frequency (1.63%) in order to prevent unreliable statistical results (193). Correlations
with the remaining 21 polymorph isms were not detected in this cohort .
5.2 Multivariate model for OS in the discovery set
The multivariate analysis model for the discovery set assuming codominant inheritance
includes eight variables, each of which had independent predictive value for OS when
adjusted for other variables in the model. Male sex, increasing age, tumors with advanced
stage (III and IV) and MSI-L/MSS were predic tive of poor survival. Along with these
clinicopathologica l variables, four genetic polymorphisms showed independent predictive
value for OS: MTHFR_G1u429Ala, ERCC5_His 46His, SERPINEI_-675 indelG and
GSTMI gene deletion.
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For ERCC5_His46His , our finding suggests worse as (-78 % increased hazard) for
patients homozygous for T allele (TT) when compared to patients homozygous for C
allele (CC). This result is similar to two other studies in which patients homozygous for T
allele had a worse as and PFS (84,87). Two other studies did not find a correlation of
this polymorphism with as (75,87). ERCC5_His46His is a non-splice site synonymous
polymorphism whose functional impact is not clearly known and its potential biological
role in prognosis of cancer patients remains to be elucidated .
In case of SERPlNEl _-675 indelG, the insG allele has been linked to lower
transcriptional activity of the gene (144). The functional role of SERPINEl in cancer
prognosis is ambiguous. For example, it has been shown to reduce tumor angiogenesis at
high concentration while at low concentration it has been shown to induce tumor
angiogenesis and metastasis (202,203). On the other hand, studies in animal models as
well as in vitro experiment s suggest that the worse prognosis of high SERPINEI
expression due to delG allele may be due to its pro-metastatic and pro-angiogenic effect
via multiple mechanisms such as altering cell migration and adhesion properties (203). In
our study, patients homozygous for the insG allele, which is associated with decreased
transcription of the gene, had - 48% reduced hazard of death compared to the patients
homozygous for delG allele, which may be due to the reduced pro-angiogenic and pro-
metastatic abilities of the protein. Our finding is concordant with that in a Swedish
colorectal cancer patient cohort in which insG homozygotes had a favorable prognosis
compared to heterozygote s and delG homozygotes (145).
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In the case ofa GSTMl gene deletion, patients with at least one copy of the GSTMl gene
showed -40% increased hazard of death when compared to patients with null genotype.
Most patients in the discovery set were treated with 5-FU based chemotherapy and/or
radiotherapy and it is known that part of the mechanism of these therapies is through
generation of reactive oxygen species (ROS) which cause oxidative damage to the tumor
cells (204,205). A possible explanation for our finding could be the enhanced efficacy of
these therapies in patients with GSTMl null genotypes leading to favorable prognosis .
This result contrasts with the findings in a small Hungarian cohort of colorectal cancer
patients in which Dukes' stage B colorectal cancer patients (n=34) with homozygous
deletion of GSTMl gene had worse as when compared to patients with at least one copy
of the gene (95). This discrepancy between our results and Csejtei et al. (95) study may
be due to differences in patient cohort size and stage (95). However, several other studies
also did not find a correlation of this gene deletion with as (77,78,96,97,101).
For MTHFR _Glu429Ala, patients homozygous for the amino acid alanine (Ala/Ala) had
- 72% increased hazard of death when compared to patients homozygous for the amino
acid glutamate (Glu/Glu). This correlation of alanine variant with poor survival is
concordant with another study in a Spanish colorectal cancer patient cohort in which
patients homozygous for the amino acid glutamate (Glu/Glu) had favorable as (137). In
another study, a result discordant with ours was reported. Female colorectal cancer
patients (mixed ethnicities) homozygous for amino acid glutamate (Glu/Glu) were
reported to have favorable as relative to other genotypes (Ala/Ala and Glu/Ala) (133).
However, several other studies did not find a correlation with this polymorphism
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(76,78,128,130,134,135). This polymorphism and its relation to prognosis are discussed
in detail in the later sections.
5.3 Multivariate analysis for OS in the validation set
We next aimed to replicate the multivariate model in the discovery set in the validation
set (consisting of252 patients from Newfoundland) including sex, age, stage, MSl-status,
MTHFR _Glu429Ala, ERCC5_His46His, SERPI NE1_-675 indeiG and GSTM l gene
deletion genotypes. In the validation set, the correlations of age, stage and MSI-status, but
not sex were replicated. Similar to the results in the discovery set, increasing age,
advanced stages (III and IV) and MSI-L/MSS were significantly correlated with worse
OS in the validation set. In the case of genetic polymorphisms, ERCC5_His46His,
SERPlNE 1_-675 indelG polymorphisms and GSTM l gene deletion were not correlated
with OS in the validation set. Therefore, their results in the discovery set were not
replicated in the validation set. However, interestingly, MTHFR _Glu429Al a
polymorphism was correlated with OS, although this time, the heterozygotes (Glu/Ala)
had worse prognosis compared to homozygotes for glutamate (Glu/Glu). This association
is different than that in the discovery set where homozygotes for alanine (Ala/Ala) had
poor prognosis.
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5.4 Possible reasons for differences in results obtained in the discovery
and validation sets
Our validation study did not validate the associations of ERCC5_His46His, SERPINEI_-
675 indelG polymorphisms and GSTMI gene deletion with OS. However, we found the
association of two different genotypes with OS in the case of MTHFR _Glu429Ala
polymorphism. While these two genotypes (CC homozygous genotype coding for the
alanine variant in the discovery set and AC heterozygous genotype coding for both
alanine and glutamate variants in the validation set) were different from each other,
nevertheless, they contained the same allele (C allele coding for alanine variant). The
possible reasons for such an observation could be:
i) Chance of correlations being false positives or false negatives
ii) Differences in study power in two cohorts
iii) Differences between the two cohorts
iv) Sex-specific effects
v) Other polymorphisms in linkage disequilibrium with MTHFR _Glu429Ala
Chance of correlation s being false positives or false negatives: It is possible that
the correlations observed in the discovery set, which were not replicated in the
validation set (ERCC5_His46His, SERPlNEI_-675indeIG, GSTMI gene deletion) are
false positives, particular ly in case of the SERPlNEI_-675 indelG, ERCC5_His46His
polymorphisms and the GSTMI gene deletion . Alternatively , it is possible that the
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results obtained in the validation set are false negatives. Considering the small sample
size of the validation set, it may not have enough power to detect a similar effect (see
below).
ii) Differences in study power in two cohorts: Our analysis showed that heterozygo tes
generally have more study power to detect a corre lation since they are in greater
numbers compared to minor allele homozygotes (data not shown). Correlations of
minor allele homozygotes with OS were observed in the discovery set for
MTHFR_G1u429Ala, ERCC5_His46His, SERP INE 1_-675 indelG polymorp hisms
and GSTMI gene deletion, but not in the validation set. This might be due to the
insuffic ient power because of the small cohort size in the validation set (less than half
the size of discovery set) and the lower number of minor allele homozygotes when
compared to the discovery set. Alternat ively, the observation may also be due to
smaller effect-size of the polymorphisms in the validation cohort than the discovery
cohort, which might have remained undetected.
iii) Differences between the two cohorts: The validation set is not fully comparab le to
the discovery set in terms of cohort size, number of events and a few variab les (e.g.
age) . Specifically, the validation set has a greater percentage (or earlier occurrence) of
deaths than the discovery cohort (62% compared to 33% in discovery set, p<O.OOI)
and this cohort is characterized by patients with a statist ically significa ntly higher
median age compared to the discovery set (p<O.OO I). It is also likely that medical care
might have been different for the discovery and validation cohort patients, since they
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were recruited at different time period s.
It is also likely that inter-patient variability in folate intake or bioavailability can
modify the prognosis of the patients . Additionally, folate pathway involves a number
of other genes which may be polymorphic (206). These variations may also modify
the effect of MTHFR _Glu429Ala in colorectal cancer prognosis. It is known that
older individuals have an impaired ability to absorb dietary folate (207) . Therefore the
age difference between the cohorts may also explain why we detected an association
with different patterns (homozygosity in discovery set and heterozygosity in the
validation set) of MTHFR _Glu429Ala with OS in these two cohorts. Possible
differences between young and old colorectal cancer patients in terms of folate
pathway are discussed in detail in section 5.4 .2.
Additionally, a significantly greater proportion of patients in the discovery set were
treated with 5-FU compared to patients in the validation set. This difference may
account for the higher OS rate of the discovery set patients compared to the validation
set patients, even after age-adjustment (section 2.3).
iv) Sex-specific effect: It is also possibl e that the differences in associations in the two
cohorts may be due to sub-group effects. For example , in females, none of the
polymorphisms were correlated with OS in the multivariate analysis in either patient
set. But in males , the association ofheterozygotes for MTHFR _Glu429Ala with OS
was detected in both sets . This result suggests that prognostic mechanisms may differ
between male and female colorectal cancer patients and it is discussed in detail in
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section 5.5.
v) Other polymorphisms in LD with M THFR_G lu429A la: MTHFR_Glu429Ala lies
in a 12 kb long LD block which has a number of other known SNPs (Figure 15). It is
possible that the true prognostic marker, if it indeed exists, may be a SNP in close
proximity to MTHFR _Glu429Ala in this LD block with a high (but not complete)
correlation with it. For example, another polymorphism MTHFR_A la222Va l is in the
same LD block as MTHF R_Glu429A la but these two SNPs are not correlated with
each other (data not shown). MTHFR _A la222Va l results in a thermolabile enzyme
and causes a more significant reduction in the MTHFR enzyme activity than
MTHFR _Glu429Ala (136,208). It is also reported that MTHFR activity is further
reduced if these two polymorphisms are present together (136,208,209). This
polymorphism was included in our study too. However, it was not associated with OS
in the discovery set. Further studies on other SNPs in this LD block and their
correlations with prognosis are warranted.
5.5 Folate pathway, MTHFR_ Glu429Ala polymorphism and their
possible relation to cancer prognosis
Although the patterns of associations differ, MTHFR _Glu429Ala polymorphism was
associated with OS in both the discovery and validation sets. In the discovery set, AlaiAla
homozygotes had - 72% increased hazard of death compared to Glu/Glu homozygotes
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Figure 15. LD block of MTHFR_Glu429Ala (rsI801131)
II II t 1 I IIII I 1 i I
---=----------=~l
The black triangle shows the LD block in which MTHF R_G1u429A la (rs I80113 1) is located (circled) .
Below the LD map. other known polymorphisms in this block are shown. rs15375l 6 and rsl3306553
(which are shown in boxes) are the first and last SNPs respectively of the LD block. rs l80 1l3 1 is circled to
help demonstrate the relative position of this polymorphism within this LD block.
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(p=0.036, HR: 1.715,95% CI: [1.04-2 .84]) while in the validation set, the heterozygotes
(Glu/Ala ) had - 71% increased hazard of death compared to Glu/Glu homoz ygotes
(p=0.005, HR: 1.713,95% CI: [1.181-2.487]) .
Both genotypes (CC, AC) are known to lead to reduced MTHFR enzyme activity
(136,208). The role of the MTHFR_G lu429Ala polymorphism in colorectal cancer
outcome seems to be complex and currently not well understood . Based on the current
literature findings about this variant and its function , the followin g mechanisms by which
MTHFR variants leads to poor outcome can be suggested .
Folate, also known as vitamin B9, is an essential molecule for one-carbon transfer
reactions. MTHFR is involved in folate metaboli sm where it converts 5,IO-methylene
tetrahydrofolate (5,IO-MTHF) to 5-methyl tetrahydrofolate (5-MTHF ), which is the
circulatory form of folate (206) . Both forms of folate mediate one-carbon transfer
reactions although for different purposes . 5, IO-MTHF is predominantl y used for the de
novo synthesi s of thymidine and purines which are used by the replicating cells for DNA
synthesis whereas 5-MTHF is predominantl y used for synthesis of methionine from
homoc ysteine , which is then used for synthesis of S-adenos yl methionine (SAM) (206).
SAM serves as a methyl donor for a large number of biological reaction s, includin g
methylation of DNA (206) (Figure 16). MTHFR enzyme has two domains, a catalytic
domain and a regulatory domain and the Glu429Ala polymorphism lies in the regulator y
domain of the protein (2 10). Studies in human lymphocytes have reported reduced
MTHFR enzyme activity in alanine variant (136 ,208). Although both heterozygotes and
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Figure 16. Folate pathway with normal MTHFR activity
Methyl donor for multip le
methylation reactions ,
including DNA methylation
5, IO-MTH F: 5, IO-methylene tetrahydro folate, 5-MTHF : 5-methyl tetrahydrof olate, MTH FR: methylene
tetrahydrofolatereductase,SAM:S-adenosylmethionine
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homozygotes have reduced enzyme activity, the effect is more severe in alanine
homozygotes which have - 60% of the normal enzymatic activity, while the
heterozygotes have - 80% of the normal enzymatic activity (136,208). Reduced MTHFR
activity can thus result in the accumulati on of 5, 10-MTHF and a concurrent reduction of
5-MTHF since the former is not efficiently converted to the latter. We believe that the
accumulation of 5, IO-MTHF and concurrent reduced availability of 5-MTHF may lead to
poor prognosis in patients. From clinical trials and animal studies, the role of folate
supplementation in prevention of colorectal cancer has been established (211). However,
reports have recently emerged which suggest different roles of folate supplementation in
different scenarios, i.e. folate supplementation indeed prevents development of colorectal
adenoma but once a colorectal adenoma has developed, high folate intake in fact aids its
growth and progression (211-214). In rat models of colorectal cancer , folate
supplementation has been associated with progression of already developed cancer (213).
Also, in the Aspirin/Folate Polyp Prevention Study, folate supplementation was
associated with higher risk of advanced adenomas as well as increased number of
adenomas in patients with previously established colorectal adenomas (211,213). It is
believed that with folate supplementation, the greater availability of nucleotide precursors
is used by the rapidly dividing tumor cells which favor tumor progression
(206,212,213 ,215). In the case of our study, it is likely that for patients with reduced
MTHFR enzyme activity (Ala/Ala homozygotes and Glu/Ala heterozygotes for
MTHFR_Glu429Ala polymorphism), the accumulation of 5, IO-MTHF, which is
predominantly used for nucleotide synthesis, may make nucleotide precursors available to
141
tumor cells in abundance. This may have assisted tumor growth and progression
eventually leading to poor prognosis (Figure 17). In a study using knockout mice with
heterozygous or homozygous deletions of the MTHFR gene, it was observed that the
amount of SAM as well as the extent of DNA methylation were significantly reduced,
suggesting that reduced MTHFR activity (in our case, due to Glu429Ala polymorphism)
may lead to similar, although less severe observation (216). A Harvard group also
reported that global DNA hypomethylation in colon tumor cells was correlated with
worse cancer-specific survival as well as as in two independent cohorts with over 600
samples (217). Thus, reduced activity of MTHFR due to MTHFR _Glu429Ala may have
led to reducedsynthesis of SAM, and this may have led to DNA hypomethylation which
in tum could have led to poor prognosis in our patients. DNA hypomethylation is known
to induce carcinogenesis by mechanisms such as rendering the DNA hypermutable and
inducing strand breaks, destabilizing the chromatin' s conformation, deregulating gene
transcription or even triggering inflammatory pathways (215,217). These mechanisms
may increase tumor aggression as well and lead to poor prognosis (217). These
hypotheses and possible explanations are based on literature findings, often ambiguous,
and hence need to be further evaluated.
5.5.1 Correlation orGlu/Ala heterozvgotes wit h worse OS in the va lida tion set
In the validation set, the heterozygotes for MT HFR_G lu429A la had a worse as
compared to Glu/Glu homozygotes while in the discovery set, Ala/Ala homozygotes had
poor as.This difference in associations may be due to the age-specific differences in the
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Figure 17. Hypothe sized changes in folate pathway with reduced MTHFR activity
due to M THFR_ Glu429Ala polymorphi sm
SAM
(methyl donor for DNA methylation)
Pur ine a nd th ymidin e synthesis
Accumu lation of 5,\ O-MTHF
maymakeabundantnucleotides
availab le for tumor cells to grow
Reduction of 5-MTHF may
cause reduced synthesis of SAM
and DNA hypo methylation
5,IO-MTHF : 5,10-methylene tetrahydrofolate, 5-MTHF : 5-methyl tetrahydrofolate, MTHFR : methylene
tetrahydrofolatereductase,SAM:S-adenosylmethionine
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folate pathway. The validation set has a significantly higher median age compared to the
discovery set (p<O.OO I). It is also known that older individuals have an inherent reduced
ability to absorb dietary folate (207). We hypothesize that although the low availability of
folate may not provide ample amount of nucleotide precursors for tumor progression,
reduced absorption of folate coupled with reduced MTHFR activity may lead to a severe
deficiency of available 5-MTHF in aged individuals. This may have caused severe
deficiency of SAM and subsequent DNA hypomethylation. Hence this association may
be age-specific in older individuals and heterozygosity of the polymorphism may be
sufficient to cause worse prognosis (Figure 17). In this case, we would also expect to
find association of the AlaiAla homozygotes with as as well. This possible association
might have been missed because of the low number of homozygotes in this cohort (i.e.
because of insufficient power).
5.6 Validation of correlation of MTHFR_ Glu429Ala polymorphism with
OS in male patients (co-dominant model )
In the sub-set of male patients, correlation of MTHFR _Glu429Ala polymorphism was
replicated in the validation set. In both the discovery and validation sets, the
hetereozygotes (Glu/Ala) had a worse as when compared to Glu/Glu homozygotes. The
AlaiAla homozygotes were also associated with worse as in the male patients of the
discovery set. However, in female patients, none of the polymorphisms were correlated
with as either in the discovery set or validation set. Although this may be due to lack
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power (i.e. false negative findings), these data sugges t a gender-specific corre lation of
this polymorphism with OS.
Reports on gender-specific diffe rences for MTHFR _G lu429Ala or in the folate pathway
are limited . In one study in healthy Singaporean Chinese individuals , males had a
significantly greater extent of methylation of the MTHFR gene compared to females
(2 18). If this does cause an inherent reduct ion in MTHF R gene expression in men, then
the lower amount of MTHF R coupled with the Glu429Ala polymorphism may have led
to increased 5, IO-MTHF and reduced 5-MTHF in males compared to females. This
increase in 5, IO-MTHF and concurrent decrease in 5-MTHF may have led to worse
prognosis in males via increased availability of nucleotide precursors for tumor cells and
increase d DNA hypomethylation respectively. This male-specific correlation with
surviva l in our study is in conflict with a previous study in a cohort of 141 metastatic
colorecta l cancer patients in which female patients homozygous for glutamate (GluJGlu)
had a longer OS compa red to female patients homozygous for alanine (Ala/Ala) or
heterozygotes (GiuJAla) after univariate analys is (133). However , all the patients in that
study were stage IV patients (metastatic colorectal cancer) and these authors did not
perform a multivariate analysis. Our study predominantly contains early stage patients
and includes multivariate analysis. Therefore their results are not directly comparab le to
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5.7 Validation of correlation of ERCC5_His46His polymorphi sm with
DFS in the validation set (co-dominant model)
DFS was our secondary end-point for analysis and included the patients who experienced
recurrence or metastasis in addition to those included in OS analysis . In the discovery set,
the ERCC5_His46His and OGG1_Ser326Cys polymorphisms along with stage and MSI
status were correlated with DFS. For ERCC5_His46His (C>T), patients homozygous for
the T allele had worse DFS compared to homozygotes for C allele (p=0.032, HR=I .54,
95% Cl= [1.04-2.29],) while for OGG1_Ser326Cys, patients homozygo us for cysteine
had worse DFS (p=0.025, HR= 1.81, 95% CI: [1.2-3.72]).
In the validation set, only the genotypes for the ERCC5_His46His polymorphism but not
OGG1_Ser326Cys, were avai lable for analysis. In this set too, patients homozygous for
the T allele had a worse DFS with - 81% increased hazard of event when compared to
patients homozygous for the C allele (p=0.018 , HR=1.805 , 95% CI: [1.107-2.943]). The
functional consequences of this polymorphism are not yet known . One possibility is that
the true correlation could be due to another polymorphism in LD with ERCC5_His46His
(Figure 18). ERCC5 is a DNA repair protein and the ERCC5_His46His polymorphism
has been reported to be associated with reduced risk of developing lung cancer in
individuals homozygous for the variant alle le (TT) in a Norwegian case-control study
(2 19). In other studies, LOH at l3q33 which encompasses the ERCC5gene is observed in
prostate cancer, head and neck cancer and ovarian cancer cells (220-223) . However, LOH
of the ERCC5 gene is less frequently observe d in colon cancer cells when compared to
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Figure 18. LD block of ERCC5_His46His (rsI047768)
Only the beginning of the LD block is shown due to space limitations. Locat ion of ERCC5_His46His
polymorph ism (rs I047768) in the block is circled .
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other cancers (224). LOH of ERCC5, as well as its down regulation were associated with
a favorable PFS in ovarian cancer patients treated with platinum-based chemotherapy,
presumably due to increased efficacy of the drugs (225). However, the role of ERCC5
and the ERCC5_His46His polymorphism in recurrence or metastasis in colorectal cancer
patients is yet to be investigated. Therefore this polymorphism or other genetic variations
closely linked to it are interesting candidates as disease-progressio n markers in colorectal
cancer and further studies are warranted.
5.8 Absence of correlations of 22 polymorphisms in the discovery set
In the discovery set, only four out of the 27 chosen polymorphisms were correlated with
OS. Thus correlations of22 polymorphisms (PTGS2_36 18NG in 3'-UT R was excluded
from analysis due to its low mAF) with survival were not detected. All 27 polymorphisms
were reported to be correlated with survival in at least one study in the literature (section
1.7) which was the primary reason for selection of these polymorphisms for inclusion in
this project. It is likely that the absence of correlations of these 21 polymorphisms
(PTGS2_c.3618NG excluded) in our study is due to differences in cohort characteristic s
between our study and previous studies, a situation commonly observed in literature
(181,182). These differences between the cohorts may be in terms of ethnicity, treatment
characteristics, variable follow-up times and variable clinical characteristics. The
discovery cohort is one of the largest colorectal cancer cohorts in which such a study has
been performed. This cohort is predominantly composed of early stage Caucasian
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patients followed up to over 10 years, a large percentage of which were treated with 5-
FU-based chemotherapy. These characteristics may not be shared by other cohorts and
we suggest that this may be a reason why these 22 polymorphisms were not correlated in
this cohort.
Our study has certain drawbacks. Firstly, the validation cohort has less than half the
number of patients compared to discovery cohort. Secondly, the discovery and validation
cohorts have dissimilariti es in terms of patient and tumor characteristics. Thirdly, the
discovery cohort is biased toward early-stage patients relative to the validation cohort .
These differences between the two cohorts may have limited the validation of
associations observed in the discovery cohort.
Genetic prognostic research is an emerging field and it currently faces certain challenges.
Multiple studies performed on the same genetic marker may not always give the same
results due to differences in cohort characteristics, treatment characteristics, study design
and statistical methods used. Hence larger studies, including meta-analysis or large
prospective studies may be necessary to establish the prognostic relevance of genetic
markers.
5.9 Conclusion
This is the first study in NL and one of the few studies in Canada to investigate the
potential for using inherited variants as prognostic markers in colorectal cancer. It is also
one of the few studies in the world that attempts to validate the results obtained in an
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additional patient cohort in colorectal cancer. We suggest that larger studies on the
MTHFR _Glu429Ala and ERCC5_His46His polymorphisms, as well as other variants in
linkage disequlibrium with these polymorphisms , should be performed. In the case of
MTHFR _Glu429Ala, sex-specific functional studies are also warranted. Eventually these
studies may help to better predict the outcome of patients and to enable personalized
treatment based on a patient's genetic profile.
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Fig At. OS plot of NFCCR cohort
(n=735)
OS plot of NFCCR cohort (n=735).
5-year OSrate - 62%.
Fig A2. OS plot of entire validation cohort
(n=280)
OS plot of entire validation coh0I1(n=280) .
5-yearOS rate - 50%.
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Table AI. Hardy-Weinberg Equilibr ium (HW E) calculations
Gene Symbol Polymorphism n lvalue p s 0.05 Genotypes in HW E
Discovery set
CCND I rs9344 Pr024 IPro AlG 530 0.01 no yes
DCC rs2229080 Arg20 lGly C/G 530 0.7 no yes
EGFR rs2227983 Arg52 1Lys G/A 530 2.6 1 no yes
ERCCI rs l 1615 Asn l 18Asn CIT 531 3.46 no yes
ERCC2 rs13181 Lvs751Gln Grr 524 4.6 yes no
ERCC5 rs1047768 His46His CIT 530 0.6 no yes
EXOI rs9350 Pro757Leu CIT 531 0.01 no yes
FAS rs l800682 c-24+733T>C 530 0.81 no yes
FGFR4 rs351855 Gly388Arg AlG 531 2.68 no yes
*GSTM I gene deletion n/a n/a n/a n/a
GSTP I rs l695 Ilel 05Vai A/G 525 0.01 no yes
*GSTT I gene deletion n,a n/a n/a n/a
IL6 rs l800795 - I74G/C in promoter 530 0.1 no yes
MLHl rs1799977 Ile219Vai AlG 531 0.1 no yes
MMPI rs l799750 -1607 indel G in promoter 532 0.76 no yes
MMP2 rs243865 -1306CIT in promoter 530 2.07 no yes
MTHFR rsl801133 Ala222Vai CIT 524 0.15 no yes
MTHFR rs l80 1131 Glu429Ala AlC 526 1.66 no yes
OGGJ rsl052133 Ser326Cys C/G 531 4.32 yes no
PTGS2 rs4648298 c.3618A1G in 3'-UTR 522 0.14 no yes
SERPlNE l rs l799889 -675 indelG in promoter 532 1.12 no yes
TYMS rs34743033 2/3 repeats of28bp 532 1.28 no yes
TYMS rs l6430 indel6 bp in 3' -UTR 526 0.02 no yes
VE GFA rs2010963 -634G/C in 5'- UTR 524 9.58 yes no
175
VEGFA I rs3025039 +936CIT in 3' -UTR I 531 I 0.5 I no I yes
XRCCl I rs25487 Arg399G ln G/A I 518 I 0.05 I no I yes
XRCC3 I rs861539 T hr241Met err I 531 I 5.42 I yes I no
Validat ion set
MTHFR I rs l801 131 Glu429AlaAlC I 250 I 0.02 I no I yes
ERCC5 I rs1047768 His46His CIT I 242 I 0.28 I no I yes
SERPI NEl I rs l799889 -675 indelG in promoter I 245 I 1.62 I no I yes
*GSTMl I gene deletion I n/a I n/a I n/a I n/a
n=number of samples genotyped. nJa= not applicable. Polymorph isms with x· value greater than 3.84 were considered to be deviating from HWE with
statistical significance (Rodriguez S et al. American Journal of Epidemiology, 2009 ). Polymorphisms deviated from HWE are shown in bold. ' For these
deletions, the methods applied did not detect heterozygotes.
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Table A2. Univariate Cox-regression analy sis for 27 polymorphisms with OS
(co-dominant model)
Variable p-value OR I 95% CI I n
ERCC2Js13 181 0.488
GTvsTT 0.315 0.848 10.6 15-1.169 1
GGvsTT 0.343 0.804 0.513-1.261 523
GSTPIJs 1695 0.66
GAvsAA 0.415 1.145 10.827-1.584 1
GGvsAA 0.483 1.175 0.749-1.843 524
MTHFRJs1801131 0.079
CAvsAA 0.654 1.0751 0.784-1.4741
CCvsAA 0.025 1.733 1.070-2.807 525
MTHFR_fs1801133 0.932
TC vsCC 0.738 1.055 10.771-1.443 1
TTvs CC 0.949 0.983 0.582-1.660 523
VEGFA_fs2010963 0.369
GCvsGG 0.705 1.0631 0.774-1.461 1
CC vsGG 0.218 0.71 0.412-1.224 523
XRCCl_fs25487 0.442
AGvsGG 0.202 1.23 10.895-1.691 1
AAvsGG 0.701 1.105 0.663-1.841 517
ERCC5_fs l047768 0.012
TCvsCC 0.097 1.347 10.948-1.914 /
TTvsCC 0.003 1.87 1.238-2.824 529
OGGIJs 1052133 0.868
GC vsCC 0.71 1.062/ 0.772-1.462 1
GGvsCC 0.655 1.141 0.641-2.030 530
ERCCl _fs 11615 0.705
TC vsTT 0.958 1.009 10.727-1.399 1
CC vsTT 0.434 1.183 0.776-1.802 530
TYMS fs16430 0.549
6 bp/- v;6 bp/6 bp 0.313 0.85 10.619-1.1661
-1-vs 6 bp/6 bp 0.482 0.836 0.507-1.378 525
MLHl JS 1799977 0.72
GAvsAA 0.701 1.062 10.782-1.443 1
GGvsAA 0.55 0.832 0.454-1.522 530
FASJS 1800682 0.478
TCvs TT 0.848 0.967 10.686-1.362 /
CCvs TT 0.348 1.214 0.810-1.820 529
lL6_fS1800795 0.146
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GCvsGG 0.079 1.361 10.965-1.9181
CCvs GG 0.892 1.032 0.654-1.628 529
EGFRJs2227983 0.209
GAvsGG 0.522 1.106 10.813-1.504 1
AAvs GG 0.079 1.662 0.944-2.926 529
DCCJs2229080 0.829
CG vs CC 0.783 1.0451 0.762-1.434\
GGvsCC 0.68 0.9 0.546-1.483 529
MMP2Js243865 0.736
CTvsCC 0.939 1.012 10. 742-1.380 I
TTvsCC 0.435 1.313 0.663-2.598 529
VEGFAJs3025039 0.373
CTvsCC 0.304 1.205 10.844-1.722 1
TTvsCC 0.305 1.826 0.578-5.769 530
FGFR4_fs351855 0.257
CTvsCC 0.103 1.2981 0.949-1.7751
TT vs CC 0.439 1.215 0.742-1.991 530
PTGS2 fs4648298 0.041 2.016 I 1.030-3.946 I 521
XRCC3_ fs861539 0.394
TCvs CC 0.209 1.234 10.889-1.714 1
TTvsCC 0.961 1.012 0.618-1.658 530
CCND1_fs9344 0.191
GAvsGG 0.237 0.813 10.5 77-1.146 1
AAvsGG 0.548 1.132 0.755-1.697 529
EX01_ fs9350 0.483
CTvsCC 0.329 1.1771 0.849-1.6321
TTvs CC 0.532 0.694 0.221-2.182 530
SERPINE1Js1799889 0.046
G/-vs -I- 0.252 0.823 10.589-1.149 /
GGvs -l- 0.013 0.557 0.35 1-0.885 531
MMP 1_f s1799750 0.126
G/-vs -I- 0.153 1.31 I 0.904-1.897 1
GGvs -l- 0.044 1.539 1.012-2.339 531
GSTTl gene deletion 0.585 0.894 I 0.597-1.339 I 531
GSTM l gene deletion 0.009 1.484 I 1.104-1.994 I 531
TYMSJs34743033 0.829
2R/3R vs 3R/3R 0.886 1.0261 0.723-1.4551
2R/2R vs 3R/3R 0.562 1.129 0.749-1.702 530
n=no. of samples available for analysis, HR-h azard ratio, CI-co nfidence interval, 6 bp m TYMS_rs16430
refers to the sequence CTTIAA, HR>1 implies increased hazard of death, HR<1 implies reduced hazard of
death.
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Table A3. Univar iate Cox-regression analysis for OS in discovery set
(reces sive model)
n-number of samples available for analysis, HR-h azard rano, CI=confidence Interval, 6 bp In
TYMS_rsl6430 refers to the sequence CTITAA, GS TTI and GS TM I gene deletions as well as
PTGS2_rs4648298 are not a part of the recessive model, HR>1 implies increased hazard of death, HR<1
implies reduced hazard of death
Variable Genotypes p-value HR 95%CI n
ERCC2 rsl 3181 GG vs GT+TT 0.524 0.871 0.57-1.332 523
GST P1 rs1695 GG vs AG+AA 0.676 1.092 0.723-1.648 524
MTHFR rsl8 01131 CCvsCA+AA 0.027 1.673 1.060-2.641 525
MTHF R rsl8 01133 TT vs TC+CC 0.865 0.957 0.580-1.580 523
VEGFA rs2010963 CC vsGC+GG 0.174 0.693 0.408- 1.177 523
XR CCI rs25487 AAvsAG+GG 0.965 0.989 0.613-1.596 517
ERCC5 rs1047768 TTvsTC+CC 0.012 1.564 1.105-2.213 529
OGGI rs lO52133 GG vs GC+CC 0.702 1.116 0.635-1.964 530
ERCC I rsl1 615 CC vs TC+TT 0.404 1.177 0.803-1.727 530
TYMS rsl 6430 -1-vs 6 bp/- + 6 bp/6 bp 0.68 0.904 0.561-1.459 525
MLHI rs1799977 GG vs GA+AA 0.476 0.808 0.450-1.452 530
FAS rsl800682 CC vs TC+TT 0.23 1.239 0.873-1.757 529
1L6 rsl800795 CC vs GC+GG 0.415 0.849 0.573-1.259 529
EGF R rs2227983 AAvsGA+GG 0.098 1.588 0.918-2.744 529
DCC rs2229080 GG vs CG+CC 0.585 0.878 0.551-1.4 529
MMP2 rs243865 TTvsCT+CC 0.436 1.306 0.667-2.557 529
VEGFA rs3025039 TTvsCT+CC 0.335 1.757 0.558-5.537 530
FGF R4 rs351855 TTvsCT+CC 0.776 1.07 0.671-1.706 530
X RCC3 rs861539 TTvs TC+CC 0.61 0.89 0.569-1.392 530
CCNDI rs9344 AA vs GA+GG 0.159 1.286 0.906-1.825 529
EXO I rs9350 TTvsCT+CC 0.481 0.663 0.212-2.077 530
SERPINE I rsl7 99889 GG vs G/- + -1- 0.03 0.634 0.421-0.956 531
MMP 1 rsl7 99750 GG vs G/- + -1- 0.135 1.29 0.924-1.803 531
TYMS rs34743033 2R/2R vs 2R/3R+3R/3R 0.551 1.111 0.785-1.572 530
-
- -
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Table A4. Univariate Cox-regression analysis for OS in discovery set
(dominant model)
n-number of samples availab le for analysis, HR=hazard ratio , CI=confidence Interval , 6 bp In DM S_rst6430
refers to the sequence CTIT AA, GSITI and GSTMI gene deletions as well as PTGS2Js4648298 are not a
part of the domi nant model, HR> l implies increased hazard of death , HR<I implies reduced hazard of
death .
Polymorphi sm Genotype n-value HR 95% CI n
ERCC2 rs13l81 GG+GTvsTT 0.239 0.836 0.621-1.126 523
GSTPI rs l695 GG+GAvsAA 0.366 1.152 0.848-1.565 524
MTHFR rs180113 1 CC+CAvsAA 0.299 1.171 0.869-1.578 525
MTHFR rsl801133 TT+TCvsCC 0.791 1.041 0.772-1.404 523
VEGFA rs2010963 CC+GCvsGG 0.85 0.972 0.720-1.310 523
XRCCI rs25487 AA+AGvsGG 0.23 1.206 0.888-1.636 517
ERCC5 rs1047768 TT+TCvs CC 0.019 1.483 1.067-2.062 529
OGGI rs1052133 GG+GCvsCC 0.634 1.076 0.797- 1.452 530
ERCCI rs l 1615 CC+TC vs TT 0.733 1.054 0.778- 1.429 530
TYMS rsl 6430 -1-+6boz- vs 6 bp/6 bo 0.275 0.847 0.628-1.141 525
MLH I rs1799977 GG+GAvsAA 0.872 1.025 0.762-1.3 77 530
FAS rs1800682 CC+TCvsTT 0.8 19 1.038 0.755-1.427 529
/L6 rsl8 00795 CC+GCvsGG 0.159 1.267 0.9 11-1.763 529
EGF R rs2227983 AA+GAvsGG 0.307 1.166 0.868-1.566 529
DCC rs2229080 GG+CGvsCC 0.922 1.015 0.750-1.374 529
MMPl rs243865 TT+CTvs CC 0.794 0.961 0.713-1.296 529
VEGFA rs3025039 TT+CTvsCC 0.232 1.235 0.874-1.747 530
FGF R4 rs351855 TT+CTvsCC 0.104 1.281 0.950-1.725 530
XRCC3 rs86 1539 TT+TC vs CC 0.29 1.187 0.864-1.630 530
CCNDI rs9344 AA+GAvsGG 0.51 0.899 0.653-1.236 529
EXOI rs9350 TT+CTvsCC 0.445 1.133 0.822-1.560 530
SERPINEI rs l799 889 GG + G/- vs -1- 0.072 0.745 0.541-1.026 531
MMPI rsl799750 GG + G/- vs -1- 0.07 1.381 0.974-1.959 531
TYMS rs34743033 2R/3R+2R/2 R vs 3R/3R 0.736 1.058 0.763-1.468 530
-
186
Tabl e AS. Univar iate Cox-regression analysis for DFS in discovery set
(co-dominant model )
Polymorphism p-value HR I 9S% CI I n
ERCC2_fs13181 0.713
GTvs TT 0.415 0.884 10.657-1.1891
GGvsTT 0.707 0.924 0.612-1.395 522
GSTP1_fS 1695 0.286
AGvsAA 0.349 1.155~
GGvsAA 0.122 1.381 0.917-2.078 523
MTHFR_fs1801131 0.394
CAvsAA 0.581 1.085 10.812-1.4491
CCvsAA 0.174 1.389 0.864-2.231 524
MTHFRJsl80 1133 0.906
TC vsCC 0.994 1.001 10.750-1.3361
TTvsCC 0.672 0.899 0.549-1.472 522
VEGFA_fs2010963 0.905
GCvsGG 0.656 1.07 10.795-1.4391
CCvsGG 0.94 1.018 0.643-1.6 11 522
XRCC1_fS25487 0.794
AGvsGG 0.892 1.02 10.763-1.3641
AAvsGG 0.555 0.864 0.531-1.404 516
ERCC5_ f S I 047768 0.037
TC vsCC 0.131 1.28 10.929-1.7631
TTvs CC 0.01 1.647 1.124-2.414 528
OGG1JsI052133 0.215
GC vsCC 0.74 1.052 10.781-1.4151
GGvs CC 0.08 1.558 0.949-2.559 529
ERCC1_fs11615 0.234
TCvs TT 0.307 1.172 10.864-1.590 I
CCvs TT 0.094 1.392 0.945-2.050 529
TYMS_fs16430 0.559
6 bp/- vs 6 bp/6 bp 0.494 0.903 10.673-1.211 1
-/- vs 6 bp/6 bn 0.573 1.134 0.733-1.754 525
MLH 1 _fS 1799977 0.83
GAvsAA 0.927 1.013 10.763-1.3461
GGvsAA 0.574 0.856 0.498-1.472 529
FAS_fs1800682 0.566
TCvs TT 0.769 0.954 10.695-1.309 1
CC vsTT 0.46 1.152 0.791-1.680 528
1L6JS 1800795 0.155
GCvsGG 0.203 1.225 10.896-1.676 1
CCvsGG 0.515 0.869 0.571-1.325 528
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EGFR_rs2227983 0.389
GAvsGG 0.952 0.991 10.746-1.3181
AA vsGG 0.187 1.44 0.838-2.476 528
DCCJs2229080 0.819
CGvsCC 0.742 1.05 10.784-1.407 1
GGvs CC 0.701 0.914 0.579-1.445 528
MMP2Js243865 0.884
CTvs CC 0.827 1.032 10.776-1.3731
TTv sCC 0.634 1.179 0.599-2.322 528
VEGFA_rs3025039 0.397
CTvsCC 0.234 1.219 10.880-1.6881
TTvs CC 0.462 1.538 0.489-4.840 529
FGFR4_rs351855 0.274
CTvsCC 0.107 1.268 10.950-1.694 1
TTvsCC 0.603 1.129 0.714-1.786 529
PTGS2 rs4648298 (GA vs AA) 0.027 1.985 11.080-3.6461 521
XRC C3_rs861539 0.465
TCvs CC 0.236 1.201 10.887-1.6271
TTvsCC 0.854 1.044 0.663-1.643 529
CCND1Js9344 0.444
GAvsGG 0.949 0.989 10.718-1.3641
AAvsGG 0.294 1.229 0.836-1.808 528
EX01Js9350 0.483
CTvs CC 0.464 1.121 10.826-1.520 I
TT vsCC 0.367 0.591 0.188-1.854 529
SERPlNE1 rs1799889 0.533
G/- ~s-I- 0.383 0.869 I 0.633-1.192 1
GGvs -l- 0.294 0.807 0.541-1.204 530
MMP 1_rs 1799750 0.149
G/-vs-I- 0.221 1.235 10.880-1.7331
GGvs -l- 0.051 1.464 0.998-2.147 530
GSTT1 Gene deletion (A vs P) 0.161 0.758 10.515-1.1171 530
GSTM1 Gene Deletion (P vs A) 0.004 1.489 1 1.133-1.9571 530
TYMSJs34743 033 0.918
2R/3R vs 3R/3R 0.846 0.969 10.705-1.3311
2R/2R vs 3R/3R 0.679 0.922 0.628-1.354 529
n=number of patients avai lable for analysis, HR=hazard ratio, CI=confidence Interval, 6 bp In
TYMSJsl6430 refers to the sequence CTlTAA, HR>1 implies increased hazard of event, HR<1 implies
reduced hazard of event.
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Table A6. Univar iate Cox-reg ression anal ysis for DFS in discovery set
(recessive model)
Polymorphism p-valu e HR 95% CI n
ERCC2 rs13181 (GG vs GHIT) 0.925 0.982 .666-1.446 522
GSTPl rs1695 (GG vs AG+AA) 0.198 1.278 .880-1.855 523
MTHF R rs180 1131 (CCvsCA+AA) 0.21 1.335 .850-2.096 524
MTHF R rs1801133 (IT vs TC+CC) 0.657 0.899 .560-1.44 1 522
VEGFA rs20 I0963 (CC vs GC+GG) 0.967 0.991 .636-1.543 522
XRCCl rs25487 (AA vs AG+GG) 0.506 0.855 .539-1.357 516
ERCC5 rs l0 47768 (IT vs CCHC) 0.034 1.422 1.027-1.970 528
OGGl rs1052133 (GG vs CC+GC) 0.085 1.531 .943-2.484 529
ERCC l rsl1 615 (CC vs TC+IT) 0.167 1.279 .902-1.812 529
TYMS rs16430 (-/- vs 6 bp/- + 6 bp/6 bp) 0.401 1.193 .790-1.802 525
MLHl rs1799977 (GG vs GA+AA) 0.546 0.851 .503-1.439 529
FAS rsl 800682 (CC vs TC+IT) 0.304 1.186 .857-1.642 528
lL6 rs1800795 (CC vs GC+GG) 0.154 0.765 .529-1.105 528
EGFR rs2227983 (AA vs GA+GG) 0.17 1.446 .854-2.448 528
DCC rs2229080 (GG vs CG+CC) 0.59 0.889 .581-1.362 528
MMP2 rs243865 (IT vs CHCC) 0.655 1.164 .597-2.272 528
VEGFA rs3025039 (IT vs CHCC) 0.507 1.473 .469-4.626 529
FGFR4 rs351855 (IT vs CHCC) 0.973 1.008 .653-1.555 529
XRCC3 rs861539 (IT vs TC+CC) 0.739 0.933 .618-1.407 529
CCNDl rs9344 (AA vs GA+GG) 0.203 1.237 .891-1.718 528
EXOl rs9350 (IT vs CHCC) 0.339 0.573 .183-1.792 529
SERPlNEl rs1799889 (GG vs G/- + -/-) 0.489 0.885 .627-1.250 530
MMP l rs l 799750 (GG vs G/- + -/-) 0.12 1.277 .938-1.739 530
TYMS rs34743033 (2R12R vs 2R13R+3R13R) 0.7 16 0.94 .675-1.310 529
n-number of patients avai lable for analysis, HR- hazard rano, CI-confidence Interva l, 6 bp In
TYMS_rs16430 refers to the sequence CTITAA, GSTTJ and GSTMJ gene deletion as well as
PTGS2Js4648298 are not included in the recessive model, HR>l implies increased hazard of event, HR<l
implies reduced hazard of event.
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Table A7. Univar iate Cox-regression an alysis for DFS in the discovery set (dominant
model )
Polymorphism p-value HR 95%CI n
ERCC2 rs l3 181 (GG+GTvsTT) 0.426 0.894 .679-1.178 522
GSTPl rsl695 (AG+GGvsAA) 0.197 1.205 .908-1.600 523
MTHF R rsl80 1131 (CA+CCvsAA) 0.381 1.131 .859-1.490 524
MTHF R rs l 801133 (TC+TT vs CC) 0.896 0.982 .745-1.293 522
VEGFA rs2010963 (GC+CC vs GG) 0.692 1.057 .803-1.393 522
XRCCl rs25487 (AG+AA vs GG) 0.939 0.989 .749-1.306 516
ERCC5 rs1047768 (TC+TT vs CC) 0.036 1.378 1.020-1.861 528
OGG l rs1052133 (GC+GG vs CC) 0.393 1.128 .856-1.488 529
ERCC l rsl1 615 (TC+CC vs TT) 0.153 1.23 .926-1.633 529
TYMS rs l 6430 (-1- + 6 bp/- vs 6 bp/6 bp) 0.7 0.947 .719-1.248 525
MLHl rs1799977 (GA+GG vs AA) 0.927 0.987 .752-1.297 529
FAS rsl8 00682 (TC+CC vs TT) 0.942 1.011 .753-1.358 528
lL6 rs l 800795 (GC+CC vs GG) 0.461 1.12 .829-1.512 528
EGFR rs2227983 (GA+AA vs GG) 0.779 1.04 .792-1.366 528
DCC rs2229080 (CG+GG vs CC) 0.88 1.022 .772-1.353 528
MMP2 rs243865 (CHTT vs CC) 0.751 1.046 .793-1.378 528
VEGFA rs3025039 (CHTT vs CC) 0.196 1.234 .897-1.697 529
FGFR4 rs351855 (CHTT vs CC) 0.128 1.238 .941-1.630 529
XRCC3 rs861539 (TC+TT vs CC) 0.297 1.169 .872-1.566 529
CCNDl rs9344 (GA+AA vs GG) 0.735 1.053 .779-1.425 528
EXOl rs9350 (CHTT vs CC) 0.644 1.073 .796-1.447 529
SERPINEl rs1799889 (GI- + GG vs -1-) 0.293 0.851 .630-1.149 530
MMPl rsl799750 (GI- + GG vs -1-) 0.099 1.307 .951-1.797 530
TYMS rs34743033 (2R/3R+2R/2R vs 3R/3R) 0.755 0.954 .708-1.285 529
n=numbe r of patients available for analyis, HR-hazard ratio, CI-co nfidence interval, 6 bp m TYMS_rs16430 refers
to the sequence CTITAA, GSTTI and GSTM I gene deletions as well as PTGS2J s4648298 are not included in the
dominant model, HR> I implies increased hazard of event, HR< I implies reduced hazard of event.
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Table AS. Multivariate anal ysis for OS in the discovery set (rece ssive model)
n- 503. GSTMI and GS TTI gene deletions were not Included In the recessive model, HR: hazard ratio, CI:
confidence interval, HR> 1 implies increased hazard of death, HR<1 implies reduced hazard of death.
Var iable p-value HR 95% ClforHR
MTHFR rs1801131 (CCvsCA+AA) 0.03 1.693 1.052 2.723
ERCC5 rs l0 47768 (TT vs CC+TC) 0.009 1.647 1.13 204
OGGIJs I052133 (GG vs GC+CC) 0.228 1044 0.794 2.624
lL6 rs1800795 (CC vs GC+GG) 0.05 0.66 00435 1.001
EGFR rs2227983 (AA vs GA+GG) 0.019 1.963 1.118 30444
SERPlNEl rs1799889 (GG vs G/- + -/-) 0.037 0.634 0041 4 0.972
Age at diagnosis 0.016 1.021 1.004 1.039
Stage <0.001
II vs I 0.174 1048 0.841 2.604
III vs I 0.005 2.223 1.274 3.879
IV vsl <0.001 13.194 7.213 24.135
MSI status (MSI-H vs MSI-L/MSS) 0.002 0.21 0.077 0.57
-
Table A9. Multivariate anal ysis for OS in the discovery set (dominant model )
Variable p-value HR 95% ClforHR
MTHFR rs1801131 (CA+CCvsAA) 0.199 1.224 0.899 1.666
ERCC5 rs l047768 (TC+TT vs CC) 0.013 1.544 1.095 2.177
Age at diagnosis 0.013 1.022 1.005 1.039
Stage <0.001
II vs I 0.102 1.597 0.911 2.801
III vs I 0.002 2.385 1.371 4.15
IV vsl <0.001 11.365 6.302 200498
MSI status (MSI-H vs MSI-L/MSS) 0.001 0.19 0.07 0.516
n=504 . GS TM I and GSTT I gene deletions are not Included In the dominant model, HR: hazard ratio, CI: confidence
interval, HR>1 implies increased hazard of death, HR< \ implies reduced hazard of death.
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Tabl e AIO. Multivariate anal ysis for DFS in th e discovery set (recessive model)
Var iable p-value HR 95% CI forHR
MTHFR rs1801131 (CCvs CA+AA) 0.067 1.564 0.97 2.523
ERCC5 rs1047768 (IT vs CC+CT) 0.069 1.379 0.976 1.95
OGGl rsl052 133 (GG vs CC+GC) 0.035 1.727 1.04 2.869
TYMS rs16430 (-1- vs 6 bp/6 bp + 6 bp/-) 0.039 1.586 1.023 2.459
DCC rs2229080 (GG vs CG+CC) 0.128 0.708 0.454 1.104
XRCC3 rs861539 (IT vs TC+CC) 0.292 0.79 0.51 1.225
Location (rectum vs colon) 0.006 1.552 1.137 2.117
Stage <0.001
II vs I 0.299 1.308 0.788 2.169
III vs I 0.009 1.951 1.185 3.212
IV vsI <0.001 5.469 3.19 9.376
MSI status (MSI-H vs MSI-L/MSS) 0.002 0.274 0.121 0.62
ERAF l Val600Glu mutation status (+ vs -) 0.022 1.87 1.095 3.193
n=466. TYMS_rs 16430 IS referred as the indel 6 bp polymorphism, 6 bp In TYMS_rs16430 refers to the
sequence CTTIAA, GS TTI and GS TM I gene deletions were not included in the recessive model, HR:
hazard ratio, CI: confide nce interval, HR>1 implies increased hazard of event, HR<I implies reduced
hazard of evenI.
Table All. Multi variate anal ysis for DFS in the discovery set (dominant model )
Variable p-value HR 95% Cl for HR
ERCC5 rs1047768 (TC+IT vs CC) 0.08 1.318 0.967 1.795
ERCCl rs11615 (TC+CC vs IT) 0.126 1.256 0.938 1.683
Location (rectum vs colon) 0.054 1.328 0.995 1.772
Stage <0.001
II vs 1 0.101 1.505 0.924 2.453
III vs I 0.002 2.139 1.322 3.46
IVvs l <0.001 5.941 3.527 10.006
MSI status (MSI-H vs MSI-L/MSS) 0.004 0.346 0.169 0.712
n-507 . GSTTI and GSTM I gene deletions are not Included In the dominant model, HR. hazard ratio, CI:
confidence interval, HR> I implies increased hazard of event, HR<I implies reduced hazard of event.
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Table A12. Chi-square test results between polymorphi sms and clinicopathological
& molecular variables (recess ive model)
Polymorphi sm Variable p-value n
CCNDlJs9344 Histology 0.03 530
CCNDl rs9344 Stage 0.016 530
FASJs1800682 Histology 0.001 530
lL6 rs1800795 Sex 0.009 530
MMP 1Js1 799750 Vascular invasion 0.04 492
SERPINE l rs1799889 Sex 0.039 532
VEGFA rs2010963 MSIstatus 0.003 503
*VEGFA rs20 10963 Grade 0.03 52 1
XRCC3 rs86 1539 BRAFJ Va1600Glu mutation status 0.027 483
'By Fisher s exact test. Only statistically significant correlat ions are shown . n. number of patients
Table AB . Chi-square test results between polymorphi sms and clinicopatholo gical
& molecular variables (dominant model)
Polymorphism Variable p-value n
CCNDl rs9344 Histo logy 0.02 530
ERCCl rs11615 Stage 0.031 531
FAS_rs 1800682 Location 0.046 530
FAS rs1800682 Familial risk 0.027 530
lL6 rs1800795 Grade 0.031 526
XRCCl rs25487 Vascular invasion 0.023 479
XRCC l rs25487 Lymphatic invasion 0.028 476
XRCCl rs2548 7 MSlstatus 0.017 499
XRCC3 rs861539 BRAF l Val600Gl u mutation status 0.Q3 483
TYMS rs34743033 Sex 0.006 53 1
OnlystalIslIcallyslgmficantcorrelalIonsare shown . n.numberofpalIents
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Table A14. Chi-square test results between polymorphi sms and clinicopathological
& molecular variables (co-dominant model)
Polymorphi sm Variable p-value n
CCNDl rs9344 Histology 0.022 530
CCNDl rs9344 Stage 0.017 530
FAS rsl800682 Location 0.014 530
FAS rs1800682 Histology 0.003 530
FGFR4 rs351855 Location 0.032 531
1L6 rsl800795 Sex 0.029 530
MMP2 rs243865 Histo logy 0.029 530
VEGFA rs20 10963 MSIstatus 0.0 12 503
XRCCl rs25487 Vascular invasion 0.046 479
XRCCI rs25487 Lymphatic invasion 0.041 476
XRCCl rs25487 MSIstatus 0.047 499
XRCC3 rs86 1539 BRAFl Val600Glu mutation status 0.024 483
TYMS rs34743033 Sex 0.018 531
Only statisticallysignificantcorrelationsare shown.n :numberof patients
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